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Background fffBoth human immunodeficiency virus (HIV) infection and tuberculosis (TB) are 
complicated by a painful distal sensory polyneuropathy (DSP) that may be due to 
virus-related HIV-DSP, antiretroviral toxic neuropathy (ATN) or isoniazid-induced peripheral 
neuropathy (INH-PN). In co-infection with and co-treatment for HIV/TB, DSP risk is increased. 
Factors driving this risk may be vitamin B6 deficiency and slow metabolism of INH mediated 
by N-acetyltransferase 2 (NAT2) acetylation, both known risk factors for INH-PN. 
Supplemental B6 in the form of pyridoxine should prevent INH-PN, but B6 requirements may 
be increased in HIV/TB because of pre-existing deficiency. The influence of slow acetylation 
on DSP risk in the context of HIV/TB has not been investigated.  
Hypothesis fffDSP in HIV/TB co-infection is associated with vitamin B6 deficiency and/or slow 
NAT2 acetylation status. 
Method fffThe study design is that of a prospective analytical cohort. Over 1 year, consecutive 
HIV-infected admissions to a district TB-hospital were assessed at baseline and followed 
monthly during hospitalisation. Clinical assessments were performed using validated 
instruments, and DSP was defined by the presence of ≥1 neuropathic symptom and 
≥1 neuropathic sign. Vitamin B6 status was determined by plasma pyridoxal 5'-phosphate 
(PLP) high pressure liquid chromatography. NAT2 polymerase chain reaction restriction 
fragment length polymorphism analysis, sequencing and computational haplotyping predicted 
acetylation phenotype (fast, intermediate or slow). Generalised linear models estimated 
prevalence ratios (PR)s for baseline risk factors. 
Results fffOne hundred and sixteen participants were assessed at baseline on admission. All 
were receiving standard doses of INH (5 mg/kg/day) as part of a combination anti-TB regimen 
initiated at the referring facility; 25% were on ART. Prior to admission, only 65% received 
pyridoxine; on admission 76% were prescribed 25 mg/day and the remainder ≥50 mg/day.  
Baseline DSP frequency was 65 (56%). Based on recall of symptom onset, 36% was 
INH-PN, 22% HIV-DSP and 5% ATN. A further 26% reported concurrent neuropathic and TB 
symptom onset (prior to anti-TB therapy) and were labelled “TB-DSP”. Previous TB was 
independently associated with baseline INH-PN (PR 4.2; 95%CI 1.2-14.8). Eighty-one 
participants had at least one follow-up assessment, and the incidence of DSP in this group 
was 12.3/100 person-months. Incident DSP was attributed to ATN in 78%.  
Twenty-five participants had B6 assessments at baseline and again at either 4 or 8 weeks. 
At baseline, B6 deficiency (PLP <30 nmol/l) was demonstrated in 1 participant; at follow-up 
there was no deficiency. Participants receiving higher dose pyridoxine (≥50 mg/day) did not 
achieve higher levels. PLP levels were no different in those with and without DSP.  
NAT2 acetylation phenotype was predicted in a subset of 80 participants: 35% slow, 50% 
intermediate and 15% fast. Slow acetylation status failed to predict baseline DSP, 
but a survival analysis revealed a trend for slow acetylators to develop DSP. Slow acetylation 
did not affect PLP levels. 
Conclusion fffDSP is prevalent in HIV/TB co-infection after the initiation of anti-TB therapy, 
and DSP continues to develop during concomitant ART. The association of INH-PN with a 
previous TB history, a previously identified risk factor for ATN, represents a possible priming 
effect or unmasking of subclinical HIV-DSP. A “TB-DSP” not related to INH-use has been 
reported anecdotally in the literature and may also represent unmasking of subclinical 
HIV-DSP. The relationship of DSP to previous and current TB requires further long-term 
investigation. Pyridoxine supplementation as an adjunct to anti-TB therapy may have 
prevented the B6 deficiency expected in this cohort, but did not prevent incident DSP cases. 
However, the contribution of prior deficiency to DSP risk cannot be excluded; pyridoxine 
supplementation in co-infected patients at the time of anti-TB therapy initiation is 
recommended. Higher dose pyridoxine (≥50 mg/day) did not equate to higher PLP levels 
when compared to standard doses of 25 mg/day; in the absence of evidence demonstrating 
additional neurological benefit, higher dose pyridoxine appears unnecessary. The trend for 
slow acetylators to develop DSP during anti-TB therapy despite adequate B6 status suggests 
an additional mechanism for DSP pathogenesis in HIV/TB, or an independent association. 
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Abbreviations and terminology 
 
4PA 4-pyridoxic acid 
acCoA acetyl co-enzyme A 
ADSP asymptomatic distal sensory polyneuropathy 
ALT alanine transferase 
ART antiretroviral therapy 
ATN antiretroviral toxic neuropathy 
AZT azidothymidine (zidovudine) 
B6 vitamin B6 
BMI body mass index 
bp base pairs 
BPNS Brief Peripheral Neuropathy Screen 
cART combination antiretroviral therapy  
CCR5 C-C chemokine receptor 5 
CXCR4 C-X-C chemokine receptor 4 
d4T 2'-3'-didehydro-2'-3'-dideoxythymidine (stavudine) 
ddC 2'-3'-dideoxycytidine (zalcitabine) 
ddI 2'-3'-dideoxyinosine (didanosine) 
d-drug dideoxynucleotide reverse transcriptase inhibitor drug 
df degrees of freedom 
DNA deoxyribonucleic acid 
dNTPs dideoxynucleotides 
DPM DP Marais SANTA TB Hospital 
DRG  dorsal root ganglion 
DSP distal sensory polyneuropathy 
EDTA ethylenediaminetetraacetic acid 
eGFR estimated glomerular filtration rate 
GOT glutamic-oxaloacetic transaminase 
gp120 glycoprotein 120 
Hb haemoglobin 
HIV human immunodeficiency virus 
HIV-DSP human immunodeficiency virus distal sensory polyneuropathy 
HPLC high pressure liqu d chromatography 
HR hazard ratio 
IENF intraepidermal nerve fibre 
INH isonicotinic acid hydrazine (isoniazid) 
INH-PN isoniazid-induced peripheral neuropathy 
IQR interquartile ranged  
MRC Medical Research Council 
mtDNA mitochondrial deoxyribonucleic acid 
MWM molecular weight marker 
n number 
NAT1 N-acetyltransferase 1 (enzyme) 
NAT1 N-acetyltransferase 1 (gene) 
NAT2 N-acetyltransferase 2 (enzyme) 
NAT2 N-acetyltransferase 2 (gene) 
NHLS National Health Laboratory Services 
NRS numerical rating scale 
NRTI nucleotide reverse transcriptase inhibitor 
OR odds ratio 
p probability value 
PCR polymerase chain reaction 
PGIC patient global impression of change 
PI protease inhibitor 
PI protease inhibitor 













PR prevalence ratio 
PTB pulmonary tuberculosis 
p-y person-years 
Q1 first quartile 
Q3 third quartile 
RANTES regulated upon activation, normal T-cell expressed and secreted 
RCT randomised control trial 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
RR risk ratio 
SD standard deviation 
SFN small-fibre neuropathy 
SNP single-nucleotide polymorphism 
SPNS Subjective Peripheral Neuropathy Screen 
TB tuberculosis 
TDF tenofovir disoproxil fumarate (tenofovir) 
TNF-α tumour necrosis factor-α 
TNS Total Neuropathy Score 
WCC white cell count 
WHO World Health Organisation 
 
Notes on terminology: 
 
There is a lack of uniformity in the terminology referring to the various HIV/TB-associated 
sensory polyneuropathies. I have endeavoured to be consistent, and to utilise concise but 
descriptive terms. “Distal sensory polyneuropathy” (“DSP”) will refer to the generic clinical 
entity it describes (independent of aetiology) – DSP is more descriptive and specific than 
“peripheral neuropathy” or “sensory neuropathy”. DSP will always refer to symptomatic DSP, 
as opposed to “asymptomatic DSP” (“ADSP”) which implies the presence of neuropathic 
signs only. The terms, “human immunodeficiency virus distal sensory polyneuropathy” 
(“HIV-DSP”) and “antiretroviral toxic neuropathy” (“ATN”), are cited by our research group and 
I have maintained this nomenclature. In contrast, no specific term refers to the 
isoniazid-induced polyneuropathy – the description is generally one of a “peripheral 
neuropathy” or “peripheral neuritis”. I refer to this entity as “isoniazid-induced peripheral 
neuropathy” (“INH-PN”). The term, “HIV associated DSP”, will refer to primarily HIV-DSP and 
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The introduction presents an exposition of and approach to the research 
question. 
1.1 Background 
Distal sensory polyneuropathy (DSP) is a frequent and problematic 
complication associated with human deficiency virus (HIV) infection and 
tuberculosis (TB). DSP can be a consequence of the infection itself in the 
case of HIV-DSP, or as a result of treatment-related neurotoxicity: 
antiretroviral toxic neuropathy (ATN) and isoniazid-induced peripheral 
neuropathy (INH-PN). Nutritional, genetic and other factors may also be 
involved1. The risk for the development of DSP is increased by concurrent HIV 
and TB infection (“HIV/TB”), and during concomitant antiretroviral therapy 
(ART) and anti-tuberculous (anti-TB) therapy2-5. HIV/TB is frequently 
encountered and co-treatment necessitated in resource-limited settings, 
particularly in sub-Saharan Africa, because of overlapping HIV and TB 
epidemics6,7. In 2008, global incident TB was estimated at 9.4 million cases, 
and HIV co-infection was prevalent in 15% of these. However, South Africa 
bears the brunt of this problem: a disproportionate 28% of worldwide HIV/TB 
occurs in this country, and of the 0.38–0.57 million incident cases of TB in 
2008, HIV co-infection was present in 70-73%8,9.  
 
HIV-associated DSP (implying HIV-DSP and ATN primarily), which is 
recognised as the commonest neurological complication seen in HIV 
infection10, occurs in 49-57% of HIV-infected South Africans11,12. It presents a 
number of challenges to the clinician and patient. Clinically significant pain 
and discomfort, which occur at high frequency11,13, may have a detrimental 
impact on quality of life13-15. Diagnostic difficulties arise from a wide differential 
and the inability to clinically distinguish aetiological processes – a delay in 
diagnosis, which is frequently missed, may lead to a subsequent intractable 
course16. Therapeutic choices are limited and poorly effective for neuropathic 
pain10,17, which is under-treated11. A lack of preventative strategies12 may 












Neuropathic side effects have the potential to impact on treatment 
adherence20,21. 
 
A high background rate of HIV-DSP11 is compounded by the use of 
combination antiretroviral therapy (cART) regimens containing neurotoxic 
nucleoside-analogue reverse transcriptase inhibitors (NRTI)s or “d-drugs”, 
such as stavudine (d4T). Despite World Health Organisation (WHO) 
recommendations to reduce and phase out the use of these agents, wide 
availability, low cost and limited alternatives in resource-limited settings 
ensures their continued use12,22.  
 
The risk of ATN due to d-drugs is associated with concurrent or previous anti-
TB therapy11,19. Conversely, during anti-TB therapy, HIV-infection increases 
the odds for the development of INH-PN4, the clinical features of which are 
markedly similar to those of HIV-associated DSP16,23. The causative agent, 
isoniazid (INH), is an integral component of first-line anti-TB therapy in 
South Africa, and elsewhere24,25, and its antagonism of vitamin B6 (“B6”) 
metabolism induces a deficiency of the co-enzyme, which manifests clinically 
as a dose-related DSP in up to 44% of TB mono-infected patients on INH23. 
Adequate concomitant B6 supplementation in this population provides almost 
complete protection from this complication26, but this preventative effect 
appears to be modulated by the presence of HIV, prompting the suggestion 
that co-infected patients may require higher doses of B6 supplementation5. 
An increased B6 requirement in HIV/TB has not yet been confirmed; however, 
current evidence demonstrates B6 deficiency present even in asymptomatic 
HIV infection27, and in TB infection prior to initiation of anti-TB therapy28. 
Despite evidence demonstrating B6 deficiency in HIV/TB populations, B6 
prophylactic coverage is poor in South Africa11. 
 
Another established modulator of the incidence of INH-PN is the rate of 
acetylation of INH, determined by polymorphisms in the gene coding for the 
hepatic enzyme, arylamine N-acetyltransferase 2 (NAT2)29. Slow acetylators, 
who may account for 40-60% of the population30, are at a higher risk for the 












function during anti-TB therapy26. While INH-PN is an established 
complication of anti-TB therapy, anecdotal reports suggest that TB itself can 
precipitate a DSP, both in TB mono-infected31 and in HIV/TB co-infected 
populations – the latter possibly representing an unmasking of subclinical HIV-
DSP5,32.  
 
In contrast to the knowledge base for INH-PN, which was studied extensively 
during the 1950s and 60s, our understanding of the pathogenesis of HIV-
associated DSP is incomplete10, with the literature presenting a complex 
interplay of various pathogenetic mechanisms33. The role of TB in these 
models is not entirely clear. Epidemiological data in HIV/TB populations is 
also lacking – current evidence is derived largely from retrospective studies in 
which DSP was not the primary outcome2,3,5. To date, there have been no 
published prospective studies specifically investigating the incidence of and 
risk factors for DSP in HIV/TB cohorts. Another deficiency in the literature is 
the lack of a consistent case definition for DSP. This bias may be addressed 
through the use of standardised instruments such as the Total Neuropathy 
Score (TNS) and Brief Peripheral Neuropathy Screen (BPNS)34-36. 
 
The prevalence of HIV-associa ed DSP remains high despite discontinuation 
of d-drug use in well-resourced settings, and is predicted to increase as life 
expectancy in HIV increases and additional age-related risk factors are 
accumulated37. ART penetration is still relatively low in resource-limited 
settings; as access is up-scaled, HIV-associated DSP is set to increase in 
frequency38. While the use of ART reduces the risk for TB, the incidence of TB 
has been shown to remain elevated at least five years after ART-initiation39. 
Even with full immune reconstitution, the risk for TB infection remains the 
same as in the general population6, which is significant in sub-Saharan 
Africa8. Furthermore, there has been a drive by the WHO to institute INH 
preventive therapy globally40. HIV/TB co-infection and co-treatment rates can 














Vitamin B6 remains a justifiable target of study. Non-pyridoxine supplemented 
INH use results in INH-PN, and HIV/TB co-infection increases the risk for this 
complication, as well as for B6 deficiency. The optimum dose of pyridoxine in 
HIV/TB is not established5, and B6 represents an affordable and simple 
potential intervention, with a minimal adverse effect profile if taken in 
appropriate dosages1. To inform the paucity of data regarding B6 needs in 
HIV/TB, a natural approach would be to assess B6 status in this population. 
Vitamin B6 status can be estimated by a number of direct and indirect assays; 
of these, ascertainment of plasma pyridoxal 5'-phosphate (PLP) concentration 
is currently considered the best indicator of whole body vitamin B6 status41,42. 
Enzymatic methods for direct estimation of plasma PLP have been used in 
recent studies of B6 status in relation to INH use28,43, while earlier studies 
relied mainly on indirect methods23,26,44. Direct measurement of plasma PLP 
together with plasma 4-pyridoxic acid (4PA), a B6 degradation product, using 
high pressure liquid chromatographic (HPLC) t chniques offers a more 
sensitive and precise method for vitamin B6 estimation42, but these 
techniques have not been utilised in the study of B6 status in relation to INH.  
 
Some authors have suggested that acetylation status inform INH dosing 
guidelines29,45, but acetylation profiles have not been well characterised in the 
various South African populations. Acetylation status can be estimated by 
direct phenotyping and/or NAT2 genotyping, but there is some uncertainty 
regarding the optimum method for ascertaining acetylation status46. Genotype 
is favoured, however, because phenotype can be unreliable in both HIV and 
TB infection47-50. 
 
High prevalence and incidence rates in a substantial population at risk; 
various diagnostic and clinical management issues; and a limited evidence 
base entreat the prioritisation of HIV/TB-associated DSP as a subject of 
research – targeted study of this clinical problem is needed. A prospective 
longitudinal approach would clarify the impact of various risk factors, offer a 
description of the natural history of HIV/TB-associated DSP and assist in 
delineating the relative contribution and interactions of contributing aetiological 












pathophysiological mechanisms for INH-PN (i.e. B6 deficiency and slow 
acetylation status), reframed within the context of HIV, and utilising modern 
validated methods, would help establish whether INH-PN is a primary 
contributor to HIV/TB-associated DSP, offer further insight into the driving 
forces behind this complication and possibly guide further research. The use 
of standardised and validated DSP instruments would reduce bias and allow 
for comparison and replication of study findings.  
1.2 Research question 
1.2.1 Primary (alternative) hypothesis 
In HIV/TB co-infection, DSP is associated with B6 deficiency and/or slow 
acetylation status. 
1.2.2 Secondary (alternative) hypotheses 
In HIV/TB co-infection: 
1. Markers of B6 status are lower in patients with DSP relative to those who 
are DSP-free;  
2. Markers of B6 status are lower in slow acetylators; 
3. DSP is more severe in B6 deficiency; 
4. DSP severity is inversely correlated with markers of B6 status; 
5. DSP is more severe in slow acetylators; 
6. A relationship exists between DSP and dose and/or duration of INH 
therapy; the dose and/or duration of pyridoxine supplementation; and the 
use of cART (exploratory hypothesis); and 
7. Markers of B6 status are correlated with the dose and/or duration of 
pyridoxine supplementation; and are inversely correlated with the dose 













The study aims: 
1. To characterise DSP in HIV/TB co-infection; 
2. To establish risk factors for and pathogenetic features of DSP in HIV/TB 
co-infection with a focus on the role of vitamin B6 and acetylation status; 
and 
3. To establish whether or not varying doses of B6 supplementation in HIV/TB 
co-infection are adequate for the prevention of DSP, thereby potentially 
informing the design of a future randomised control trial (RCT), and/or 
treatment guidelines. 
1.3 Research approach 
A suitable HIV/TB population in which prospective longitudinal study could be 
implemented was identified: co-infected inpatients at a TB hospital. Validated 
instruments and case definitions for the detection of DSP were selected: 
≥1 neuropathic symptom plus ≥1 neuropathic sign by BPNS/TNS. Accurate, 
reliable and validated methods for the estimation of B6 and acetylation status 
were chosen: PLP/4PA by HPLC and NAT2 genotyping, respectively. A 
research proposal and protocol were drawn up accordingly, and the specific 
objectives of the study were then: 
 
1. To determine the baseline frequency and severity of DSP by BPNS/TNS in 
a population of HIV/TB co-infected inpatients at a TB hospital shortly after 
the initiation of B6-supplemented INH-containing anti-TB therapy; 
2. To determine DSP incidence and the rate of worsening of baseline DSP 
during the period of admission; 
3. To determine baseline and follow-up plasma PLP/4PA levels by HPLC, in 
order to determine the frequency and incidence of B6 deficiency and its 
association with baseline/incident/worsening DSP; 
4. To describe NAT2 genetic variation in the population and to predict 
acetylation phenotype accordingly; 
5. To establish the association between NAT2 genetic variation/predicted 












6. To determine whether a predicted slow acetylation phenotype is related to 
plasma PLP deficiency, and whether slow acetylators demonstrate lower 
PLP levels; 
7. To determine whether higher doses of B6 supplementation are more 
protective for baseline/incident/worsening DSP over the standard dose; 
8. To identify risk factors associated with baseline/incident/worsening DSP, 
and possible contributing aetiologies; and 












2 Literature review 
This review presents a summary of the current knowledge base for 
HIV/TB-associated DSP, with an emphasis on vitamin B6 and NAT2 as 
pathogenetic risk factors. The review uses a standard clinical approach, 
namely: epidemiology, clinical features/diagnosis, pathogenesis and 
treatment/prevention. As the literature pertaining specifically to 
HIV/TB-associated DSP is limited, separate treatment of HIV-DSP, ATN and 
INH-PN was frequently necessitated. 
2.1 Epidemiology 
This section first contextualises then examines the epidemiological evidence 
for HIV/TB-associated DSP. Contributing HIV-DSP, ATN and INH-PN 
epidemiology data are also presented and briefly discussed. 
2.1.1 Population 
The population at risk for HIV/TB-associated DSP comprises individuals 
infected with concurrent HIV and active (as opposed to latent) TB: HIV+TB 
(Figure 2-1A ). The respective therapies further define HIV/TB “sub-
populations”: (HIV+TB)+anti-TB, (HIV+TB)+ART and (HIV+TB)+anti-TB+ART 
(Figure 2-1B ). In terms of the literature examining adverse events in HIV/TB, 
TB infection is often equated with anti-TB therapy, as the two are rarely 
studied independently, and anti-TB therapy often implies the use of INH, the 
primary aetiological factor associated with TB-related DSP1. ART 
presupposes HIV-infection, simplifying this approach further. Thus, the 
populations at risk for HIV/TB-associated DSP can be considered: HIV+INH 
(co-infection) and ART+INH (co-treatment) (Figure  2-1C). Frequently, HIV 
populations are mixed ART-treated and -untreated (i.e. not stratified), hence 
an additional category: HIV±ART+INH. Six papers inform the epidemiological 
evidence for HIV/TB-associated DSP within this population framework 
(Table 2-1 ). The population approach is laboured because it serves to 















Figure 2-1  Venn diagrams illustrating HIV/TB populations at risk for DSP: (A) HIV+TB; 
(B) *(HIV+TB)+anti-TB, **(HIV+TB)+anti-TB+antiretroviral therapy (ART) and 
***(HIV+TB)+ART (i.e. A + corresponding therapies); and (C) a simplified approach: 
HIV+isoniazid (INH) and ART+INH. Adapted from Wittes51. 
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Table 2-1  Comparison of study design, study populations, DSP case definitions and 
pyridoxine supplementation among studies relating to HIV/TB-associated DSP. 






HIV+INH vs. INH Presence of 
paraesthesiae 
Not stated 
Breen et al.2 
 
Retrospective ART+INH vs. ART Not stated Not stated 
Dean et al.18 
 
Retrospective HIV±ART+INH Not stated Not stated 
Breen et al.3  
 
 
Retrospective HIV±ART+INH vs. 
INH 















Marks et al.5 Retrospective HIV±ART+INH vs. 
INH*** 
Decrease in sensation to 
knees 
10 mg/day 
ART=antiretroviral therapy, INH=isoniazid. 
*See Figure 2-1 . 
**Pyridoxine was prescribed but supplementation status within the cohort could not be 
established because of technical reasons. 
***Adults and children were studied. 
 
 
Population categories do not remain static – for example, an individual can 
progress from HIV to HIV+INH to ART+INH: 25% of South African patients 
initiating ART are receiving anti-TB therapy6. Westreich et al. has modelled 
the chronological relationship of initiation of anti-TB therapy to ART: anti-TB 
therapy is “ongoing” if commenced prior to the initiation of ART, and “incident” 
anti-TB therapy is commenced after (“concurrent” anti-TB therapy is 
commenced within two weeks of commencing ART)19 (Figure 2-2A ). This 
model serves to orientate risks associated with the timing of treatment 
initiation, considered an important determinant of clinical outcomes7,19. The 
model is expanded in Figure 2-2B  to better illustrate the temporal 
heterogeneity of exposures within HIV/TB populations. In this model, the 














Figure 2-2  (A) Timeline relating relationship of anti-TB therapy to antiretroviral therapy (ART) 
as presented in Westreich et al.19. (B) Timeline relating relationship of populations at risk for 
DSP (see Figure 2-1 ) and aetiological factors contributing to DSP. INH=isoniazid, 
ART=antiretroviral therapy, INH-PN=isoniazid-induced peripheral neuropathy, HIV-
DSP=HIV-distal sensory polyneuropathy, ATN=antiretroviral toxic neuropathy. 
 
2.1.2 Incidence and risk in HIV/TB co-infection and co-treatment 
DSP is cited as the most common adverse event during INH-containing 
anti-TB therapy in three reports of HIV/TB co-infected and co-treated 
cohorts3,4,18. The incidence rate of DSP in this population has been estimated 
Incident 
anti-TB  
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at 64.9 per 100 person-years4. In Perriëns et al., a RCT of extended anti-TB 
therapy conducted prior to the introduction of ART, the cumulative incidence 
of DSP in the HIV/TB co-infected (HIV+INH) group was 21%, as compared to 
9% for the TB mono-infected (INH) comparator group52. In contrast, the post-
ART data of Marks et al. presents a cumulative incidence of 8.3% for the 
HIV±ART+INH group vs. 1.9% for the INH group5, and Breen et al. presents a 
cumulative incidence of 14% vs. 2%3. Neither of these studies stratified the 
HIV±ART+INH groups in terms of ART use. In Breen et al., DSP developed in 
a greater proportion of patients receiving INH/d4T versus comparator patients 
who received d4T but not INH2. Figure 2-3  graphically demonstrates 
compounding DSP risks in these HIV/TB populations.  
 
Multiple factors may contribute to the differences in the observed incidence 
among studies: inconsistent or absent case definitions for DSP, and lack of 
validated instruments; the retrospective nature of many of the studies; 
ill-defined study populations (no ART stratification, and in Marks et al., an 
unknown proportion of children); and varying pyridoxine supplementation 
regimens (Table 2-1 ). 
 
Other evidence also points to increased DSP risk conferred by current or 
previous anti-TB therapy. In a cohort of ART-treated outpatients, the risk for 
withdrawal of d4T due to the development of DSP was 1.5 times higher in 
participants with incident or ongoing anti-TB therapy19, and in another 
prospective cohort, TB at baseline increased the hazard for DSP during d4T-
containing ART53. A history of previous TB has also been shown to be 
associated with DSP, increasing the odds for this complication in one cross-
sectional study11; however, the association with previous TB has not been a 
consistent finding12,22,54,55, possibly because of universal pyridoxine 















Figure 2-3  Schema of compounding risk for distal sensory polyneuropathy (DSP) in HIV/TV 
populations. Each step up from population to population represents increasing risk for DSP. 
On the left, additional risk for INH-PN is conferred by HIV and ART. On the right, risk for ATN 
is conferred by INH.. Based on and quoting the following evidence: *Perriëns et al.52, 
**Lanternier et al.4, ***Marks et al.5 and Marks56, ****Dean et al.18, and *****Breen et al.2. 
ART=antiretroviral therapy, INH=isoniazid, OR=odds ratio, RR=relative risk. 
 
2.1.3 HIV-DSP, ATN and INH-PN 
Epidemiological data and associated risk factors for HIV-DSP, ATN and 
INH-PN individually are summarised in Table 2-2 . These data should also be 
interpreted cautiously – multiple factors limit comparison and generalisability: 
selected study populations, heterogeneity regarding exposure to d-drug-
containing regimens, use of varying diagnostic criteria (see Section 2.2.4.1), 
and variable periods of observation, among others16,57-59. These factors may 
also account for the often contradictory risk associations among studies. 
Mostly consistent risk factors for HIV-DSP are low CD4+ T cell count and other 
markers of advanced HIV infection; for ATN, age and low nadir CD4+ T cell 
count16,59. 
 
The incidence of treatment-related neurotoxicity is dose-dependent. Higher 
dose d-drug increases the risk for ATN when compared with lower 
doses71,73,75: for example, in Lichtenstein et al., d4T at 80 mg/day vs. 









9% vs. 21% (p<0.001)* 
 
11% vs. 55% 
(p<0.001)***** 
RR 1.69 (p=0.074)**** 
Significant association 
Trend 
OR 3.5 (CI 1.1-13.7)*** 













Table 2-2  Epidemiological evidence and risk factors for INH-PN, HIV-DSP, ATN and mixed 
HIV-associated DSP. 
 INH-PN HIV-DSP ATN HIV-ass. DSP 
Population at risk 
 
INH HIV HIV+ART HIV±ART* 
Incidence  
 









(2-12 months)23  
 
33-64%  














     
Risk factors**     
  Age --- ++ +++/--- ++ 
  Gender ---   -- 
    Male     
    Female   ++  
  Weight  ++/--  -- 
  Height  -- +++/-- ++/-- 
  BMI  -- ++/--- -- 
  Race   +++/--  
  Recent CD4+ N/A +++/-- ++/--- --- 
  Nadir CD4+ N/A  +++/--- ++/-- 
  WHO stage IV N/A  -- +++ 
  Viral load N/A  +++/--- -- 
  HIV dementia N/A ++   
  Previous INH + -- +++/-- ++/-- 
  Alcohol +/- -- -- -- 
  Diabetes mellitus - -- +++/-- -- 
  Nutritional status +/-    
  D-drug exposure N/A N/A +++/--- +++/--- 
  Hepatitis C ---  ++/-- -- 
  Duration of HIV N/A +++ -- ++ 
  Duration of ART N/A N/A   
    Increasing     ++ 
    Decreasing    +++  
  PI exposure   +++/-- ++ 
INH-PN=isoniazid-induced peripheral neuropathy, DSP=distal sensory polyneuropathy, 
p-y=person-years, p-m=person-months, CD4+=CD4+ T cell count, ART=antiretroviral therapy, 
BMI=body mass index, N/A=not applicable, PI=protease inhibitor 
*Mixed cohorts comprising HIV-infected ART-naïve and ART-treated individuals (HIV±ART). 
**Risk factor indicators: (+): associated; (-): no association; (+/-): conflicting evidence; ( ): no 
evidence. Best level of evidence: (+) and (-): anecdotal or no analysis; (++) and (--): cross-
sectional or retrospective; (+++) and (---): prospective cohort or trial. 
Evidence: INH-PN65-69, HIV-DSP11,62,64,70,71, ATN12,53,54,61,72,73, mixed HIV-associated 
DSP11,57,58,74. 
 
2% of patients receiving INH at 3-5 mg/kg/day (without supplementary 
pyridoxine) developed INH-PN; at the much higher dosage of 16-24 
mg/kg/day, the cumulative incidence was 44%. In this study, increasing dose 












INH-PN in low-dose INH therapy is not a consistent finding, however. In 
patients presumed to be malnourished, 4-6 mg/kg/day INH produced INH-PN 
in 20%, suggesting the possibility that a poor baseline B6 status might 
predispose to overt deficiency76. Lack of a consistent case definition and the 
deliberate non-systematic elicitation of neuropathic symptoms may also 
account for the discrepancies – in the former study, symptoms may have been 
milder in the low-dose group, resulting in a response bias.  
 
Duration of exposure to aetiological agents and duration of observation are 
other relevant considerations. For HIV-DSP, this is demonstrated in Husstedt 
et al., a prospective cohort of 42 ART-naïve patients: in just over a year, the 
frequency of DSP increased from 33% to 64%62. HIV-DSP incidence 
increases in tandem with HIV disease progression (as evidence by CD4+ T 
cell count)71, and nerve damage is evident in virtually all autopsy specimens 
of those dying from acquired immune-deficiency syndrome16. Originally, d-
drug-induced neurotoxicity was thought to accumulate with ongoing exposure; 
however, after an initial peak at around three months, the incidence of ATN 
appears to decline, particularly after the first year of therapy72,73. Moreover, 
the use of d-drug-containing cART has in fact been found to be protective for 
DSP after the first year of therapy13,22,73, suggesting recovery of neurological 
function in tandem with immune recovery57,79. However, this seemingly 
neuroprotective effect has been ascribed to survival bias (those at risk for 
ATN do so early in the course of therapy and are then switched to less 
neurotoxic agents, while those who are less at risk remain on neurotoxic 
therapy)77,78. 
 
The incidence of ATN during post-exposure prophylaxis is reported as 6% in 
one month58; the incidence of DSP in a group of mixed HIV-infected and 
-uninfected miners during pyridoxine-supplemented INH preventive therapy 












2.2 Diagnosis and assessment 
HIV-DSP, ATN and INH-PN share many clinical features which may preclude 
aetiological diagnosis in HIV/TB populations. Diagnosis is further hindered in 
both clinical and research settings by the lack of a formal case definition for 
DSP. 
2.2.1 Clinical diagnosis 
Characteristic subjective sensory symptoms and/or objective neuropathic 
signs in a distal symmetric lower-limb distribution inform the diagnosis of DSP. 
In advanced cases, there may be upper limb involvement76,80. Neuropathic 
signs in the absence of symptoms is termed asymptomatic DSP (ADSP). 
2.2.1.1 Presentation 
Distal symmetric and primarily lower limb pain, paraesthesiae and allodynia 
(positive symptoms), as well as numbness (a negative symptom), are the 
hallmark subjective sensory features of HIV-DSP, ATN and 
INH-PN34,64,65,68,70,80-82. Neuropathic pain is a prominent symptom in 
HIV-associated DSP, a primarily small fibre neuropathy (SFN)83,84. It is 
characterised as burning, stabbing and shooting80, but is also variously 
described in terms of other unpleasant sensations84. 
2.2.1.2 Physical Examination 
Examination findings reveal features consistent with both a SFN (impaired 
pinprick and temperature sensation) and a large fibre component (impaired 
vibration sensation and reduced ankle reflexes) in a length-dependant glove-
and-stocking distribution. These features are similar for INH-PN, HIV-DSP and 
ATN34,64,65,68,70,80-82. Motor weakness, especially of ankle dorsiflexion, has 
been described for HIV-DSP71,85, ATN82 and INH-PN69 in advanced cases but 
is never the predominant feature. 
2.2.2 Differential diagnosis 
In the general population, sensory polyneuropathy has multiple causes: for 












chronic renal failure and other metabolic syndromes; neoplastic syndrome; 
and neurotoxic agents such as ethanol, among others. HIV/TB populations 
are likewise at risk for these polyneuropathies and their active exclusion in 
clinical settings is recommended16,64,71.  
 
HIV is also associated with a spectrum of non-DSP neuropathic disorders: 
acute and chronic inflammatory demyelinating polyneuropathies; mononeuritis 
multiplex due to cytomegalovirus infection (which also causes a progressive 
polyradiculopathy of the cauda equina), herpes zoster reactivation and 
myelopathies10,84. Mono-neuropathies due to nerve compression in poorly 
mobile patients can also occur86. A neurasthenic syndrome has been 
described in patients undergoing anti-TB therapy with INH76, although this 
refers more to symptomatic fatigue. 
2.2.3 Diagnostic investigations 
Special investigations are useful to rule out alternative neuropathic processes, 
to elucidate specific nerve involvement and to quantify DSP progression, but 
do not serve to differentiate neuropathies of diverse aetiologies16. They are 
employed in some screening instruments and diagnostic criteria34,87 (see 
Section 2.2.4); however, their use is not considered necessary in routine 
clinical practice16. 
2.2.3.1 Electrophysiology 
Nerve conduction studies in HIV-associated DSP are often normal in 
predominantly SFN, but may reveal a sensory axonal neuropathy when there 
is large fibre involvement84,85. Decreased sural sensory nerve action potentials 
with normal distal latencies and velocities are typical findings10,82. Abnormal 
nerve conduction findings were associated with lower CD4+ T cell counts in an 
untreated HIV-infected cohort, as were serum albumin levels and 
haemoglobin88, probably reflecting the severity of HIV infection. Animal 
models of INH-PN demonstrate slowing of sensory conduction velocity within 
days of INH administration, followed by an increase in the duration of the 
compound motor action potential within weeks, without slowing of the efferent 













Quantitation of intraepidermal nerve fibre (IENF) (C-fibre non-myelinated 
nociceptor) density in lower limb punch skin biopsies is considered an 
objective measure of HIV-associated SFN84. IENF quantitation involves 
specialised histochemical techniques; nevertheless, IENF quantitation has 
been employed as a reference standard for validation of DSP instruments35 
and as an outcome measure in drug trials83, as well as clinically84. The 
primary findings are reduced IENF densities and features of degeneration90; 
IENF densities correlated with CD4+ T cell count and inversely with plasma 
viral load in one study35,83. No reports of IENF quantitation in INH-PN appear 
in the literature.  
 
Nerve biopsies are rarely performed in the diagnostic work-up of DSP 
because they are invasive16, non-specificity limits their usefulness in 
differentiating aetiological processes91 and pathological findings are not well 
characterised in ATN10. Wallerian/”dying back” axonal degeneration is a 
pathological finding common to all HIV/TB-associated DSPs, with loss of small 
and large myelinated fibres, as well as loss of unmyelinated fibres85,86,92 – the 
latter is prominent in HIV-associated DSP86. Myelin abnormalities such as 
splitting and oedema were seen in rat models of ATN and INH-PN; myelin-
containing macrophages were observed infiltrating peripheral nerves in the 
INH-PN model93. The presence of inflammatory cells, particularly activated 
macrophages, is a consistent finding in HIV-DSP important to its 
pathogenesis10 (see Section 2.3.1.2). DRG neuron mitochondrial 
abnormalities are observed in ATN86 (see Section 2.3.2.2.1) and also in rat 
INH-PN94. The pathology of HIV-associated DSP and INH-PN overlap, 
suggesting common underlying pathogenetic processes. 
2.2.3.3 Quantitative sensory testing 
Quantitative sensory testing is a computer-based technique quantifying 
sensory thresholds to vibration and hot and cold stimuli80. Temperature 
thresholds are a measure of small fibre function and correlate with IENF 












confirm a SFN79. Quantitative sensory testing has received criticism for having 
poor reproducibility87 and are less suited to resource-limited and clinical 
settings77,84. 
2.2.4 Research diagnosis and assessment 
Issues surrounding the research diagnosis and assessment of DSP relate to 
the establishment of a case definition and how best to measure the elements 
defining it, in light of the lack of a reference standard. Various composite 
instruments, comprising both clinical and investigative elements, which 
provide a quantitative appraisal of DSP status, have been developed to 
address these issues. Instruments range from single question screening tools 
such as the Subjective Peripheral Neuropathy Screen (SPNS)80 to more 
involved composite scoring systems such as the TNS34. Many have been 
developed or adapted for HIV-associated DSP35,80,95: the BPNS (see Section 
2.2.4.2) and modified TNS (see Section 2.2.4.3) have attained widespread 
use.  
2.2.4.1 Diagnostic criteria and reference standards 
Diagnostic criteria focus on the establishment of typical symptoms, signs and 
investigative findings in a distal symmetrical distribution71,87. The consensus 
evidence-based definition of DSP presented by the American Academy of 
Neurology concluded that emphasis should be placed on simple multi-criterion 
definitions which include assessment of a combination of neuropathic 
symptoms and signs, and that nerve conduction study should be integral to 
the case definition. A definition for small fibre neuropathy was deferred87. 
Benatar criticised the evidence informing this consensus statement for its 
predisposition to spectrum bias (the use of healthy controls, as opposed to 
controls with a risk profile similar to that of cases) and incorporation bias 
(when the instrument incorporates elements of the reference standard) which 
both artificially inflate sensitivity and specificity. The latter issue is partially a 
result of the lack of an independent gold reference standard36 (“the best 
available method for establishing the presence or absence of the condition of 
interest”96). Similarly, proposed diagnostic criteria for SFN in Devigili et al.84 













Lack of a gold standard not only limits development of a consensus DSP case 
definition, but also development and validation of screening instruments. Both 
have come to rely on multiple varied reference standards, such as neurologist 
assessment or quantitation of IENF densities, among others35,80,95  
(Figure  2-4).  
 
Figure 2-4  Schema of Brief Peripheral Neuropathy Screen (BPNS) and Total Neuropathy 
Score (TNS) validation studies. (1) McArthur80; (2) Cherry et al.35; (3) Cornblath et al.34; and 
(4) Ellis et al.95. SPNS=Subjective Peripheral Neuropathy Screen, QST=quantitative sensory 
testing, NCS=nerve conductions study, IENF=intraepidermal nerve fibre density quantitation, 
NSS=Neuropathy Symptom Score, NIS=Neurologic Impairment Score, mTNS=modified 
clinical TNS. 
 
Instrument-specific diagnostic criteria include the widely applied 
≥1 neuropathic symptom plus ≥1 neuropathic sign for the BPNS12,55,74,97, 
which improves sensitivity95 relative to the more stringent ≥1 neuropathic 
symptom plus ≥2 neuropathic signs11,13,22,77. The former definition was utilised 
in the validation of the BPNS35. ADSP may also be defined as ≥1 or ≥2 





























2.2.4.2 The Brief Peripheral Neuropathy Screen  
The purely clinical BPNS is adapted from the SPNS (Figure 2-4 ), an early 
symptom screening tool validated for the assessment of HIV-associated 
DSP80, Specifically, the symptom component of the BPNS is derived from the 
SPNS and is comprised of three 11-point numerical rating scales (NRS)s 
which patients use to rate symptoms of pain, paraesthesia and numbness 
from 0 (i.e. not present) to 10. In the BPNS, the highest NRS score 
(irrespective of specific modality) is used to establish a symptom grade. NRSs 
are widely used and well-established instruments for the measurement of 
pain98. The examination component of the BPNS includes assessment of 
ankle reflexes relative to knee reflexes and vibration sense at the big toe35. 
Though developed primarily for research purposes, the BPNS has also found 
clinical utility – a study of its acceptability to health practitioners found that its 
use impacted minimally on resources and time spent61,97. Two studies have 
validated the BPNS in HIV populations35,95 (Figure 2-4 ). 
2.2.4.3 The Total Neuropathy Score  
The TNS was developed for the assessment of chemotherapy-induced 
neuropathy and validated in this population against the Neuropathy Symptom 
Score and Neurologic Impairment Score (Figure 2-4 ) with good intrarater and 
interrater reliability (0.984 and 0.938, respectively)34. The score is a composite 
of clinical assessments (neuropathic symptoms, reflexes, pinprick sensation, 
vibration sense and motor function), nerve conduction study and quantitative 
sensory testing. It has been criticised for the inclusion of time-consuming and 
expensive investigations99 – exclusively clinical scales are considered more 
feasible in many research and clinical settings100.  
 
An attempt to remove these measures in order to simplify the TNS for HIV 
research purposes was presented in Evans et al. The analysis compared the 
full score with various combinations of TNS components (as well as EINF 
densities) using receiver operator characteristic curves. It showed that 
elimination of all TNS components other than quantitative sensory testing 












the full score with acceptable sensitivity and specificity (85% and 80%, 
respectively). The authors also presented an algorithm for the diagnosis of 
DSP using the simplified score; however, because of the necessity of 
retaining at least one aspect of quantitative sensory testing, the objective of 
developing an exclusively clinical tool was not met101. Nevertheless, a purely 
clinical modified TNS has been utilised in several studies11,63,95,102. 
Importantly, the modified TNS retains pinprick sensation as a measure of 
small-fibre function. A modified 16-point63 and 20-point TNS11 score have 
been used as markers of HIV-associated DSP severity. 
2.2.4.4 Symptom and single question screening 
A single question screen as a means of further simplifying diagnosis is 
proposed in Robinson-Papp et al.99 and Kandiah et al.103. In the former, “self-
reported” pain and/or paraesthesiae predicted the presence of at least one 
abnormal objective item on the TNS with a sensitivity of 52% and a specificity 
of 92%. The low sensitivity was likely as a result of the high frequency of 
ADSP in the population. The high specificity supports the presence of pain 
and/or paraesthesiae as a useful rule-in test for the diagnosis of DSP; 
however, as the presence of symptoms was actively queried, unsolicited self-
reported symptoms will not carry the same specificity – the use of the term 
“self-reported” in this study is therefore misleading. These findings contrast 
somewhat with those of Kandiah et al. in which a single question screen was 
compared to the BPNS with 96% sensitivity and 80% specificity103; however, 
incorporation bias might have played a role in inflating these data. The 
England et al. meta-analysis concludes that individual symptoms alone are 
poor indicators of DSP status87, because of the frequent finding of a number 
of patients with isolated neuropathic symptoms (in the absence of neuropathic 
signs) (see Section 2.2.5.2). 
2.2.5 Natural history 
2.2.5.1 Onset 
In isolated INH-PN, time to symptom onset is between 5 weeks and 6 months, 












For HIV-DSP symptom onset is slow and insidious60,82, with presentation 3-16 
months relative to documentation of HIV infection reported in one study85. The 
median time to onset of ATN after initiation of ART is 6 months75, with a peak 
at 3 months60. Compared to HIV-DSP, the onset of ATN is more abrupt33,82. 
 
In the HIV±ART+INH population in Lanternier et al., the mean time to onset of 
DSP after initiation of INH was 81 days (range 10-152 days)4. This is 
somewhat later than the median of two months reported in Dean et al.18. In 
Marks et al., DSP occurred entirely within the first four months of treatment, 
and this pattern of onset was similar in the INH only comparator group5. In the 
ART+INH population in Breen et al.2, four months (range 2-15 months) is 
reported. (See Table 2-1  for descriptions of these studies). The pattern of 
onset in these mixed populations is similar to that for the INH, HIV and ART 
only populations.  
2.2.5.2 Progression 
INH-PN is slowly progressive in terms of both symptoms and signs, both of 
which spread proximally68; paraesthesiae and numbness often precede 
painful symptoms65,69. This pattern has also been described in HIV-DSP91. In 
contrast, ATN progresses rapidly and pain is an early feature91. Later in the 
course of HIV-associated DSP, primarily positive symptoms evolve to 
primarily negative symptoms83.  
 
The review of Simpson and Tagliati suggests the possibility that ATN 
represents the unmasking of sub-clinical HIV-DSP71, while Marks et al. 
suggests clinical unmasking occurs by TB-infection5. It has been postulated 
that ADSP precedes the full DSP-complex33,79,97, but this has not been 
established: in a mixed cohort of ART-treated and -untreated individuals, 
ADSP did not predict incident DSP over 2.5 years of follow-up57. Pathological 
abnormalities have been noted prior to the onset of neuropathic 
symptoms84,90, however. Purely symptomatic individuals do not differ from 
asymptomatic individuals in terms of non-clinical objective measures of DSP, 












significance of isolated neuropathic symptoms as a clinical entity, or as a 
prodrome preceding demonstrable DSP, is yet to be determined.  
 
Progression from SFN to a mixed fibre picture has been described in non-
HIV/TB-associated DSP84. 
2.2.5.3 Reversibility 
In Breen et al.2, DSP is reported to have resolved after withdrawal of the 
d-drug component of the ART regimen; however, details regarding the rate 
and completeness of resolution are lacking for this observation, and further, 
the contribution of INH discontinuation at the end of anti-TB therapy to this 
reversibility is also unclear.  
 
In HIV-only populations, ATN is also reported to resolve after withdrawal of 
the d-drug: ATN resolved after didanosine (ddI) was withdrawn shortly 
(3-5 weeks) after ART-initiation in one report71; however, ATN may worsen 
initially after withdrawal (“coasting”), and resolution of ATN may not be 
complete – neuropathic signs persisted over a year after zalcitabine (ddC) 
withdrawal in another study33. In a recent large meta-study of RCTs, 
symptomatic DSP persisted in over a third of participants after withdrawal of 
d-drugs. In this study increa ing age was associated with decreased odds for 
recovery74. Similarly, INH-PN in TB-mono-infected populations resolves if INH 
is withdrawn soon after DSP onset, but prolonged use will result in a more 
protracted resolution, often with persisting neurological signs23,67,104.  
2.2.5.4 Distinguishing aetiological processes in HIV/TB 
Onset or worsening of DSP following initiation of a d-drug, and subsequent 
improvement following d-drug withdrawal suggests ATN91. Natural history can 
therefore offer clues to an aetiological diagnosis in HIV-associated DSP. In 
prospective study, the onset of DSP is observed; however, patient recall of 
symptom onset has also been used to retrospectively make an aetiological 
diagnosis54. In cross-section, the distinction between HIV-DSP and ATN has 
been made simply by the presence or absence of ART exposure11. In HIV/TB-












initiation of therapy has been employed: in Lanternier et al., DSP is attributed 
entirely to INH-PN4, and in Breen et al., DSP is attributed to ATN2.  
2.2.5.5 Longitudinal DSP assessment 
The study of DSP natural history contrasts with the longitudinal study of DSP 
incidence in that instruments are required that can detect changes in DSP 
severity over time; standard instruments such as the TNS and BPNS have not 
been validated for these purposes34. Nevertheless, the TNS has been used as 
a marker of DSP severity54, and absolute differences in TNS scores have 
been utilised as measures of change in DSP status over time, both in HIV and 
non-HIV populations77,100. Serial nerve conduction studies62 and quantitative 
sensory testing79 have both been utilised to assess DSP progression.  
 
Worsening of baseline DSP is an outcome measure in two longitudinal studies 
of HIV-associated DSP, albeit with contrasting but equally complex case 
definitions: Simpson et al.77 and Hung et al.22. 
2.3 Pathogenesis 
HIV/TB-associated DSP is a product of multiple intersecting pathogenic 
processes1. These are discussed under broad headings, with particular 
attention to the role of vitamin B6 and NAT2 acetylation. A proposed unified 
pathogenic model is also presented. 
2.3.1 Direction infection and immune factors  
Viral factors and immune responses are considered the primary pathogenic 
processes surrounding HIV-DSP.  
2.3.1.1 Direct infection 
HIV infection of nerve cell bodies in the dorsal root ganglion (DRG) has been 
demonstrated in autopsy specimens of patients with HIV-DSP105; however, 
this finding has not been consistent86, and local infection is now thought to be 
limited to Schwann cells and infiltrating macrophages33. The TB bacillus is not 












2.3.1.2 Viral toxicity and immune factors 
The HIV envelope-derived glycoprotein 120 (gp120) induces cytochrome c 
and caspase-dependent peripheral nerve apoptosis and axonal 
degeneration106. The mechanism of neuronal injury in DRG cell bodies is 
indirect: gp120 binds to the C-X-C chemokine receptor type 4 (CXCR4) on 
Schwann cells inducing “regulated upon activation, normal T-cell expressed 
and secreted” (RANTES)-mediated neuronal tumour necrosis factor-α (TNF-α) 
release. TNF-α then binds to TNF receptors on the neuron, and, in an 
autocrine fashion, results in apoptosis106 (Figure 2-5 ). Axonal injury may also 
be independent of cell body injury and Schwann cell chemokine release – 
gp120 will bind directly to axonal CXCR4 and C-C chemokine receptor type 5 
(CCR5) causing axonal degeneration107. Direct axonal injury suggests that cell 
body apoptosis may be a process separate to that causing axonal 
degeneration108, and may partially explain the distal length-dependent nature 
of HIV-associated DSP107. 
 
 
Figure 2-5  Model of glycoprotein 120 (gp120)-induced neuronal injury. HIV-derived gp120 
binds to C-X-C receptor type 4 (CXCR4) on Schwann cells causing release of “regulated 
upon activation, normal T-cell expressed and secreted” (RANTES). RANTES binds to C-C 
chemokine receptor type 5 (CCR5) on neuronal cell bodies, inducing release of tumour 
necrosis factor-α (TNF-α) which acts in an autocrine fashion on neurons, causing apoptosis. 
Adapted from Keswani et al.106. 
 
Peripheral nerve gp120 may be derived from the circulation or secreted from 
infiltrating macrophages106 – DRG infiltration by HIV-infected activated 
macrophages is a consistent finding in HIV-DSP10,16 (see Section 2.2.3.2). 
Macrophages, whose activation is unopposed because of HIV-induced 
immune dysregulation10,108, migrate to the DRG in response to gp120-
HIV 
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mediated neuronal injury109 where they may further contribute to neuronal 
injury by further cytokine release108, in addition to providing a source of gp120. 
Macrophage-derived cytokines also mediate neuropathic pain and 
hyperalgesia by binding to receptors on both injured and uninjured DRG cell 
bodies causing neuronal excitation or reducing the action potential 
threshold109. 
 
Concurrent gp120 and d-drugs may act synergistically to activate chemokine 
signalling pathways110 suggesting that immune factors may play a role in the 
pathogenesis of ATN109, in addition to those factors discussed in Section 
2.3.2.2. Though macrophages have been demonstrated in models of INH-PN 
(see Section 2.2.3.2), their contribution to neuronal injury in this context is not 
known. 
2.3.1.3 Inflammation 
HIV and TB are inflammatory disorders50,111, but the role of systemic 
inflammation in the pathogenesis of HIV/TB-associated DSP is not clear. 
Plasma TNF-α levels are elevated in TB50 but their effect on neurons in this 
context is not known. Research in ur group suggests that the incidence of 
ATN is not related to the elevation of any specific plasma inflammatory 
marker112. Systemic inflammation may represent an additional source of 
oxidative stress (see Section 2.3.2.2.2) and thereby contribute to the risk for 
DSP. 
2.3.2 Pharmacotherapeutic agents 
An array of pharmacotherapeutic agents may contribute to DSP in HIV/TB1,91; 
the focus here is on the role of INH and d-drug NRTIs.  
2.3.2.1 Isoniazid 
Isonicotinic acid hydrazide (hence “INH”), also known as isonicotinylhydrazide 
or isoniazid, is an anti-microbial agent with activity against mycobacteria 
currently used in combination anti-TB therapy. INH monotherapy has been 
used historically for the treatment of TB26,65,68, and is presently employed as 













The chemical structure of INH, which is characterised by a hydrazide 










Figure 2-6  Acetylation of isoniazid (INH). The chemical structure of INH (with the hydrazide 
functional group highlighted) and the acetylated derivative, acetylisoniazid (AcINH), are 
shown. The conversion to AcINH is catalysed by N-acetyltransferase 2 (NAT2); acetyl 
coenzyme A (AcCoA) provides the acetyl group. 
 
2.3.2.1.1 Metabolism of INH 
INH is metabolised extensively in humans113: the primary pathway is 
acetylation of the hydrazide functional group by the xenobiotic metabolising 
enzyme, NAT2, yielding acetylisoniazid (AcINH) (Figure 2-6 ), but other 
pathways are also involved. The acetylation of acetylhydrazine (an AcINH 
derivative), to diacetylehydrazine, is also mediated by the NAT2 enzyme114 
(Figure 2-7 ).  
 
 
Figure 2-7  Isoniazid metabolic pathways. NAT2=N-acetyltransferase 2. Adapted from 
Preziosi114 and Bryskier and Grosset115.  
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NAT2, which is expressed primarily in the cytosol of liver and gastrointestinal 
cells, acetylates a wide array of xenobiotics, in addition to INH, including other 
hydrazine drugs and carcinogenic aromatic amines114,116,117. Acetylation in 
humans is also mediated by the structurally similar N-acetyltransferase 1 
(NAT1) enzyme; however, NAT1 differs from NAT2 in terms of substrate 
affinity (although some overlap exists), and has a wider tissue expression118. 
NAT1 has not been implicated in the metabolism of INH114. 
 
The rate of NAT2 acetylation is variable among individuals within a particular 
population, as a result of variation in the highly polymorphic NAT2 gene (see 
Section 2.3.3.1)116,118. The distribution of acetylation phenotypes within a 
population is trimodal – individuals can be categorised as phenotypically slow, 
intermediate or fast acetylators119,120; the proportion of individuals expressing 
each of these phenotypes differs from population to population. In Asian 
populations, the slow phenotype is rare (5-30%), while in European and 
African populations the slow phenotype is more frequent (40-90%)30. 
Acetylation phenotypes have been characterised in some South African 
populations: the mixed ancestry (“Cape coloured”) population, which draws 
ancestry from Khoi-San, Asian, European and African population groups, 
demonstrates 35% slow acetylators119 while a mixed population in Cape Town 
demonstrated slow acetylation in 18%121. Phenotype distributions in South 
African populations have also been estimated from genetic studies (see 
Section 2.3.3.1). 
 
The acetylation phenotype results in differential risk for adverse drug 
reactions118,119. Slow acetylators receiving anti-TB therapy with INH reach 
higher INH plasma concentrations and are more prone to INH toxicity such as 
hepatitis and INH-PN that fast acetylators26,45,68. Fast acetylation is associated 
with lower INH concentrations, but acetylation phenotype has not been 
demonstrated to affect TB cure rates. However, the impact of this phenotype 













NAT2 acetylation phenotype can be determined by the administration of NAT2 
probe drugs followed by the measurement of metabolite and unchanged 
probe concentrations in plasma or urine, the ratios of which (the “metabolic 
ratio”) are used to estimate acetylation status29,50,119. The most commonly used 
NAT2 probe is caffeine, because of its relative safety and convenience, and 
because it is principally metabolised by NAT2122; this method has also been 
standardised and validated123. INH has also been utilised for acetylation 
phenotyping, because of its therapeutic relevance119,120. However, choice of 
metabolic probe may have an effect on the observed phenotype distribution 
and there is concern that phenotype classification is substrate-specific and not 
generalisable across the range of xenobiotics metabolised by NAT249,120; for 
example, discrepancies between observed phenotypes have been 
demonstrated for caffeine and sulphadimidine within the same population124.  
 
A number of other factors may further influence observed phenotype. NAT2 
activity is dependent on availability of the acetyl donor, acetyl-coenzyme A 
(acCoA), which may be depleted in certain clinical situations46,125. Reduced 
acetylation of a particular substrate may be a result of competitive inhibition of 
the enzyme by other xenobiotics; preferential acetylation of other substrates 
may also cause acCoA depletion47. However, exploratory data presented in 
O'Neil et al. did not support the hypothesis that acetylation of particular 
substrate is reduced by concomitant administration of other NAT2 substrates; 
further studies are required in this regard. Intra-individual variation in day-to-
day caffeine acetylation capacity is 11-14.5% and could account for 
misclassification of phenotype in individuals whose metabolic ratios straddle 
the antimode122. Impaired renal clearance45 might also account for phenotype 
variation.  
 
Disease states can influence acetylation ability, as has been postulated and 
demonstrated for diabetes, TB and HIV. The rate of acetylation is faster in 
type 1 diabetics, presumably as a result of hyperglycaemia increasing the 












on INH demonstrated a slow acetylation phenotype compared with 45% of 
healthy matched controls50. Slow acetylation phenotype was over-represented 
in patients with advanced HIV in one study, possibly because of 
genotype/phenotype discordance48 (see Section 2.3.3.1.1), but in another 
study of less advanced infection, the distribution was normal47. Cascorbi et al. 
found no differences in acetylation capacity between hospitalised patients and 
healthy controls122.  
2.3.2.1.2 Effect of INH on vitamin B6 metabolism 
Vitamin B6 refers to a group of several related compounds: pyridoxine, 
pyridoxal and pyridoxamine, along with their phosphorylated counterparts: 
pyridoxine 5'-phosphate, pyridoxal 5'-phosphate (PLP) and pyridoxamine 
5'-phosphate. Their interrelation and common metabolic pathways are shown 
in Figure 2-8 . The major metabolite of B6 metabolism is 4-pyridoxic acid 
(4PA), formed by the action of aldehyde dehydrogenase; it has no B6 activity 
and is excreted in the urine126. 
 
 
Figure 2-8  Pathways of vitamin B6 metabolism. The phosphorylation of pyridoxine, pyridoxal 
and pyridoxamine is catalysed by *pyridoxal kinase, while the reverse reaction is catalysed by 
**phosphorylases. All pathways, other than the formation of pyridoxic acid by ***aldehyde 
oxidase, are reversible. Adapted from Weiner and Klawans127; Brin126; and Meisenberg and 
Simmons128. 
 
The predominant active form, PLP, functions as a coenzyme in a wide range 
of metabolic reactions; transamination of amino acids and neurotransmitter 
synthesis are notable examples127,128. Synthesis of PLP is dependent on the 
phosphorylation of pyridoxal by pyridoxal kinase (Figure 2-8 )126 but its action 



























pyridoxal26,114. The inhibitory effect as evidenced by a reduced glutamic-
oxaloacetic transaminase (GOT) activity, a functional assay of PLP status 
(see Section 2.3.4.1.3), can be demonstrated even in patients receiving 
pyridoxine-supplemented INH and who have elevated total B6 blood levels26.  
 
In addition to its effect on pyridoxal kinase, the pyridoxal-INH complex also 
interferes with the function of B6 as a coenzyme; however, the effect is 
probably apoenzyne-specific127. Complex formation may also reduce the 
amount of B6 available for use by tissues114. Urinary loss of the complex, 
which is excreted proportionally to the dose of INH administered, results in B6 
deficiency23. The form of the pyridoxal-INH complex has been characterised 
as either pyridoxal isonicotinoyl hydrazone (a non-reversible imine)  


















Figure 2-9  Irreversible formation of pyridoxal isonicotinoyl hydrazone from pyridoxal and 
isoniazid (INH). 
 
Slow acetylators receiving INH demonstrate lower GOT activity than fast 
acetylators, but B6 concentrations do not differ between the two26. 
2.3.2.1.3 Neurotoxicity of INH 
The neurotoxicity profile of INH is characterised by both central and peripheral 
phenomena. Central effects include seizures; restlessness and irritability; 
nervous system depression; and cognitive impairment, which is reversible. 
INH can also trigger psychosis69. Toxicity to peripheral nerves is manifested 
as INH-PN, the epidemiology and clinical features of which are discussed in 
Sections 2.1.3 and 2.2.1. 
















B6 deficiency is widely accepted to account for the peripheral neurotoxicity of 
INH1,26,114 based on the observation that INH-PN occurs concurrently with a 
deficiency state26, and that it can be prevented by and reversed on 
administration of pyridoxine supplementation130 (see Section 2.4.1.2). Limited 
availability of B6 for use by neurons, with subsequent impaired 
neurotransmitter synthesis and impaired essential fatty acid metabolism, has 
been proposed as a possible mechanism of neuronal toxicity associated with 
B6 deficiency94,114,127. Another theory is that B6 deficiency disrupts ion 
gradients, thus accounting for the periaxonal swellings observed in 
histological specimens94. The predominant axonopathy of INH-PN supports 
the role of B6 – phosphorylation of pyridoxine occurs in the cell body and PLP 
is therefore more rapidly replaced proximally94. The precise mechanism of 
neurotoxicity associated with INH-induced B6 deficiency is still not 
conclusively established, however1. 
 
Slow acetylators experience INH-PN more frequently than fast acetylators 
(20% vs. 3% in Devadatta et al.) – presumably as a result of elevated plasma 
INH26,68. The role of NAT2 acetylation in reducing neurotoxicity is supported 
by the fact that the metabolite, AcINH, does not share the neurotoxicity profile 
of the non-acetylated drug113.   
 
The neurotoxic effects of INH may not be limited to those mediated by a 
functional and/or overt B6 deficiency. Hydrazines are toxic to dorsal root 
ganglia, plausibly as a result of free radical formation and resulting oxidative 
stress – in vitro neuronal cell death induced by hydrazine in one study was 
decreased in the presence of anti-oxidants, while pyridoxine was less 
protective131. Hydrazine toxicity may also account for the central nervous 
system effects of INH, in addition to other mechanisms, such as the inhibition 
of glutamic acid decarboxylase127. 
2.3.2.2 Nucleoside-analogue reverse transcriptase inhibitors 
NRTIs form the backbone of most first-line highly active cART regimens59. 












transcriptase, and by the termination of viral ribonucleic acid (RNA) 
transcription after incorporation of the nucleotide analogue into the growing 
RNA strand132. NRTIs must be phosphorylated intracellularly before this can 
occur133. 
2.3.2.2.1 Effect of NRTIs on mitochondrial function 
By similar mechanisms, NRTIs inhibit the function of mitochondrial 
polymerase-γ, the enzyme responsible for replication of mitochondrial DNA 
(mtDNA)133. The inhibition of polymerase-γ by NRTIs was initially thought to 
reduce mtDNA levels134; new evidence points to elevated levels, and the 
accumulation of mtDNA deletions and point mutations caused by increased 
turnover135. These mtDNA abnormalities cause defective structure and 
function of respiratory chain proteins leading to impaired oxidative 
phosphorylation, diversion to anaerobic metabolism and a rise in lactate132,136. 
Mitochondrial dysfunction also contributes to oxidative stress, the imbalance 
between the generation and clearance of reactive oxygen species, which can 
then cause further mitochondrial damage136. These mechanisms are thought 
to account for the various adverse effects associated with NRTI use: ATN, 
myopathy, pancreatitis, steatosis and potentially fatal lactic acidosis; a similar 
array of clinical manifestations are seen in inherited mitochondrial 
disorders133. 
2.3.2.2.2 Neurotoxicity of NRTIs 
Of the NRTIs, the dideoxynucleosides (hence “d-drugs”), ddC, ddI and d4T, 
can cause ATN33. The relative neurotoxicity of the d-drugs, in order of 
decreasing toxicity is: ddC > ddI > d4T137. Consequently, the former agents, 
ddC and ddI, are no longer widely used in first-line cART regimens; however, 
d4T is still utilised in resource limited settings22. 
 
Various explanations are offered for the differential neurotoxic effects of the 
d-drugs. The energy-intensive metabolism of neurons relies mostly on aerobic 
energy production – processes that disrupt oxidative phophorylation will 
therefore have an effect on neuron function132. Another proposed mechanism 












tissue-specific thymidine kinase isoforms, and the affinity of the enzyme for 
any particular nucleoside analogue133. The absence of neurotoxic effects 
induced by other non-d-drug NRTIs is also accounted for: zidovudine (AZT), 
for example, does not cause ATN because its inhibition of mitochondrial 
polymerase-γ occurs at concentrations higher than those causing cellular 
toxicity91. 
 
That ATN is related to a mitochondrial cytopathy is supported by the observed 
association between elevated serum lactate and ATN137 (although this has not 
been a consistent finding11,77), as well as the the presence of mitochondrial 
abnormalities in pathological specimens134 (see Section 2.2.3.2). The axonal 
and length-dependent nature of ATN lends further support: mtDNA mutations 
increase distally as a function of distance from the cell body, the site of 
mitochondrial biogenesis136, and height has been shown t  be a risk factor for 
HIV-associated DSP, at least by some groups12,55. 
2.3.2.3 Other agents 
Ethambutol, used in combination anti-TB therapy, can cause an optic neuritis 
in addition to sensory neuropathy in 4%. Cycloserine and ethionamide (both 
therapies for multidrug-resistant TB) are also associated with DSP, possibly 
through their interference with B6 metabolism1. Metronidazole, vincristine, 
steroids, dapsone, amphotericin B and phenytoin, agents that are used in the 
treatment of HIV-related illnesses, may all cause DSP91. Non-d-drug ART may 
be neurotoxic – a multivariate analysis in Ellis et al. found ART use predicted 
DSP even after adjustment for d-drug use13. Protease inhibitors may be 
implicated73,74, but their association with DSP has been questioned13. 
2.3.3 Genetic factors 
The NAT2 gene and its relation to acetylation phenotype will be the main 
focus of this section. Several genes that influence the risk for HIV-associated 
DSP will also be discussed. 
2.3.3.1 NAT2 
NAT2 codes for the acetylating enzyme, NAT2, whose role in the metabolism 












single-exon intronless gene that spans 870 base pairs (bp) and is located on 
chromosome 8p116. Variation in the NAT2 gene is a result of single-nucleotide 
polymorphisms (SNP)s of which at least 25 have been reported138. The 
functional effects of frequently encountered NAT2 SNPs have been 
determined using various in vitro, in vivo and in silico techniques116  
(Table 2-3 ). NAT2 SNPs can occur in combination – to date, 66 haplotypes 
have been describedin Human NAT2 alleles (haplotypes)139 (available from: 
http://n-acetyltransferasenomenclature.louisville.edu/) utilising the standard 
nomenclature. NAT2*4 is arbitrarily designated the wild type reference allele.  
 
Table 2-3  Common NAT2 single-nucleotide polymorphisms and associated amino acid 
changes, resultant functional effects and corresponding NAT2* haplotype clusters. 
SNP* Amino acid  ∆ Effect on NAT2 enzyme rs ID Cluster** 
  Activity Stability Levels   
G191A Arg64 → Gln ↓ ↓ ↓ 1801279 NAT2*14 
C282T None None None None 1041983 NAT2*13 
T341C Ile114 → Thr ↓ None ↓ 1801280 NAT2*5 
A434C Glu145 → Pro ↓ None ↓ - NAT2*17 
C481T None None None None 1799929 NAT2*11 
G590A Arg197 → Gln ↓ ↓ ↓ 1799930 NAT2*6 
A803G Lys268 → Thr None None None 1208 NAT2*12 
A845C Lys282 → Thr None*** None None 5605745 NAT2*18 
G857A Gly286 → Arg ↓ None ↓ 1799931 NAT2*7 
SNP=single nucleotide polymorphism, rs ID=restriction site identifier. 
*Relative to the NAT2*4 wild type allele. 
**Each SNP defines a haplotype cluster in the standard nomenclature139. 
***Substrate-dependent. 
Adapted from: Human NAT2 alleles (haplotypes)139 (available from: 
http://n-acetyltransferasenomenclature.louisville.edu/), Hein138 and Hein et al.140. 
 
NAT2 SNP and haplotype frequencies are population-dependent: for example, 
in African populations, the wild type allele is rare, whereas in European 
populations it is common116. Conversely, the G191A SNP is found in African 
populations, whereas it is not present in other populations141. Differences in 
haplotype frequencies account for the heterogeneity of acetylation phenotype 
distributions among populations116 (see Section 2.3.2.1.1).   
2.3.3.1.1 Prediction of acetylation phenotype 
The prediction of phenotype based on genotype is dependent on establishing 
the presence or absence of SNPs known to code for NAT2 enzymes with 
reduced activity (“slow alleles”) (Table 2-3 )138. Phenotypic expression of NAT2 
alleles follows a co-dominant pattern – slow alleles are additive at each locus 












alleles results in a slow phenotype, heterozygosity results in an intermediate 
phenotype and homozygosity for wild type alleles results in a fast 
phenotype119. However, a recessive pattern expressing a bimodal phenotype 
distribution, in which heterozygosity or homozygosity for a slow allele results 
in a slow phenotype, is cited widely in the literature46. Nonetheless, co-
dominance corresponding to a trimodal phenotype distribution is based on 
clear evidence, albeit under specific experimental conditions, and is the 
currently accepted view of NAT2 expression119,120. It should be noted, 
however, that one study failed to re-demonstrate a trimodal distribution under 
similar conditions69, and phenotype distribution as related to genotype may be 
population-specific46 or substrate-specific124 (i.e. trimodal for one particular 
population or substrate, bimodal for another). A “gene-dose” effect in which 
the total number of mutated alleles (slow and non-slow) are additive has also 
been proposed, but probably requires further exploration142. 
 
The concordance rate between actual phenotype and that predicted by 
genotype is 94-100%47,48,119. However, a number of caveats relate to the 
determination and prediction of acetylation status by both phenotyping and 
genotyping methods which may contribute to an apparent discordance138 
(Figure 2-10 ). Discordance can result in failure to identify disease association, 
and non-replication of findings138. 
 
Figure 2-10   Schema of factors influencing concordance and discordance between predicted 



















































Prediction of phenotype rests on the determination of slow alleles present in 
the genotype, but the assumption that a particular allele is slow or fast may 
not be true, resulting in discrepancies between observed and predicted 
phenotype123. Assuming that alleles defined as slow are in fact true slow 
alleles, failure to type any of these alleles, particularly if frequent in a given 
population (for example, the G191A in Hispanics, Arabs and South Indians), 
will result in bias towards non-slow predicted phenotypes46. Population 
differences in predicted phenotype distribution among studies have been 
attributed in part to differences in the completeness of genotyping48.   
 
Another caveat in the literature is the failure to recognise a co-dominant 
expression pattern and resulting trimodal distribution of acetylation phenotype 
in the population – some instances of genotype/phenotype discordance, for 
example in Bolt et al.123, are readily explained by the trimodal model. 
 
Polymorphisms in non-coding regions may a play a role in NAT2 transcription, 
translation, expression and phenotype. Polymorphisms in the NAT2 promoter 
region have been identified; however, their functional significance has not 
been characterised143,144. No NAT2 epigenetic factors are known46. Silent 
NAT2 mutations, such as the C282T, do not alter the amino acid sequence and 
are therefore not assumed to have any functional effect (Table 2-3 ); however, 
this concept has been challenged by findings that suggest that silent 
mutations may affect codon usage and messenger RNA folding, and thereby 
alter protein translation and function145. Although probably not playing a role in 
INH acetylation, NAT1 has been shown to overlap somewhat with NAT2 in 
terms of substrate-specificity, and is also subject to genetic variation – failure 
to account for the contribution of NAT1 to acetylation may be a factor leading 
to discordance116.  
 
When heterozygous slow alleles are present at two or more loci, the genotype 
is said to be ambiguous and phenotype prediction requires the determination 
of the phase of each allele – if located on the same chromosome, the opposite 
chromosome will carry no slow alleles and the predicted phenotype will be 












mutated116. Phase can be resolved by parental genotyping and other 
molecular or computational techniques146. 
 
Apparent discordance between observed and predicted phenotype may be 
substrate-dependent: discordance has been shown to be greater for caffeine 
than for dapsone49,138. Such discrepancies may limit the utility of both 
genotyping and phenotyping tests in disease-association studies124. 
 
Finally, discordance was demonstrated in a cohort of moderately advanced 
HIV patients wherein 24% of those with a fast predicted phenotype were 
found to be slow acetylators on caffeine phenotyping, and 12% demonstrated 
the reverse (slow to fast)49. In this study, markers of immune suppression did 
not predict discordance; however, patients with less advanced HIV do not 
demonstrate discordance47. 
 
Other factors that influence the observed phenotype and thereby apparent 
concordance with genotype are discussed in Section 2.3.2.1.1. 
2.3.3.1.2 NAT2 and DSP risk 
NAT2 genotype (as opposed to phenotype) has not been studied extensively 
in relation to the incidence of INH-PN. In Hiratsuka et al., an INH-mono-
treated cohort, all of two cases of INH-PN occurred in genotypically slow 
acetylators; however, as the INH-PN group formed part of the total adverse 
event group in the analysis, genotypic risk for INH-PN was not established. It 
is worth noting that, in this study, predicted phenotypes corresponded with 
metabolic ratios, but not with INH concentrations (see below). The observed 
association between acetylation and INH-related adverse reactions may be 
attributable to a metabolic process unrelated to absolute INH concentration45.  
 
NAT2 as an independent risk factor for HIV-associated DSP is currently being 
investigated in our group. 
2.3.3.2 Other genetic factors 
The variably penetrant apolipoprotein E4 allele, which has received attention 












nervous system disease, was shown to be associated with HIV-DSP in a 
small longitudinal study147. Delayed peripheral nerve regeneration, as 
demonstrated in mouse models148, may account for the association. 
 
The presence of mitochondrial haplogroup T in white patients receiving either 
ddI plus d4T-based or AZT plus lamivudine-based cART regimens was 
demonstrated to independently increase the odds for ATN; the odds were 
further increased in those receiving the former regimen (i.e. two d-drugs), 
reflecting an increased mitochondrial susceptibility to mitochondrial-toxic 
agents conferred by this haplogroup. The frequency of this allele in the white 
population is estimated at 10-15%149. 
  
In the same cohort, heterozygosity for the G845A mutation in the 
haemochromatosis CFE gene was shown to independently decrease the odds 
for ATN induced by d-drug use; the odds were further reduced by limiting the 
analysis to white participants. Ten percent of the white population are 
heterozygous carriers of the mutation150.  
 
The TNFA-1031*2 allele, coding for a variant TNF-α protein, has also been 
shown to increase the risk for ATN54. A mutation of the mitochondrial 
polymerase-γ gene could increase susceptibility to d-drug-induced 
mitochondrial toxicity151, although an association with ATN has not yet been 
demonstrated. 
2.3.4 Metabolic and nutritional factors 
The most clearly defined nutritional factor relating to HIV/TB-associated DSP 
is vitamin B6 deficiency; its association with INH-PN is reviewed in Section 
2.3.2.1.3. The possible contribution of dietary B6 deficiency to DSP, as well as 
the role of other metabolic and nutritional factors, are discussed here.  
2.3.4.1 Vitamin B6 
2.3.4.1.1 Dietary source and deficiency 
Vitamin B6 is obtained from the diet mainly as pyridoxine and its glucoside 












offal is particularly B6-rich. Absorption of B6 takes place by passive diffusion 
primarily in the jejunum, and the bioavailability of dietary B6 is about 
75%126,152,153. Markers of B6 status correlate with dietary intake, particularly as 
intake levels approach those approximating that obtained from pyridoxine 
supplementation27. 
   
B6 deficiency is rare in the general population, and when present is usually a 
component of a multivitamin deficiency130. At risk are pregnant women, the 
elderly, alcohol abusers and those with bowel and renal disease130,153,154. Both 
HIV-infection and TB are associated with B6 deficiency, irrespective of 
concurrent treatment status. In one study, ART-naïve males with WHO stage I 
HIV disease had significantly reduced markers of B6 status when compared 
with matched controls, and over a third demonstrated overt deficiency, despite 
adequate dietary B6 intake and without clinically demonstrable deficiency27. In 
a cohort of 20 South African TB-infected patients, five of whom were HIV/TB 
co-infected, B6 deficiency was universal prior to the start of anti-TB therapy28. 
In a cohort of children receiving INH (along with 0.5-1.0 mg/day 
supplementary pyridoxine), 50% of those who were HIV-infected were 
B6-deficient, compared with 15% of those who were HIV-uninfected43. 
Ongoing research in our group demonstrates that HIV-infected individuals are 
B6-deficient before and after commencing cART: of 159 patients in our 
outpatient cohort, almost all of whom received vitamin B-complex, 51% were 
B6-deficient at baseline, and 54% after three months of cART112. 
 
Proposed mechanisms of B6 deficiency in HIV-infected individuals with 
adequate dietary B6 intake include malabsorption from enteropathy, renal 
losses and impaired B6 metabolism from hepatic insufficiency27. Another 
possible mechanism is inflammation, which is associated with B6 deficiency in 
rheumatoid arthritis155. A similar association may be implicated in 
HIV-infection and TB, as systemic inflammation is prominent in both50,111. The 
acute phase response has been proposed to explain the presence of B6 
deficiency in TB-infected individuals prior to anti-TB therapy28. This is based 
on evidence that deficiency demonstrated in healthy patients undergoing 












be explained by a concurrent drop in albumin, a known acute phase 
indicator154,156, and the primary B6-carrier protein (see Section 2.4.1.2.3). 
Hypoalbuminaemia is also common in both HIV-infection and TB157. Finally, 
as muscle is the primary store of B6 in the body155, muscular wasting, also 
common in HIV/TB157, could be implicated.  
2.3.4.1.2 The role of dietary B6 deficiency in DSP 
There are no descriptions of DSP resulting from a pure dietary B6 deficiency 
(although central nervous system effects are seen in severe deficiency 
states)130,158 which may suggest that pure dietary deficiency is not an 
important contributory factor to HIV/TB-associated DSP. However, pre-
existing B6 deficiency could well be exacerbated by INH administration, 
increasing the risk for DSP, and the need for supplementation. This has been 
proposed in Marks et al.5 but has not been shown. Possible explanations for 
the discrepancy in risk for DSP between INH-induced and dietary B6 
deficiency include a B6-independent INH neurotoxicity114 (see Section 
2.3.2.1.3), and the complex metabolism of B6 being affected differentially by 
each aetiological process, with differing resultant phenotypes127. Inflammation 
and immune dysregulation contribute to HIV-associated DSP (see Section 
2.3.1) and are also associated with B6 deficiency27,156 – the association might 
be causal. Diabetics with neuropathy demonstrated lower serum pyridoxal 
when compared to diabetics without neuropathy in one study159, but a follow-
up RCT failed to show a benefit of pyridoxine supplementation in alleviating 
diabetic neuropathy160.  
2.3.4.1.3 B6 status estimation 
In humans, B6 status can be assessed by various assays performed on blood, 
plasma/serum and urine samples, and are generally directed at estimation of 
the circulating active coenzyme, PLP, currently considered the best 
approximation of whole body B6 status42,155. The assertion that PLP alone is 
an adequate estimate has been challenged, however41 – the recommendation 














Table 2-4  Indirect and direct assays of vitamin B6 status. 
Assay  Biochemical pathway Method Notes 











xanthurenate in urine by 
chomatographic methods 
following an oral load of 2 
grams of tryptophan 
 









in methionine catabolic 
pathway 
 
Measurement of urinary 
cystathionine following 












Measurement of the 
activity of erythrocyte 
alanine or aspartate 
transaminases before 
and after stimulation with 
excess PLP and 
expressed as a ratio 
 
Indicator of long 
term status - delay 
in reflecting recent 











labelled CO2 released by 





Direct  methods 
   
Total B6 
 
 Microbiological assay No longer in use 
Pyridoxal 
5‘-phosphate  





























PLP=pyridoxal 5‘-phosphate, GOT=glutamate oxeloacetate transaminase, EAST=erythrocyte 
aspartic acid transaminase. 
Adapted from: Shane162, Ubbink et al.163, Leklem41, Rybak and Pfeiffer42 and Cilliers et al.43. 
 
Several indirect and direct methods of B6 estimation have been developed. 
Indirect methods are functional assays that estimate PLP concentration by the 
measurement of apoenzyme activity both in vivo and in vitro41 (Table 2-4 ), 












review23,26-28,43,155. However, these methods are imperfect and 
conflicting26,44,161. 
 
Direct estimation of B6 is achieved through microbiological and 
chromatographic assays. The former measures total B626; the latter allows 
independent quantitation of the different B6 fractions, including 4PA42,153. 
Refinement of HPLC methods has resulted in sensitive and precise 
estimations of B6 status42. 
2.3.4.2 Malnutrition and other vitamin deficiencies 
Malnutrition is frequent in HIV/TB populations; several micronutrient 
deficiencies have been described of which several are known to cause 
syndromes with DSP as a component. Deficiencies associated with TB are 
thiamine, folate and vitamin E; these are also seen in HIV, along with B12 
deficiency153,157. The latter and its relation to HIV-associated DSP was studied 
in a selected sample of HIV-infected patients on AZT: a third with DSP 
demonstrated B12 deficiency compared to none without DSP. In the same 
study, improvement in neurological signs occurred in 5/8 receiving B12 
replacement, thereby strengthening the association and the assertion that B12 
deficiency is contributory to HIV-associated DSP164; however, there is some 
doubt about the relevance of this evidence153. Reduced antioxidant activity in 
vitamin E deficiency may also play a contributory role165. 
 
While it is conceivable that various vitamin deficiencies can contribute to 
HIV/TB-associated DSP, the extent of the contribution is not known59.  
2.3.4.3 Other metabolic factors 
The metabolic syndrome, defined as the presence of three or more of 
hypertension, dyslipidaemia, dysglycaemia and obesity, was an independent 
risk factor for small fibre neuropathy in a retrospective study of a mixed 
neuropathy population166. Similarly, elements of the metabolic syndrome 
(hypertriglyceridaemia and diabetes) are associated with HIV-associated 
DSP11,37. HIV infection and ART use can increase risk for the metabolic 












an increasingly ageing ART-treated population may also contribute by 
accumulation of metabolic risk factors37. Alcoholism is a known cause of 
neuropathy, most likely as a result of a multivitamin deficiency, and is 
therefore a plausible contributory factor to HIV/TB-associated DSP153; 
however, the evidence does not reflect this (Table 2-2 ). HIV-infected 
individuals suffering with DSP may turn to alcohol for relief of symptoms167. 
2.3.5 Model 
It is evident that HIV/TB-associated DSP pathogenesis is multi-factorial. The 
prevailing hypothesis is that peripheral nerve injury is cumulative over time 
and each neurological insult is contributory to the final clinicopathological 
phenotype, and to the final clinically relevant endpoint of DSP: pain19,33,71. 
Figure 2-11 presents a hypothetical model based on that in Cherry et al.33, 
and is a synthesis of the evidence for HIV/TB-associated DSP presented in 
this review. 
2.4 Treatment and prevention 
Neuropathic pain responds poorly to analgesia17, and in HIV, impairs quality 
of life13-15 and is associated with maladaptive behaviours21,168. Both 
pharmacological and non-pharmacological approaches to the treatment and 
prevention of DSP in HIV/TB are explored in this section. 
2.4.1 Pharmacological therapies 
Treatment of HIV-associated DSP is largely symptomatic, as there are 
currently no disease-modifying agents16, though cytokine receptors are a 
promising therapeutic target109. Oral pyridoxine supplementation is an 
established prevention and treatment strategy for INH-PN. 
2.4.1.1 Symptomatic treatment of neuropathic pain 
HIV-related pain is under-treated in a South African setting169; HIV-associated 
DSP is a notable example – in one study, under 7% of symptomatic 
individuals were receiving analgesia for their neuropathic pain11. Under-
diagnosis, under-estimation and under-treatment are recognised issues in the 



























































Three major classes of pharmacotherapeutic agents are used for symptomatic 
relief of neuropathic pain: antidepressants (amitriptyline, duloxetine, 
venlafaxine), anti-epileptic drugs (carbamazepine, gabapentin, lamotragine, 
pregabalin) and topical agents (capsaicin, lignocaine)16. Non-steroidal anti-
inflammatories, paracetamol and opioids are also used to treat neuropathic 
pain, but are unproven16,71.  
 
The tricyclic antidepressant, amitriptyline, which is commonly prescribed for 
neuropathic pain in South Africa19, is poorly effective170 – a recent meta-
analysis presented a numbers needed to treat (NNT) of >10 for HIV-
associated DSP. Pregabalin had a similar NNT in this analysis while 
lamotrigine fared better (NNT=~5), as did topical capsaicin (NNT=6.5)17. 
Pregabalin is considered a promising agent but was found to be mostly 
ineffective in an RCT; methodological issues in this study might have 
contributed to the negative findings78. An international multi-centre trial 
reinvestigating this agent is currently under way.  
2.4.1.2 Pyridoxine 
2.4.1.2.1 Indications 
In individuals with a low risk profile for B6 deficiency or DSP, it is not 
considered necessary to give supplementary pyridoxine routinely during 
standard dose INH therapy – the incidence of INH-PN in this group is 
extremely low130. In high-dose INH therapy, as employed in the 1950s, the 
addition of pyridoxine should prevent the majority of INH-PN cases that would 
be expected in unsupplemented therapy at similar INH doses23,26. Based on 
both observation76,104 and clinical prudence130, pyridoxine supplementation is 
recommended in high risk groups (see Section 2.3.4.1.1), even during low-
dose INH therapy. However, HIV is not mentioned as a high risk group in the 
South African TB management guidelines24 in contrast to international 
guidelines and the South African Medicines Formulary which recommend 













Once INH-PN is established in unsupplemented anti-TB therapy with INH, 
treatment with pyridoxine can be effective67; earlier pyridoxine therapy is 
associated with a better neurological outcome26,67. 
 
It is not known whether pyridoxine supplementation has any impact on the 
incidence of HIV-associated DSP (in the absence of INH therapy), and 
whether it might have any therapeutic value – our group is currently 
investigating the role of vitamin B6 in HIV-associated DSP112. 
2.4.1.2.2 Dosage 
Consensus is lacking in terms of the optimum dose of prophylactic pyridoxine; 
dosing guidelines are inconsistent with recommended doses ranging from 
10-50 mg/day1,171. Pyridoxine needs are probably a function of INH dose104 
but doses as low as 6 mg/day have been demonstrated to prevent INH-PN 
during high-dose INH in TB mono-infected26. In HIV/TB co-infection, 10 
mg/day pyridoxine failed to prevent incident DSP as reported in Marks et al.5; 
in light of pre-existing B6 deficiency (see Section 2.3.4.1.1) there is value in 
reinvestigating B6 needs in this group. 
 
Recommended dosages for treatment of INH-PN are usually higher than 
those for prophylaxis1: 50-200 mg/day in the South African Medicines 
Formulary172. Recommendations are contradictory in the South African TB 
management guidelines: 10-25, 25 and 100 mg/day are cited in three 
separate instances within the same document24. The basis for the increased 
dose approach is not clear. 
2.4.1.2.3 Pharmacokinetics and effect on B6 status 
Oral pyridoxine, generally given as the hydrochloride, is readily absorbed from 
the gut into the systemic circulation by first-order kinetics; particular 
formulations can influence bioavailability, however173. Soon after oral 
ingestion, PLP levels rise and return close to baseline levels after 
5-6 hours162. After a period of daily supplementation, PLP levels increase 
>10-fold and 4PA levels increase around 50-fold from baseline physiological 












however,154,163,173 and appear to be saturable at higher dosages (>50 mg/day) 
– PLP in plasma is bound to albumin and levels of the two are 
correlated154,161. Excess unbound PLP is probably hydrolysed and excreted as 
4PA154,163. Consequently, there appears to be little benefit conferred by high-
dose pyridoxine regimens in terms of B6 status. 
 
As studies of B6 status during supplementation are limited to those performed 
on healthy volunteers, little is known about pyridoxine pharmacokinetics in 
disease states163,173. Furthermore, determination of pharmacokinetic 
parameters is particularly challenging. Parameters are influenced not only by 
the agent itself, but also by baseline B6 status, dietary and endogenous 
factors. Further complications arise because of the lack of consensus on the 
most representative marker of B6 status154,173. 
2.4.1.2.4 Toxicity 
Pyridoxine in doses of ≥2 g/day is known to cause a sensory neuropathy 
characterised by neuropathic pain; impaired reflexes, vibration, light touch, 
pinprick and temperature sensation; ataxia; abnormal nerve conduction study 
findings; and sensory neuronopathy on histological examination174. These 
doses are far higher than those recommended for INH-PN prevention and 
treatment (see Section 2.4.1.2.2); doses up to 100 mg/day are considered 
safe1. A single case report describes aggravation of pre-existing INH-PN by 
pyridoxine at a dose of 150 mg/day175. In vitro neurotoxicity has been 
demonstrated in dorsal root ganglia and may be attributable to feedback 
inhibition of pyridoxal kinase175. 
2.4.1.3 Multivitamin supplementation 
A RCT of multivitamin supplementation demonstrated reduced DSP in the 
treatment arm of the trial, which comprised both INH and HIV+INH 
participants176, but the influence of the pyridoxine component (25 mg) could 
easily have accounted for the reduction in risk177 whereas administration of 
vitamin B-complex not containing B6 failed to prevent INH-PN in TB mono-












of protective effect of B-complex supplementation in an out-patient ART 
cohort112. 
2.4.2 Non-pharmacological therapies 
Withdrawal of the d-drug is a self-evident approach to the management of 
ATN12,16; dose reduction might also be effective71. Withdrawal of INH is 
indicated in severe cases of INH-PN, but pyridoxine supplementation is 
preferable in most cases23,67.  
 
Acupuncture has been trialled for HIV-associated DSP and found to be largely 
ineffective170; however, other complementary therapies such as reflexology, 
massage and meditation were reported to offer relief in a large multi-centre 
survey of HIV-associated DSP self-management. Self-care practices such as 
taking a hot bath, staying off feet, exercise and rubbing were also effective for 
some167. Lack of effective therapies might cause individuals to turn to 
alternative methods of pain control, some of which are maladaptive – up to 
30% reported use of alcohol and/or illicit substances in the above-mentioned 
survey; in particular, more severe pain was associated with increased use of 
“hard” drugs168. The contribution of psychological factors, such as depression 
or pain catastrophising, to the perception of and coping mechanisms 
associated with neuropathic pain are under-estimated. These factors should 
be addressed appropriately and holistically21,167. 
2.4.3 Prevention 
Pyridoxine is effective for the prophylaxis of INH-PN (see Section 2.4.1.2.2) 
but prevention strategies for HIV-associated DSP are limited. There is some 
evidence that earlier initiation of ART (at CD4+ T cell counts >350 cells/µl) 
might be protective13. Identification of risk factors for DSP and the avoidance 
of d‑drugs in patients at risk is a strategy that has received attention in the 
literature12,54,55. Avoidance of d-drugs is obviously dependent on the 
availability of alternatives – while d4T is being phased out in South Africa178, 













Study design and methodology. 
3.1 Ethics approval 
The study was approved by the University of Cape Town Human Research 
Ethics Committee (REC REF: 079/2010).  
3.2 Study design 
The study design is that of a prospective analytical non-interventional cohort 
with a baseline cross-sectional component. The primary outcomes were 
baseline (prevalent) and incident or worsening DSP. The primary exposures 
of interest were plasma PLP deficiency and a slow predicted NAT2 acetylation 
phenotype. 
3.2.1 Study site 
The study was undertaken at DP Marais SANTA TB Hospital (DPM), a public 
sector hospital located in Retreat, Cape Town, South Africa. 
3.2.1.1 Site access 
Site access was granted by the Division of District Health Services and 
Programmes, Provincial Government of the Western Cape in February 2010 
(2010 RP 27). 
3.2.1.2 About DPM 
DPM is a 260-bedded hospital which, in conjunction with Brooklyn Chest 
Hospital in Ysterplaat, Cape Town, provides inpatient services for adult TB 
patients referred from all primary, secondary and tertiary facilities in the 
greater Cape Town region. DPM is primarily a male hospital, while Brooklyn 
Chest caters for female patients; however, there are both male and female 
wards at each – the male-to-female bed ratio at DPM is 4.2:1. According to 
hospital records, the bed occupancy rates average 82.4%, with approximately 
20 admissions per week. The average admission period is two months, but 












extended stays (several months). The approximate mortality rate at DPM is 
5-8 patients/month. 
 
National guidelines24 inform the management of patients at DPM. Anti-TB 
regimen 1 is prescribed for new TB cases while regimen 2 is for retreatment 
cases (Table 3-1 ). Patients receive fixed dose combinations of the oral agents 
according to weight; specifically, patients receive 4-6 mg/kg of INH daily, 
irrespective of regimen or phase of treatment. At the time of admission to 
DPM, the majority of patients will have already initiated anti-TB therapy at the 
referring facility. While not stipulated in national guidelines24 (see Section 
2.4.1.2.1), supplemental prophylactic pyridoxine-HCl is administered to all 
patients admitted to DPM at a dosage of at least 25 mg/day, in addition to two 
vitamin B-complex tablets, each containing 0.5 mg pyridoxine. The usual 
practice at DPM is to prescribe 25 mg/day on admission, but if DSP is 
diagnosed, the dose is boosted to 50 or 100 mg/day. Amitriptyline is 
commonly prescribed in escalating doses for symptomatic relief. All morning 
medications, including anti-TB therapy and pyridoxine, are dispensed daily at 
08:00. 
 
Table 3-1  Department of Health National TB Guidelines anti-TB regimens. 
 Intensive phase Continuation phase 




















Adapted from Department of Health24. 
 
HIV-infected patients not on cART at the time of their admission to DPM are 
assessed for eligibility for treatment according to national guidelines178, and 
are worked up in a separately run onsite ART clinic. Prior to May 2010 (during 












or AZT; in May 2010 the national guidelines switched d4T to tenofovir (TDF) 
as the preferred first-line NRTI backbone agent (but d4T could still be 
prescribed if TDF and AZT were contraindicated, and could be continued in 
those stable on therapy) (Table 3-2 ). 
 
Table 3-2  New South African Antiretroviral Treatment Guidelines regimens. 
 NRTI “backbone” Second NRTI NNRTI/PI 
First-line regimen Tenofovir (TDF) or 
Zidovudine (AZT) or 
Stavudine (d4T) 
Lamivudine (3TC) or 
Emtricitabine (FTC) 
Efavirenz (EFV) or 
Nevirapine (NVP) 
Second-line regimen Zidovudine (AZT) or 
Tenofovir (TDF) 
Lamivudine (3TC) or 
Emtricitabine (FTC) 
Lopinavir + Ritonavir 
(LPV/r) 
NRTI=nucleoside/nucleotide reverse transcriptase inhibitor, NNRTI=non-nucleoside reverse 
transcriptase inhibitor, PI=protease inhibitor 
Adapted from Department of Health178. 
 
Similar to many public sector institutions in South Africa, DPM is a resource-
constrained environment – for example, with one part-time doctor and three 
full-time doctors during the study period, the patient-doctor ratio was around 
60:1. The hospital also has no x-ray facilities, no on-site laboratory and a 
limited dispensary.  
3.2.1.3 Patient population 
Patients are referred to DPM for a variety of reasons including, but not limited 
to, a requirement for continuing inpatient care after stabilisation on anti-TB 
therapy; significant co-morbidities or disability; drug resistant TB; adverse 
drug reactions necessitating monitoring and drug re-challenge; a poor 
compliance history; indigence or other social issues; substance abuse; mental 
illness or other cognitive impairment; and poor clinic access (particularly for 
patients on regimen 2 who require daily intramuscular streptomycin 
injections). The result is a heterogeneous inpatient population comprising both 
relatively well and unwell patients. The former are admitted for mostly 
practical reasons and are ambulant, while the latter are largely ill, but stable, 
patients with co-morbidities – acutely ill patients cannot be accommodated at 
DPM. Around 70% of admissions to DPM are HIV co-infected, and represent 
a spectrum of degree of immune suppression, and current or previous 













3.2.2 Selection criteria and sampling methods 
DPM inpatients satisfying the following criteria were eligible for enrolment in 
the study:  
 
Inclusion criteria 
1. Age ≥ 18; 
2. HIV/TB co-infection; and 
3. The patient understood the purpose and requirements of the study and 
provided written informed consent. 
 
Exclusion criteria 
1. Cognitive impairment which was felt to preclude informed consent or 
cooperation with the study protocol; 
2. Signs and symptoms suggestive of either a radiculopathy or myelopathy, 
or other focal neurological signs, that, in the opinion of the investigator, 
complicated the diagnosis of DSP; 
3. Spinal or CNS infection – these carry an increased risk for potentially 
confounding focal neurology and/or cognitive impairment; 
4. Patient was deemed generally too ill to participate in the study or to reliably 
complete study follow-up; 
5. The use of non-standard anti-TB therapy regimens, such as those for post-
drug toxicity re-challenge or multi-drug resistant TB – because of variation 
in treatment exposures and potential confounding; 
6. Diabetes mellitus – because of the high risk of potentially confounding 
peripheral neuropathy; 
7. Pregnancy – because of potentially confounding vitamin B6 deficiency; 
8. Inability to obtain consent because the patient was not aware of or in 
denial about their HIV status; and 
9. Inability to assess limbs symmetrically – for example, one or more limbs 













The following criteria were also applied during the initial pilot period, before 
the study design was modified (see Section 3.2.5): 
 
1. ART-naïve or no ART exposure within the preceding three months; and 
2. Qualified for ART according to national guidelines (at the time, CD4+ T cell 
count <200 cells/µl). 
 
During the initial pilot period (see Section 3.2.5), sampling was convenience; 
thereafter, sampling was sequential (consecutive eligible admissions). 
3.2.3 Case definitions and outcomes 
DSP was defined as the presence of ≥1 neuropathic symptom and 
≥1 neuropathic sign. No DSP or DSP-free was defined in all participants not 
satisfying the above criteria, including those classified with ADSP (symptom-
free and with ≥1 neuropathic sign).  
  
Incident DSP was defined in either those participants who were DSP-free at 
baseline and subsequently developed DSP at follow-up (thus including those 
with ADSP at baseline who developed symptoms at follow-up). Worsening 
DSP was defined in participants who had DSP at baseline and subsequently 
demonstrated a 2-point increase in the NRS for pain and/or paraesthesia, or a 
2-point increase in the composite 20-point TNS score (for a description of the 
TNS see Sections 2.2.4.3 and 3.3.6). Longitudinal outcomes are tabulated in 
Table  3-3. 
 
Table 3-3  Incident and worsening DSP definitions. 
Baseline Follow-up 
 Incident DSP Worsening DSP 
DSP-free 
 
New symptoms and signs  
Asymptomatic DSP New symptoms 
 
 
Symptoms only New signs 
 
 
(Symptomatic) DSP  2-point increase in NRS for pain and/or 
paraesthesia, or 
2-point increase in TNS score* 
DSP=distal sensory polyneuropathy, NRS=numerical rating scale, TNS=Total Neuropathy  
Score 












DSP severity was gauged by the composite 20-point TNS score. Higher 
scores denoted more severe DSP. 
 
Participant recall of the temporal relationship between neuropathic symptom 
onset and the onset of TB symptoms, the initiation of anti-TB therapy and the 
initiation of cART if he or she was receiving cART, guided the assignment of a 
baseline aetiological diagnosis: HIV-DSP, ATN or INH-PN. Neuropathic 
symptom onset concurrent with TB symptom onset was further labelled as 
possible “TB-DSP” (Table 3-4 ). 
 
Table 3-4  Assignment of aetiological diagnosis based on participant recall of relation of 
neuropathic symptom onset to TB symptoms, anti-TB therapy and ART. 
Neuropathic symptom onset* Diagnosis 








Concurrent with TB 
symptoms but before 
anti-TB therapy 
 





HIV-DSP (or “TB-DSP”) 
 
ATN 






DSP=distal sensory polyneuropathy, ART=antiretroviral therapy, ATN=antiretroviral 
toxic neuropathy, INH-PN=isoniazid-induced peripheral neuropathy 
*Based on participant recall. 
 
3.2.4 Study schedule and censorship 
Participants were assessed at baseline shortly after admission to DPM and 
then four-weekly for the period of admission (Table 3-5 ). 
 
Study censorship occurred on patient discharge or transfer from DPM 
(including self-discharge); withdrawal of consent (opting out); the development 
of drug toxicity and acute illness preventing continuation with the study; or at 
the end of the study period (17 August 2011). Transferred patients who later 
returned to DPM continued to be followed-up monthly if possible, even if they 













Table 3-5  Study schema. 
Evaluation Baseline Longitudinal follow-up* 
Informed consent X  
Documentation of HIV status X  
Medical and social history X  
Medication review (anti-TB therapy, 
ART, pyridoxine or other) 
X X 
Neuropathy assessments 
  BPNS 








  NAT2 genotype (9 ml EDTA) 







ART=antiretroviral therapy, BPNS=Brief Peripheral Neuropathy Screen, TNS=Total 
Neuropathy Score, NAT2=n-acetyltransferase 2, PLP=pyridoxal 5‘-phosphate, 
4PA=4-pyridoxic acid 
*Longitudinal follow-up performed four-weekly for duration of admission. 
 
3.2.5 Pilot study 
An initial pilot period ran from 1 March - 26 April 2010. In the original study 
protocol, it was envisaged that participants would be followed from just prior to 
the initiation of cART and for a period of at least two months thereafter; the 
emphasis was on longitudinally assessing the impact of ART on vitamin B6 
status and the risk for DSP (this design is employed by another study in our 
group). However, during the pilot period, it was found that in many cases the 
period of admission was far shorter than anticipated. It also became apparent 
that only a minority of patients were ART-naïve and also eligible for cART 
(according to the more restrictive national guidelines in place at the time) and 
in those patients who were eligible for cART, there was a significant lag 
between admission and cART initiation. The potential for long-term follow-up 
was then further reduced. Consequently, a decision was taken by our group to 
relax the study criteria to include all HIV-infected admissions regardless of 
ART treatment status (see Section 3.2.2). This would improve enrolment rates 
and also provide a baseline comparator. Pilot participants were included as 
part of the final sample but were not included in descriptions and comparisons 













3.3 Study procedures 
3.3.1 Field visits 
Field visits to DPM took place bi-weekly (Mondays and Wednesdays). During 
the morning, potential and enrolled study participants were identified and 
located. Two lists were compiled and provided by DPM administrative staff for 
this purpose: a recent admissions list and a discharge list. Folders of new 
admissions were reviewed for eligibility. Participants already enrolled and due 
for imminent discharge were prioritised for follow-up assessment if this had 
not occurred in the preceding two weeks. Study assessments were begun at 
13:00 and were done consecutively. 
3.3.2 Facilities 
Study procedures, including taking of informed consent, clinical assessments 
and blood sampling, were conducted in a private consultation room allocated 
specifically for study purposes during the afternoons of field visit days. 
3.3.3 Personnel 
All field visits and nearly all neurological assessments were performed 
personally. I was accompanied on most visits to DPM by a registered nurse 
who assisted with translation, informed consent, folder review, participant co-
ordination and blood sampling. 
3.3.4 Informed consent 
All subjects provided written informed consent and retained a patient 
information sheet (Appendix 1). The information sheet was not available in 
translated versions; however, the consent process was performed in the 
preferred language of the subject (English, Afrikaans or IsiXhosa) by a fluent 
speaker. Consent was provided for both the clinical and investigational 
aspects of the study – permission was granted or denied for the NAT2 genetic 












3.3.5 General history and folder review 
The following data were documented based on history provided by the 
participant and confirmed where necessary by folder review: general medical 
history including previous TB episodes; duration of current TB episode; site of 
TB infection; anti-TB regimen administered; HIV status and period of infection; 
WHO clinical stage; previous ART exposure and/or current cART regimen; 
current and previous pyridoxine dose and period of supplementation; and 
other current medication. If a diagnosis of DSP was recorded in the patient 
folder, this was also documented. A single question alcohol screen179 was 
used to identify problem drinking. Height and weight measurements were 
obtained. Self-assigned race category was obtained from hospital records. 
 
Results of the following basic chemistry, haematology and serology laboratory 
investigations, provided by the National Health Laboratory Services (NHLS), 
were obtained by folder review: serum urea, creatinine, alanine transferase 
and aspartate transferase; white cell count, haemoglobin, mean red cell 
volume, platelet count and CD4+ T cell count; and hepatitis B surface antigen. 
Results of investigations confirming TB infection (direct observation of acid 
fast bacilli, culture, polymerase chain reaction, fluid adenosine deaminase or 
radiological confirmation) were also obtained. Where results were unavailable 
an attempt was made to locate them using the NHLS website. 
 
Data were recorded on a data collection form (Appendix 2). 
3.3.6 DSP assessment 
DSP was assessed using both the BPNS and the modified clinical TNS11 (see 
Section 2.2.4.3), complemented by additional questioning. 
3.3.6.1 Neuropathic symptoms 
To assess neuropathic symptoms, participants were shown three 11-point 
visual NRSs (also translated into isiXhosa) for each of the modalities of pain, 
paraesthesia and numbness, as per the BPNS. Participants selected a rating 
from 0 (no pain) to 10 (worst pain) for each. The single highest NRS score of 












(grade 0 for no symptoms; 1 for a highest score of 1-3; 2 for 4-6; 3 for 7-8; and 
4 for 9-10). In the TNS, sensory symptoms in all modalities are assessed as a 
single entity and scored by anatomical extent rather than severity. A higher 
score is obtained for more proximal involvement (0 for no symptoms; 1 for 
soles/toe; 2 for ankle; 3 for knee; and 4 for more proximal involvement). In 
addition to the above, the presence or absence of lower limb cramps was 
established.  
 
An effort was made to characterise symptoms as neuropathic in nature; that 
is, distal-to-proximal, symmetrical and not related to other pathologies (spinal, 
joint, musculoskeletal or dermatological). If the pattern of symptoms was 
obviously non-neuropathic in nature this was noted on the data collection form 
and a score of 0 was given. 
 
If symptoms were absent at the time of the baseline assessment, an enquiry 
was made as to whether any symptoms had been experienced in the past 
(yes or no). At baseline, participants were asked to recall the onset of 
symptoms (if present) relative to the onset of TB symptoms and the initiation 
of anti-TB therapy (before TB symptoms; concurrent with TB symptoms but 
before anti-TB therapy; after anti-TB therapy; or unsure). At baseline and 
follow-up, prevalent or incident symptoms were compared to the onset of 
cART initiation (before, after or unsure). At follow-up, a 5-point patient global 
impression of change (PGIC) was used to assess subjective change in 
symptom status if symptoms had been present at the previous visit.  
3.3.6.2 Neuropathic signs 
For the examination portion of the assessment, subjects were seated facing 
the examiner with their lower limbs exposed and hanging over the edge of an 
examination couch. All procedures were explained clearly to the patient 
beforehand. Vibration sense was assessed at the distal interphalangeal joint 
of each first toe by the firm application of a vibrating 128 Hz tuning fork. In the 
BPNS, the vibratory thresholds are recorded for each toe and a score is 












TNS, the extent of impaired vibratory thresholds (<10s) is recorded in a similar 
fashion to that for symptoms (see above).  
 
Tendon reflexes were assessed using a long-handled patellar hammer with a 
weighted circular rubberised head. Ankle reflexes were elicited by first 
dorsiflexing the foot with one hand and then striking the Achilles tendon with 
the hammer. While dorsiflexing a finger was placed on the tibialis anterior 
tendon to ensure the subject was not flexing of his or her own accord. Clonus 
was assessed by rapid dorsiflexion of the foot; more than two beats was 
considered abnormal. The ankle reflex response was assessed using that of 
the knees as a reference. In the BPNS, only ankle reflexes are considered 
(4 for absent; 3 for reduced; 2 for normal; 1 for hyperactive; and 0 for clonus). 
In the TNS, all reflexes are considered (0 for all normal; 1 for ankle reflexes 
reduced; 2 for ankle reflexes absent; 3 for ankle reflexes absent and others 
reduced; and 4 for all reflexes absent).  
 
Pinprick sensation and power were assessed as part of the TNS. Impairment 
of pinprick sensation was assessed anatomically, again scored as for 
symptoms (see above), while toe/ankle dorsiflexion was assessed using the 
Medical Research Council (MRC) grading system (0-4). In addition, 
proprioception at the big toe was assessed (normal, reduced or absent). 
 
Neuropathy findings were recorded on a neuropathy capture form 
(Appendix 3). 
3.3.7 Blood sampling and sample handling 
Peripheral venous blood was drawn with 22 gauge needles by standard 
techniques and utilising the Vacutainer system (BD, Franklin Lakes, NJ, USA). 
If venous access was difficult, no more than two attempts at venepuncture 
were made. One 9 ml clot-activated sample (for serum) and one EDTA 
sample (for buffy coat and plasma) were obtained at each visit (Table 3-5 ). 
The samples were placed immediately within a cool box containing frozen ice 














The number of hours that had elapsed since the morning dosing of pyridoxine 
supplementation (08:00) was recorded. Samples were obtained a minimum of 
five hours post-dosing; plasma PLP levels approach pre-trough levels after 
4 6 hours162. 
3.4 Plasma vitamin B6 HPLC 
Plasma PLP and 4PA were determined by HPLC at the Centers for Disease 
Control and Prevention, Atlanta, GA, USA. Samples for a pilot analysis were 
selected sequentially: the first 25 patients with any follow-up data were 
analysed. Preparation of the samples was as follows: plasma was fractioned 
from whole blood by centrifugation within 1-4 hours of sample acquisition; 
exposure to light was minimised and the samples were kept cool in the interim 
period. Storage was at -80°C until cold-chain air shipp ing to Atlanta. HPLC 
was performed according to the method of Rybak et al.42,180. Vitamin B6 
deficiency was defined as <30 nmol/l153. 
3.5 NAT2 molecular methods 
NAT2 genetic variation was assessed by both genotyping and sequencing, 
and NAT2 acetylation phenotype predicted in a subset of the cohort (all 
participants with any longitudinal follow-up data).  
3.5.1 Genotyping 
Genotyping was performed utilising a combination of polymerase chain 
reaction (PCR), restriction fragment length polymorphism (RFLP) analysis and 
allele-specific amplification, as adapted from the method of Doll et al.181. 
Genotype was determined at the following positions: 191, 282, 341, 434, 481, 
590, 803, 845 and 857. 
3.5.1.1 NAT2 amplification by polymerase chain reaction 
Deoxyribonucleic acid (DNA) was extracted from buffy coat isolated from 
peripheral blood using the QIAamp Mini Kit (Qiagen, Hilden, Germany) 
according to the instructions of the manufacturer. Each DNA sample was 












optimised PCR in a 100 µl mixture containing ≤150 ng DNA; 0.04 µmol mixed 
dideoxynucleotides (dNTPs); 0.01 µmol MgCl2; and 2.5 units (u) 
Taq polymerase in corresponding reaction buffer (Promega, Madison, WI, 
USA) and distilled water using the NAT2-specific primers, 
5'-ATGGACATTGAAGCATATTTT-3' (forward) and 5'-AAGGGTTTATTTTG-
TTCCTTAT-3' (reverse) (Integrated DNA Technologies, Coralville, IA, USA), 
under thermocycling conditions summarised in Table  3-6. The resulting 
predicted 895 bp fragment was then electrophoresed in an ethidium bromide-
containing agarose gel and visualised under ultraviolet light. 
 
Table 3-6  Cycling conditions for NAT2 PCR, allele-specific PCR and cycle sequencing. 
 NAT2 PCR Allele-specific PCR Cycle sequencing 
PCR step  Temperature* Duration Temperature* Duration Temperature* Duration 






















Final extension 72º 5 min 72º 5 min - - 
PCR=polymerase chain reaction.  
*Temperatures are in degrees Celsius. 
 
3.5.1.2 Restriction fragment length polymorphism analysis 
Seven restriction enzymes in four separate reactions, “A”, “B”, “C” and ”D”, 
were used to identify the presence of eight different SNPs in the NAT2 gene: 
G191A, C282T, A434C, C481T, G590A, A803G, A845C and G857A. The restriction 
enzymes used in each reaction, along with their recognition and cleavage 
sites, are listed in Table 3-7 . A schematic representation of the cleavage of 
the 895 bp NAT2 fragment, as predicted by RestrictionMapper version 3 
(available from: http://www.restrictionmapper.org/), is presented in Figure 3-1 . 
Each 40 µl enzyme digestion reaction contained 20 µl PCR products and 10 u 
of each restriction enzyme in corresponding reaction buffer (Fermentas, 
Vilnius, Lithuania) and distilled water, and was incubated as per Table 3-6 . 
Digestion products were applied to a 2-3% ethidium bromide-containing 
agarose gel and electrophoresed at 80-100 V for 1-2.5 hours, visualised and 
photographed. 
 













Figure 3-1  Schema of the predicted cleavage of the NAT2 fragment in each restriction 
enzyme digestion “A”, “B”, “C” and “D”.
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Table 3-7  Restriction enzyme digestion mixtures, recognition and cleavage sites and 
incubation conditions. 

















37° 3 h 
“D” HpyF3I (DdeI) 5’-C^TNAG-3’ (3) 37° 3 h 
*BseGI corresponds to FokI, AdeI to DraIII and HpyF3I to DdeI.  
**The 5’-3’ recognition sequence only is presented; the point of cleavage is represented 
by a caret. Overhang on the complementary strand is represented in parentheses as the 
number of base pairs difference; for AdeI/DraIII the cleaved 3’-5’ strand has a 3 bp 
overhang. 
 
3.5.1.3 Allele-specific amplification 
In order to detect the presence of the T341C SNP, allele-specific PCR was 
employed. After optimisation for temperature and MgCl2 concentration, a 25 µl 
reaction mixture was set up containing ≤100 ng genomic DNA; 0.01 µmol 
mixed dNTPs; 0.04 µmol MgCl2 and 1 u Taq polymerase in corresponding 
reaction buffer (Promega, Madison, WI, USA) and distilled water, and run 
according to cycling conditions in Table 3-6 . In two separate reactions, the 
forward primer, 5'-CTCCTGCAGGTGACCAT-3', was used to selectively 
amplify wild-type NAT2 at the 341 locus and 5'-CTCCTGCAGGTGACCAC-3' 
was used to amplify the C-substitution. The reverse primer used in both 
reactions was 5'-GGAGACGTCTGCAGGTATG-3'. All primers utilised in the 
allele-specific PCR were manufactured by Inqaba Biotec (Cape Town, South 
Africa). Each reaction was loaded separately onto a 1.5% ethidium bromide-
containing agarose gel and electrophoresed at 160 V for 45 min before 
visualisation. 
3.5.2 Sequencing 
Confirmation of genotype by sequencing was performed in a subset of 
samples. Cycle sequencing of 10 µl reactions containing 2 µl PCR products; 
2 µl dye termination mix and 2 µl corresponding buffer (Applied Biosystems, 
Foster City, CA, USA); and 3 µl distilled water was done according to cycling 












forward and reverse NAT2 primers as per Section 3.5.1.1. After ethanol 
precipitation, the samples were capillary electrophoresed on an ABI PRISM 
3130X genetic analyser (Applied Biosystems, Foster City, CA, USA) and an 
electropherogram was generated.  
 
Two computer programs, BioEdit Sequence Alignment Editor version 
7.0.9.0182 and ChromasPro version 1.5 (Technelysium Pty Ltd, Tewantin, 
QLD, Australia) were used to visually examine the electropherogram and 
confirm the corresponding nucleotide sequence before aligning both forward 
and reverse sequences with the reference NAT2*4 sequence (GenBank: 
X14672.1).  
3.5.3 Genetic analysis and phenotype prediction 
SNP frequencies were evaluated for Hardy-Weinberg equilibrium using the 
χ2 test for goodness of fit to detect differences between observed and 
predicted frequencies of homozygous and heterozygous SNPs. The level of 
significance was 0.05 (df=1). 
 
A diplotype with nine positions (191, 282, 341, 434, 481, 590, 803, 845 and 
857) was generated based on: 0=two wild-type alleles, 1=heterozygous for the 
SNP and 2=homozygous for the SNP. Probable NAT2 haplotypes and 
frequencies were then predicted using computational haplotyping: diplotypes 
were entered into PHASE version 2.1.1183,184 and initial settings set at 1 000 
iterations, 500 burn-in iterations and a thinning interval of 1, as described by 
Agúndez et al.146. As this resulted in inconsistent total numbers and 
frequencies of predicted haplotypes, burn-in iterations were increased to 
10 000, and iterations increased stepwise from 10 000 through 20 000, 
100 000 and 500 000 until haplotype frequencies were consistent within 0.1% 
among eight independent runs, each run based on a random number seed 
obtained from RANDOM.ORG (available from: http://www.random.org). 
Recombinant rate variation modelling was not specified, and the default model 
was used. Predicted haplotypes were then matched to known haplotypes  














Phenotype was predicted based on the number of homozygous or 
heterozygous slow alleles: G191A, T341C, A434C, G590A, A845C and G857A 
(Table 3-8 ). In the case of heterozygosity for two or more slow alleles, the 
ambiguity in the prediction of phenotype was as a result of the inability to 
determine the phase of the slow alleles (i.e. if located on the same 
chromosome the predicted phenotype would be intermediate; if located on 
opposite chromosomes, slow). The phase of ambiguous genotypes was 
informed by the reconstructed haplotypes generated by PHASE. 
 
Table 3-8  Prediction of phenotype based on number of homozygous and heterozygous slow 
alleles. 
Homozygous slow alleles* Heterozygous slow alleles* Predicted phenotype 
0 0 Fast 
0 1 Intermediate 
0 ≥2 Intermediate or slow (ambiguous) 
≥1 Any number Slow 
*Slow alleles were G191A, T341C, A434C, G590A, A845C and G857A. 
 
To assess genotypic associations with outcomes, binary variables were 
generated. For SNPs: homozygous vs. heterozygous/wild type alleles, and for 
phenotypes: slow vs. intermediate/fast. Haplotype frequencies were compared 
between those with and without baseline DSP, and between race groups, 
using the PHASE case-control function. 
3.6 Data management and analysis 
3.6.1 Data capture and management 
Data were captured personally and entered into an Access 2007 relational 
database (Microsoft Corporation, Redmond, WA, USA). The database was 
designed in two parts: a baseline cross-sectional table and a stacked 
longitudinal table. Queries were built using the Structured Query Language to 
extract and recode data from the database while preserving the integrity of the 
original dataset. The database was password-protected and contained no 
identifiable data other than patient initials and date of birth. Data were 
imported directly and dynamically into the statistical software using Open 












3.6.2 Statistical methods 
Stata version 11 (College Station, TX, USA) was used for statistical analysis. 
STATA is one of only a few widely available packages capable of performing 
a generalised linear models analysis for estimating prevalence ratios (see 
below). Graphical representations, other than those generated by Stata for the 
survival analysis, were drawn by GraphPad Prism version 5.04 (La Jolla, CA, 
USA). Probability (p) values were considered significant at <0.05. All statistical 
analyses were supervised by a statistician, Dr Henri Carrara, School of Public 
Health and Medicine, University of Cape Town. 
3.6.2.1 Baseline (cross-sectional) data 
Descriptive statistics were used to define the study sample: binary data were 
described by frequencies and proportions; the mean and standard deviation 
(SD) were calculated for continuous data that were established as normally 
distributed on Shapiro-Wilk testing (p≥0.05), or after appropriate 
transformation. The median and first to third quartiles (Q1-Q3) were calculated 
for ordinal or non-normally distributed continuous data. However, the mean 
and SD were used to describe neuropathy scores. Baseline characteristics 
were tested for association with baseline DSP by the use of the χ2 test, rank-
sum test and Student’s t-test, as appropriate. The prevalence ratio (PR) and 
95%CI was then estimated by generalised linear models using Stata’s glm 
command (a Gaussian distribution was specified) with DSP as the dependent 
variable. All crude ratios were adjusted for age and gender. Multivariate 
analysis was performed based on p<0.2 on univariate analysis. The strength 
and significance of the correlation between numerical variables was 
established by Pearson and Spearman rank-sum testing: for normally 
distributed continuous variables the former was utilised, and for one or two 
ordinal or non-normally distributed continuous variables, the latter. GraphPad 
Prism was then used to estimate and plot the function and 95%CI of the 
correlation by linear regression. 
3.6.2.2 Follow-up (longitudinal) data 
The Student’s t-test for paired samples and Wilcoxon rank-sum test for 












and follow-up. Non-parametric trend estimation using Stata’s nptrend 
command was employed to assess the significance of increasing or 
decreasing trends in the values of continuous variables over multiple time 
points. DSP incidence and rate of worsening with corresponding 95%CIs were 
calculated using Stata’s stptime command and the denominator adjusted to 
100 person-months. A Kaplan-Meir survival analysis described the 
probabilities of remaining DSP-free, or free of worsening DSP, through the 
course of the study. A “left-shifted” survival analysis was also run using 
historical data collected from participants and folders – the date of initiation of 
anti-TB therapy was used as the origin of the analysis, and participant report 
of symptom onset relative to this “virtual” time point informed failure status. In 
other words, if symptom onset was after anti-TB therapy initiation, the 
participant would fail at the baseline assessment. The Cox proportional 
hazards model compared the hazards of incident/worsening DSP conferred by 
fixed baseline covariates, and a hazard ratio (HR) plus 95%CI was calculated. 
Again, all crude ratios were adjusted for age and gender, and multivariate 
analysis was performed based on p<0.2 on univariate analysis. 
3.6.2.3 Sample size 
Based on 170 potentially eligible patients at DPM in a 12-month period, and 
expecting a 60% (+/- 5%) DSP frequency (based on Maritz et al.11), 













The study findings are presented in terms of two analyses: a cross-sectional 
analysis at baseline and a longitudinal analysis. Results of the PLP/4PA 
HPLC and NAT2 genetic analysis are presented in detail separately.   
4.1 Sample 
The study sample comprised 116 participants. During the period 1-24 March 
2010, prior to systematic screening of admissions, 14 eligible patients referred 
by DPM medical staff provided informed consent and enrolled into the study. 
Between 25 March 2010 and 11 April 2011*, 881 admissions were screened, 
of which a further 109 patients met eligibility criteria, provided informed 
consent and enrolled into the study (Figure 4-1 ). Of the 160 patients who 
were approached to take part in the study, 36 (23.0%) declined to participate 
and 15 (9.0%) were unable to provide consent because they were either 
unaware of their HIV infection status or because they did not understand the 
purpose and procedure of the study. Twenty-one pilot participants were 
included in the final sample. 
 
After enrolment, six participants were excluded because of the uncovering of 
pre-existing focal neurological signs or neurological disease. An additional 
participant (T095) who, at baseline, had distal symmetrical sensory symptoms 
and signs subsequently developed a motor neuropathy; nerve conduction 
studies confirmed demyelinating sensorimotor polyneuropathy and he was 
excluded. 
 
Eighty-one participants (70.0%) had one or more follow-up assessments; 55 
(47.0%) had two follow-up assessments (i.e. up to and including the eight 
week assessment), the minimum follow-up period anticipated at the start of 
the study. The mean attrition rate was 43.3% per visit. For those participants 
with any follow-up, the median duration of participation in the study was 56 
                                            












days (1st quartile [Q1]-3rd quartile [Q3] 29-63). Reasons for loss-to-follow-up 
were varied (Figure 4-2 ). 
 
 
Figure 4-1   Flowchart of screening, selection and enrolment process. *Tthere was a one 
month break in recruitment from 18/11/10-14/12/10 due to an injury. **Based on folder review. 
***See Section 3.2.5. ****Based on examination plus further folder review. 
 
Readmissions:  61 
Unavailable: 78  
 Already discharged or transferred: 71 
 Died shortly after admission: 7 
No data: 62 
 
Admitted: 1082  
Screened: 881  
Not eligible: 710  
 Not confirmed HIV-infected: 313 (36%) 
   HIV uninfected: 289  
   Untested: 24 
 Non-standard anti-TB regimens: 180 (20%) 
   Multi-drug resistance: 146 
   Rechallenge: 34 
 Too ill: 85 (10%) 
 Pre-existing neurological disease**: 52 (6%) 
 Confused: 34 (4%) 
 Did not meet pilot criteria***: 23 (3%) 
 Diabetes mellitus: 11 (1%) 
 Limb amputated or in cast: 4  
 Pregnant: 4 
 Confirmed short admission: 3 
 Under 18 years: 1 
  
Eligible: 171  
Did not consent: 51  
 Declined: 36 
 Unable to consent: 15 
Missed: 11  
Enrolled: 108  
Excluded: 7  
 Presence of pre-existing neurology****: 7 
  

















Figure 4-2   Flowchart of participant retention and attrition. 
 
4.2 Baseline cross-sectional analysis 
4.2.1 Baseline characteristics 
Baseline characteristics of the study sample are summarised in Table 4-1 . All 
participants had reliably confirmed TB infection, and HIV infection was 
documented in the clinical notes of all participants enrolled; all participants 
Baseline assessment: 116  
Lost to follow -up: 36  
 Discharged: 11 
 Too ill or developed treatment toxicity: 8 
 Transferred: 7 
 Opted out: 5 
 Self-discharged: 3 
 Died: 2 
Four week assessment: 80  
Lost to follow -up: 26  
 Discharged: 17 
 Too ill or developed treatment toxicity: 2 
 Transferred: 1 
 Opted out: 3 
 Self-discharged: 2 
 Died: 1 
Eight week assessment: 54  
Lost to follow -up: 34  
 Discharged: 29 
 Transferred: 1 
 Opted out: 2 
 Self-discharged: 2 
Twelve week assessment: 20  
Lost to follow -up: 34  
 Discharged: 9 
 Self-discharged: 1 
Sixteen week assessment: 10  
Lost to follow -up: 4  
 Discharged: 4 
Twenty week assessment: 6  
Lost to fo llow -up: 5  
 Discharged: 5 












confirmed that they were aware of their HIV status. HIV infection was present 
(time since diagnosis) a median of nine months (Q1-Q3 2.4-46.2), as 
documented in the clinical notes, or based on participant recall. The majority 
were either black South African (predominantly isiXhosa-speaking) (52.6%), 
or mixed ancestry (46.5%); one participant was black Mozambican.  
 
Table 4-1  Baseline demographic and clinical characteristics. 
Characteristic Reference n=116  
Age, years, mean (SD)*   35.9 (8.4) 
Female, n (%)   64 (55.2) 
Race, n (%)     
  Black   62 (53.5) 
  Mixed   54 (46.5) 
Weight, kg, mean (SD)*   48.7 (9.9) 
Height, cm, median (Q1-Q3)  n=112 164.5 (157-170) 
BMI, kg/m2, mean (SD)*  n=112 18.3 (3.6) 
Problem alcohol use, n (%)   41 (35.3) 
Renal dysfunction, n (%)   8 (6.9) 
TB diagnosis, n (%)     
  Pulmonary   75 (64.7) 
  Extra-pulmonary    13 (11.2) 
  Disseminated   28 (24.1) 
INH/weight, mg/kg, median (Q1-Q3)   5.0 (4.6-5.4) 
Previous TB, n (%)   71 (61.2) 
Pyridoxine dose, mg/day, n (%)     
  25   88 (75.9) 
  ≥50   28 (24.1) 
WHO stage IV, n (%)   61 (52.6) 
CD4+, cells/µl3, median (Q1-Q3)  n=114 101.5 (45-189) 
Current cART, n (%)  n=95** 24 (25.3) 
  d4T backbone, n (%)   10 (10.5) 
  TDF backbone, n (%)   9 (9.5) 
  AZT backbone, n (%)   5 (5.3) 
Previous cART, n (%)   28 (24.1) 
cART ever, n (%)  n=95** 39 (33.6) 
  d4T ever, n (%)  n=95** 17 (14.7) 
Creatinine, µmol/l, median (Q1-Q3) 49-104 n=107 63 (50-76) 
eGFR***, ml/min, median (Q1-Q3)  n=107 92.4 (66.9-117.8) 
ALT, IU/l, mean (SD)* 5-40 n=89  34.8 (49.2) 
Hb, g/dl, median (Q1-Q3)* 13-17 n=104 9.3 (7.6-10.2) 
WCC, x 109/l, median (Q1-Q3)* 4-10 n=103 6.5 (3.6-8.6) 
SD=standard deviation, Q1=1st quartile, Q3=3rd quartile, BMI=body mass index, 
INH=isoniazid, WHO=World Health Organisation, CD4+=CD4+ T cell count, 
cART=combination antiretroviral therapy, d4T=stavudine, TDF=tenofovir, 
AZT=zidovudine, cART=combination antiretroviral therapy, eGFR=estimated 
glomerular filtration rate, ALT=alanine transaminase, Hb=haemoglobin, WCC=white 
cell count. 
*Data deemed normal by Shapiro-Wilk testing (p≥0.05) (after transformation to 
inverse for age and BMI; to inverse of square root for weight and ALT; and without 
transformation for Hb). 
**Pilot sample excluded. 













The baseline assessment was performed a median of 5 days (Q1-Q3 2-7) 
after admission to DPM and 16.5 days (Q1-Q3 11-39.5) after the initiation of 
anti-TB therapy. In the majority (90.5%), anti-TB therapy was commenced at 
the referral facility; the remainder initiated treatment after admission to DPM 
(Figure 4-3 ). All participants were receiving intensive phase anti-TB regimens 
at the time of the baseline assessment. Regimen 2 (see Section 3.2.1.2) was 
prescribed for TB retreatment in 68 (58.6%) participants; three participants 
with a history of previous TB did not receive regimen 2.  
 
All participants were receiving at least 25 mg/day of supplementary pyridoxine 
at the time of the baseline assessment; however, 41 (39% of those who 
initiated treatment at a referral facility) did not recall having received 
pyridoxine supplementation prior to referral, and there was also no 
documentation of supplementation in the transfer letter of these participants. 
Most participants also received two tablets of vitamin B complex daily, each 
tablet containing an additional 0.5 mg of pyridoxine; two participants did not 
receive B complex, and one received one tablet/day only.  
 
The first 21 participants were cART-naïve due to the more restrictive inclusion 
criteria implemented during the pilot period (see Section 3.2.5); these 
participants have not been included in descriptions and analysis of baseline 
cART status. In subsequent participants, at baseline, cART was ongoing in 
24 (25.3%) for a median duration of 20 days (Q1-Q3 4-120) (Figure 4-3 ). The 
majority of participants (90.5%) were receiving co-trimoxazole prophylaxis; 
those not receiving it did so presumably in omission as they were not 
receiving dapsone. 
 
Routine laboratory test results for serum urea were available for 
60 participants in whom the median level was 3.9 mmol/l (Q1-Q3 2.5-5.6); all 
were normal, aside for that of one participant who had HIV-associated 
nephropathy. Liver function tests other than ALT were available in a minority 
only. Hepatitis B surface antigen test results were available for 53 participants, 
and were positive in four (8.0%). HIV viral load assessments were not done or 













Females differed from males in terms of baseline characteristics: females 
were younger (34.4 vs. 37.8; p=0.029), lighter (46.9 vs. 51.0 kg; p=0.005) and 
shorter (159 vs. 170 cm; p<0.001) (but BMIs were no different). They also had 
lower CD4+ T cell counts (76 vs. 155 cells/µl3; p=0.016) and lower 
haemoglobin levels (8.7 vs. 9.6 g/dl; p=0.040). 
4.2.2 Baseline DSP 
At baseline, DSP (≥1 neuropathic symptom plus ≥1 neuropathic sign) was 
present in 65 participants (56.0%) (Table 4-2 ). Using the more stringent 
criteria of ≥1 neuropathic symptom plus ≥2 neuropathic signs, the frequency 
of baseline DSP was 41 (35.3%). Based on the criteria presented in 
Section 3.2.3, baseline DSP was ascribed to HIV (HIV-DSP) in 31 (47.7%), to 
INH (INH-PN) in 24 (36.9%) and to ongoing ART (ATN) in three (4.6%); the 
aetiology was indeterminate in seven (10.8%). Of those classified as 
HIV-DSP, 17 (57.0%) reported neuropathic symptom onset concurrent with 
the onset of TB symptoms (but prior to the initiation of anti-TB therapy).  
 
Neuropathic symptoms were severe by BPNS sensory grade (highest NRS 
score ≥7) in 53.9% of those participants with baseline DSP. The most 
commonly reported symptom was pain (69.2%), and the mean NRS score for 
this modality was 4.5 (SD 3.9). Examination findings suggested a primarily 
small fibre DSP (impaired pinprick sensation only) in 21.9%, a primarily large 
fibre DSP (impaired vibration sense and/or reduced or absent ankle reflexes) 
in 26.6% and mixed fibre involvement in 51.6%. Fourteen participants 
exhibited weakness of toe and ankle dorsiflexion – the weakness was mild 
(MRC grade 4) in 12 and moderate (MRC grade 3) in two. The mean TNS 
score was 6.1/20 (SD 3). 
 
Six participants (5.2%) experienced isolated neuropathic symptoms (in the 
absence of neuropathic signs) of whom three experienced severe symptoms. 
Seven participants (6.0%) were asymptomatic at baseline but reported having 














Figure 4-3  Timeline of HIV infection, anti-TB therapy, pyridoxine supplementation, antiretroviral therapy (ART) and hospital admission preceding (          )  
and following (          ) the baseline assessment. Note: all time values are medians. *Based partly on recall. **Relative to anti-TB therapy. (cf. Figure 2-2 ). 

































Table 4-2  Baseline neuropathic symptoms and signs. 
Characteristic Signs only DSP Symptoms only 
n (%) 28 (24.1) 65 (56.0) 6 (5.2) 
Symptoms       
  Pain, n (%)   45 (69.2) 4 (66.7) 
    NRS, mean (SD)   4.5 (3.9) 2.7 (2.9) 
  Paraesthesia, n (%)   41 (36.9) 4 (66.7) 
    NRS, mean (SD)   3.9 (3.7) 3.5 (3.9) 
  Numbness, n (%)   41 (36.9) 5 (100) 
    NRS, mean (SD)   3.9 (3.5) 5.2 (3.1) 
  BPNS grade ≥3*, n (%)    35 (53.8) 3 (50.0) 
  Cramps**,***, n (%)   36 (55.4) 4 (66.7) 
Signs, n (%)       
  Impaired vibration 10 (35.7) 31 (47.7)   
  Reduced/absent ankle reflexes 19 (67.9) 42 (64.6)   
  Impaired pinprick  10 (35.7) 48 (73.9)   
  Toe/ankle dorsiflexion weakness*** 1 (3.6) 14 (21.5)   
  Impaired proprioception**,*** 6 (21.4) 30 (46.2)   
  Small fibre signs only 6 (21.4) 14 (21.5)   
  Mixed fibre signs 4 (14.3) 34 (52.3)   
  Large fibre signs only 18 (64.3) 17 (26.2)   
TNS, mean (SD)  2.7 (1.7) 6.1 (3.0) 1.2 (0.4) 
DSP=distal sensory polyneuropathy, NRS=numerical rating scale, SD=standard deviation, 
BPNS=Brief Peripheral Neuropathy Screen, TNS=Total Neuropathy Score. 
*Equivalent to severe symptoms (highest NRS score ≥7). 
**Not included in BPNS or TNS. 
***Does not contribute toward DSP case definition. 
 
at the time of the baseline assessment). Twenty-eight participants (24.1%) 
had neuropathic signs only (ADSP). Seventeen participants (14.6%) were 
entirely free of both neuropathic symptoms and signs.  
 
Just over a third of those with baseline DSP (36.9%) had a diagnosis of 
neuropathy documented in the clinical notes – most were prescribed 
amitriptyline and half received higher dose pyridoxine (≥50 mg/day), as per 
the hospital protocol. Of the 49 participants with neuropathic pain (irrespective 
of DSP status), 19 (38.8%) were prescribed amitriptyline and one patient 
received tramadol. There was no significant difference in the overall subjective 
pain scores between those who were prescribed analgesia and those who 
were not (mean pain NRS 6.8 vs. 6.0; p=0.317).   
4.2.3 Comparison of baseline characteristics 
Participants with DSP at baseline were heavier than those without DSP, and a 
greater proportion had a BMI>18.5, but median heights were no different. 
Additionally, a greater proportion of those with DSP had extrapulmonary TB 












proportion of those with baseline DSP were receiving higher dose pyridoxine 
as per DPM protocol for DSP management (Table 4-3 ). Duration of anti-TB 
therapy was no different between the two groups. 
 
Table 4-3  Comparison of characteristics of participants with and without DSP at baseline. 
Characteristic n=116 No DSP (n=51) DSP (n=65) p-value 
Age, years, mean (SD)  36.5 (9.6) 35.4 (8.3) 0.589 
Female, n (%)  27 (52.9) 37 (56.9) 0.669 
Black, n (%)  22 (43.1) 39 (60.0) 0.123 
Weight, kg, mean (SD)  46.1 (8.0) 50.8 (10.8) 0.013 
Height, cm, median (Q1-Q3) n=112 163 (156-168) 165 (157-170) 0.197 
BMI, kg/m2, mean (SD) n=112 17.8 (3.9) 18.7 (3.4) 0.110 
BMI >18.5, n (%) n=112 36 (73.5) 35 (55.6) 0.051 
Problem alcohol use, n (%)  20 (39.2) 21 (32.3) 0.434 
Extrapulmonary TB, n (%)  13 (25.5) 28 (43.1) 0.049 
Previous TB, n (%)  26 (51.0) 45 (69.2) 0.045 
INH, mg/kg, median (Q1-Q3)  5.1 (4.6-5.5) 5 (4.7-5.4) 0.691 
Pyridoxine ≥50 mg/day, n (%)  5 (9.8) 23 (35.4) 0.001 
Prior pyridoxine, n (%)  33 (64.7) 42 (64.6) 0.992 
WHO stage IV, n (%)  23 (45.1) 38 (58.5) 0.152 
CD4+, cells/µl3, median (Q1-Q3) n=114 110 (49-202) 84 (45-179) 0.306 
CD4+ <100, n (%) n=114 21 (41.2) 35 (53.9) 0.175 
Current cART use, n (%) n=95* 10 (25.6) 14 (25) 0.944 
Current d4T use, n (%) n=95* 4 (10.3) 6 (10.7) 0.943 
Previous cART use, n (%)  8 (15.7) 20 (30.8) 0.059 
cART use ever, n (%) n=95* 13 (33.3) 23 (41.1) 0.444 
d4T use ever, n (%) n=95* 6 (15.4) 11 (17.9) 0.751 
Cr, µmol/l, median (Q1-Q3) n=107 64 (55.5-72.5) 60 (49-81) 0.756 
eGFR**, ml/min, median (Q1-Q3) n=107 85.5 (63.3-106.9) 95.2 (72.0-127.9) 0.151 
ALT, IU/l, mean (SD) n=89 34 (47.5) 35.4 (5.8) 0.465 
Hb, g/dl, mean (SD) n=104 9.3 (2.0) 8.9 (2.1) 0.353 
WCC, x 109/l, median (Q1-Q3) n=103 5.4 (4.3-7.6) 5.7 (3.5-8.9) 0.860 
DSP=distal sensory polyneuropathy, SD=standard deviation, Q1=1st quartile, Q3=3rd quartile, 
BMI=body mass index, INH=isoniazid, WHO=World Health Organisation, CD4+= CD4+ T cell 
count, cART=combination antiretroviral therapy, d4T=stavudine, Cr=creatinine, 
eGFR=estimated glomerular filtration rate, ALT=alanine transaminase, Hb=haemoglobin, 
WCC=white cell count. 
*Pilot sample excluded. 
**Calculated using the Cockcroft-Gault formula. 
 
In those with DSP at baseline, DSP severity (as determined by TNS score, 
Table 4-2 ) correlated significantly with patient height (ρ=0.33; p=0.009). For 
the entire cohort, the TNS correlated with the period since diagnosis of HIV 
infection (ρ=0.24; p=0.027). There was an inverse correlation between 
numbness NRS score and number of years since the most recent TB episode 
(in those with a history of previous TB): participants with more recent infection 
had more severe numbness (ρ=-0.31; p=0.008). 
 
Baseline characteristics differed between participants with INH-PN and those 












female, and had a history of previous TB. Participants with HIV-DSP were 
heavier and taller; a greater proportion had a CD4+ T cell count <100 and a 
history of previous cART use. Participants with INH-PN experienced more 
severe pain than those with HIV-DSP (mean NRS 5.5 vs. 3.4; p=0.049). 
 
Table 4-4  Baseline characteristics in participants with INH-PN vs. those with HIV-DSP*. 
Characteristic  HIV-DSP (n=31) INH-PN (n=24) p-value 
Female, n (%) 12 (38.7) 18 (75.0) 0.007 
Weight, kg, mean (SD) 55.9 (9.9) 44.7 (9.3) <0.001 
Height, cm, median (Q1-Q3)) 169.0 (163-177) 157.5 (156-169) <0.001 
BMI >18.5, n (%) 17 (54.8) 5 (22.7) 0.019 
Previous TB, n (%) 19 (61.3) 21 (87.5) 0.030 
CD4+ <100, n (%) 21 (67.7) 8 (33.3) 0.011 
Previous cART use, n (%) 13 (41.9) 4 (16.7) 0.044 
HIV-DSP=HIV-distal sensory polyneuropathy, INH-PN=isoniazid-associated peripheral 
neuropathy, Q1=1st quartile, Q3=3rd quartile, BMI=body mass index, CD4+= CD4+ T cell 
count, cART=combination antiretroviral therapy. 
*Significant differences only are presented. 
 
Participants in the pilot study differed from the main sample in terms of ART 
use (by definition) and were younger (34.9 vs. 40.5; p=0.013). 
4.2.4 Baseline risk factors 
Univariate analysis revealed increasing weight and height, the presence of 
extra-pulmonary TB and a history of prior cART use to predict baseline DSP 
(Table 4-5 ). Cumulative neurological insults (1 point for each episode of TB, 
1 point for any d-drug exposure and 1 point for a CD4+ T cell count <100) was 
a significant predictor of DSP status (PR 1.1 per each additional insult; 
95%CI 1.01-1.3). Multivariate analysis using generalised linear models was 
performed incorporating risk factors significant at a level of p<0.2 on 
univariate analysis (crude ratios were adjusted for age and gender). Each risk 
factor entered into the model is listed in Table 4-5 . In the multivariate model, 
independent risk factors for DSP were female gender (PR 1.5; 
95%CI 1.01-2.2), black race (PR 1.4; 95%CI 1.02-2.0) and increasing weight 
(PR 1.03 per 1 kg increase; 95%CI 1.0002-1.05). 
 
Multivariate analyses were also performed using INH-PN and HIV-DSP as the 
dependent variables. Prevalence ratios with 95%CIs were calculated relative 
to DSP-free individuals (univariate data not shown). A history of previous TB 












1.20-14.8). Increasing weight was independently associated with HIV-DSP 
(PR 1.04; 95%CI 1.02-1.07). 
 
Table 4-5  Univariate analysis of baseline DSP risk factors. 
Covariate n % DSP PR (95%CI)* 
Age**    0.995 (0.98-1.01) 
Female 
  No  














  No  













Weight**   1.02 (1.007-1.06) 
Height**   1.02 (1.003-1.05) 
BMI>18.5, n (%) 
  No   














  No 














  No  













WHO stage IV 
  No   














  No 














  No  













DSP=distal sensory polyneuropathy, PR=prevalence ratio, 
BMI=body mass index, WHO=World Health Organisation, 
CD4+C=CD4+ T cell count, cART=combination antiretroviral 
therapy. 
*Adjusted for age and gender. 
**Per 1 u it increment. 
 
4.3 Longitudinal analysis 
4.3.1 Longitudinal characteristics 
Participants that were lost to follow-up before the eight week assessment (see 
Figure 4-2 ) were heavier at baseline than those who remained in the study till 
at least eight weeks (50.6 vs. 46.6 kg; p=0.038) and had a higher mean BMI 
(19 vs. 17.4 kg/m2; p=0.018). A higher proportion had a history of renal 
dysfunction (87.5% vs. 12.5%, p=0.045), but estimated glomerular filtration 
rates were not lower in this group. There were no significant differences in 












the eight week assessment and those who remained in the study till at least 
eight weeks. 
 
Of the 92 participants who were not receiving ongoing cART at the time of 
admission, 56 (61.0%) commenced cART during the course of the study; the 
median time to commencement of cART was 14 days (Q1-Q3 8-18) post-
admission (Figure 4-3 ). Twenty-three (41.1%) commenced a d4T-based 
regimen, 19 (33.9) a TDF-based regimen and 14 (25.0%) an AZT-based 
regimen. Those who did not commence cART were either discharged before 
ART could be initiated, or did not satisfy national criteria for cART initiation. 
Twelve participants switched cART regimen during the course of the study, 
mostly (n=7) from a d4T-based to a TDF-based regimen. Switches were  
protocol-driven and not due to adverse events. 
 
Patients switched to the continuation phase of anti-TB therapy (see Section 
3.2.1.2) during the course of the study, but the INH dose remained 
unchanged. However, the effective INH dose, a function of body weight, 
increased as body weight and BMI increased through the course of the study, 
trend estimation revealing the increases to be statistically significant – for INH 
dose/body weight: p<0.001, for body weight: p=0.027 and for BMI: p=0.047 
(for a description of trend estimation see Section 3.6.2.2). 
 
Additional laboratory results were available for a minority of participants at 
follow-up as routine blood testing at DPM is usually done on admission only, 
unless clinically indicated. 
4.3.2 Longitudinal DSP 
4.3.2.1 Incident and worsening DSP 
There were nine cases of incident DSP among the 37 participants who were 
DSP-free at baseline and had follow-up assessments. Based on the criteria 
presented in Section 3.2.3, incident DSP could be categorised as ATN in 












receiving TDF, two d4T and one AZT. The incidence of DSP was 12.3/100 
person-months.  
 
Worsening DSP occurred in 21 of the 65 participants with baseline DSP; in 
14 (66.7%), worsening occurred after initiation of cART. Six had been initiated 
on AZT, five on d4T and three on TDF. Worsening of baseline DSP occurred 
at a rate of 39.0/100 person-months. Incident DSP cases were evident 
throughout the study period (Figure 4-4A ), while worsening DSP tended to 
occur soon after baseline (Figure 4-4B ).  
 
Figure 4-4   Kaplan-Meier survival plots for (A) incident and (B) worsening DSP with the origin 
of analysis at the baseline assessment. Wedges indicate censoring events. 
 
4.3.2.2 DSP natural history 
In participants with baseline DSP, neuropathic symptoms improved over 
12 weeks (mean NRS scores for each modality decreased significantly), but 
the mean TNS score did not change significantly. For participants who were 
DSP-free at baseline, the mean TNS increased significantly, driven by 
increases in mean vibration and reflex scores (Figure 4-5 ). 
 
Subjective changes in DSP severity were reflected in the PGIC scores for 
each time point (participants were asked to compare their current symptoms 
to symptoms present at the previous [as opposed to the baseline] visit). The 
scores were coded -2 for “much worse”, -1 for “worse”, 0 for “no change”, 1 for 
“better” and 2 for “much better”. The mean PGIC for each time point was 
















Figure 4-5  Symptom natural history over 12 weeks as demonstrated by change in the 
numerical rating scale (NRS) score for each modality of pain, paraesthesia and numbness in 
(A) participants DSP-free at baseline and (B) those with DSP at baseline. Total Neuropathy 
Score (TNS) and physical finding scores for each examination modality of reflexes, pinprick 
and vibration over 12 weeks in (C) participants DSP-free at baseline and (D) those with DSP 
at baseline. Note: n=116 at 0, n=80 at 4, n=54 at 8 and n=20 at 12 weeks. Error bars omitted 
for clarity. Trend analysis tested the significance of score changes over time.  
 
4.3.3 Longitudinal risk factors 
For the calculation of hazard ratios for incident DSP, the origin of the analysis 
was set at the date of anti-TB therapy initiation, which was treated as a virtual 
time point (a “left-shifted” survival analysis, see Section 3.6.2.2). Covariates 
were not time-varying – baseline values were used. A univariate analysis 
showed a clinical history of renal dysfunction, a history of prior TB, the 
presence of extrapulmonary TB, WHO stage IV HIV disease and the absence 
of cART at the time of anti-TB therapy initiation to be associated with incident 
DSP (Table 4-6 ). Risk factors significant at a level of p<0.2 (those listed in 
Table 4-6 ) informed a multivariate analysis: renal dysfunction (HR 4.2; 
95%CI 1.2-14.4), prior TB (HR 6.6; 95%CI 2.5-17.4) and extrapulmonary TB 















Table 4-6   Univariate analysis of incident DSP risk factors. 
Covariate p-m at risk  Events Event rate HR (95% CI)* 
Age**    0.98 (0.95-1.02) 
Female 
  No 
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WHO stage IV 
  No 
















cART at anti-TB  
therapy start 
  Yes 





















Haemoglobin**    0.8 (0.7-1) 
p-m=person-months, HR=hazard ratio, WHO=World Health Organisation, 
cART=combination antiretroviral therapy. 
*Adjusted for age and gender. 
**Per 1 unit increase. 
***Based on a history of renal dysfunction in the clinical notes. 
 
 
Worsening of DSP could not be extrapolated to the virtual time point (as 
worsening was observed during the study period only), thereby precluding 
worsening DSP as an outcome in this analysis. When using the baseline 
assessment as the origin, there were no significant predictors for DSP 
worsening. 
4.4 Vitamin B6 analysis 
Plasma PLP and 4PA levels were determined in a pilot sample of 25 subjects 
at baseline, and again at one follow-up time point: 14 subjects had levels 
determined at the four week follow-up (group “A”), and the remaining 
11 subjects at the eight week follow-up (group “B”). Neither baseline DSP 
frequency nor baseline PLP or 4PA levels were significantly different between 













At baseline, the mean plasma PLP level was 95.7 nmol/l (SD 35.6). Follow-up 
PLP levels were higher than baseline levels; this difference was significant in 
group “B” (124.3 vs. 89.6 nmol/l; p=0.028) (Figure 4-6 ). Median 4PA levels 
did not differ between time points. PLP levels at all time-points were within the 
normal range (≥30 nmol/l) aside from those for one participant whose baseline 
PLP was 25.8 nmol/l (and 4PA 48.0 nmol/l). This subject had not received 
supplementary pyridoxine at the referring facility and was assessed on the 
day of admission. After eight weeks of pyridoxine 25 mg/day, the PLP level 
rose to 130 nmol/l, and 4PA to 430 nmol/l. 
 
Figure 4-6  Pyridoxal 5‘-phosphate (PLP) levels at baseline and follow-up in groups “A” 
and “B”. 
 
Plasma samples for vitamin B6 analysis were obtained a minimum of 
approximately five hours and a median of six hours (Q1-Q3 5.5-6.5) post-
pyridoxine dosing; there was no correlation between number of hours post-
dosing and PLP or 4PA levels. Participants receiving higher dose pyridoxine 
supplementation (≥50 mg/day) achieved higher baseline PLP levels than 
those receiving standard doses (25 mg/day) at baseline (116.4 vs. 
87.6 nmol/l) – the difference was significant by single-tailed t-test only 
(p=0.034) (Figure 4-7A ); however, a significant correlation between baseline 
PLP levels and cumulative pyridoxine dose was evident (ρ=0.480; p=0.014) 
(Figure 4-8A ). The relationship between pyridoxine dose (current or 
cumulative) and PLP levels was not evident at follow-up; although follow-up 
PLP levels were inversely correlated with daily INH dose (ρ=-0.61; p=0.001) 
(Figure 4-8D ). The relationship fell away after adjusting for weight, however. 
Median 4PA levels were significantly higher in those receiving higher dose 













Figure 4-7  Pyridoxal 5‘-phosphate (PLP) levels at (A) baseline, and (B) follow-up; and 
4-pyridoxic acid (4PA) levels at (C) baseline and, (D) follow-up in those receiving standard 
(25 mg/day) and higher dose (≥50 mg/day) pyridoxine. Horizontal bar indicates mean for PLP 
and median for 4PA. 
 
 
Figure 4-8   Pyridoxal 5‘-phosphate (PLP) levels as a function of cumulative pyridoxine dose 
at (A) baseline, and (B) follow-up. PLP levels as a function of daily INH dose per body weight 
at (C) baseline, and (D) follow-up. Solid line indicates regression line, dashed lines indicate 

















4.5 NAT2 genotyping and sequencing 
4.5.1 Genotyping 
Eighty-one participants were selected for genotyping on the basis of 
availability of follow-up data. Buffy coat was unavailable for one participant, 
and NAT2 genotyping was performed on the remaining 80 participants.  
4.5.1.1 PCR RFLP analysis 
Extraction of DNA from buffy coat yielded genomic DNA in concentrations 
ranging from 20.5 to 630.1 ng/µml. Amplification by PCR resulted in products 
of ~895 bp, which were of good integrity. 
 
RFLP analysis revealed the presence of the G191A, C282T, C481T, G590A, A803G 
and G857A NAT2 SNPs at frequencies and as inferred from the products of 
restriction enzyme digestions “A”-“D” presented in Figure 4-9 to Figure 4-12 . 
The A434C and A845C SNPs were not detected in any samples.  
 
Digestion of two samples (T059 and T103) in digest “A” yielded unexpected 
fragments of ~800 bp (Figure 4-9 , lane 5), even after repeat DNA extraction, 
PCR and restriction enzyme digestion. Troubleshooting steps were taken to 
resolve the fragments (see Section 5.1.12). 
4.5.1.2 Allele-specific PCR 
Allele-specific PCR designed to detect mutations at the 341 locus revealed 
homozygosity for the wild type allele (341T) in 29 participants, while the 
remainder appeared heterozygous for the T341C SNP (Figure 4-14A ). The 
lack of homozygosity for the mutation, which was out of keeping with 
Hardy-Weinberg equilibrium, suggested a lack of specificity in amplification of 
the 341 allele where the primer specific for the allele was employed 
(i.e. amplification occurred where the 341T allele was not present). After 
multiple unsuccessful attempts at optimising the reaction across temperature 






















































481/191 2 (2.5) 
Figure 4-9  Single nucleotide polymorphism (SNP) combinations demonstrated in restriction 
fragment length polymorphism digest “A” (MspI and KpnI) along with illustrative digestion 
schema and frequencies of each combination. Note: the A434C SNP, which was not 
demonstrated in any sample, has been omitted for clarity. The bolded numbers are base pairs 
corresponding to the bands in the relevant lanes. MWM=molecular weight marker. 











































































































































590/857 2 (2.5) 
Figure 4-10  Single nucleotide polymorphism (SNP) combinations demonstrated in restriction 
fragment length polymorphism digest “B” (TaqI and BamHI) along with illustrative digestion 
schema and frequencies of each combination. The bolded numbers are base pairs 
corresponding to the bands in the relevant lanes. MWM=molecular weight marker.
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Figure 4-11  Single nucleotide polymorphism (SNP) combinations demonstrated in restriction 
fragment length polymorphism digest “C” (FokI and DraIII) along with illustrative digestion 
schema and frequencies of each combination. Note: the A845C SNP, which was not 
demonstrated in any sample, has been omitted for clarity. The bolded numbers are base pairs 
corresponding to the bands in the relevant lanes. MWM=molecular weight marker. 
 
4.5.2 Sequencing 
Sequencing in the forward direction was performed for the 51 samples 
appearing heterozygous for the T341C SNP on allele-specific PCR. It revealed 
homozygosity in seven, and heterozygosity in 44. Electropherograms 















































































Figure 4-12  Single nucleotide polymorphism (SNP) combinations demonstrated in restriction 
fragment length polymorphism digest “D” (DdeI) along with illustrative digestion schema and 
frequencies of each combination. The bolded numbers are base pairs corresponding to the 
bands in the relevant lanes. MWM=molecular weight. 
 
The two samples with ambiguous RFLP findings presented in Section 4.5.1.1 
above were sequenced in both directions and confirmed heterozygous for 
each of the G191A and C481T SNPs (Figure 4-13 ). A further six random 
samples were also sequenced in both directions, in order to confirm RFLP 






















































findings for the G191A, C282T, C481T, G590A and A803G SNPs; however, as the 
857 locus was unclear in the majority of the electropherograms, the presence 
of the G857A SNP was confirmed in only one of three samples. No novel SNPs 
were identified, nor were instances of the A434C or A845C SNPs.  
 
 
Figure 4-13  Electropherograms demonstrating heterozygous SNPs at the (A) 191 locus, and 
(B) 481 locus, for sample T059; and electropherograms demonstrating wild type alleles at the 
(C) 191 locus, and (D) 481 locus, for comparison. 
 
4.6 Genetic data analysis and predicted phenotypes 
4.6.1 SNPs 
The most common SNP was the A803G, while there were four instances only 
of the G191A and three of the G857A. All SNPs other than the C282T and C481T 
were in Hardy-Weinberg equilibrium (p=0.017 and 0.047, respectively) 
(Table 4-7) . The lack of equilibrium for the C282T SNP was due to over 
representation of homozygous samples, five of which were sequenced and 
confirmed homozygous. For the C481T, homozygosity was under represented, 
and again sequencing confirmed the genotype in 32 samples. 
 
Individual SNP frequencies predicted neither baseline DSP nor INH-PN using 
generalised linear models to estimate prevalence ratios, nor incident DSP 

















Figure 4-14  (A) Agarose gel of NAT2 allele-specific PCR products demonstrating 341T 
homozygosity (in lanes 6, 14 and 17) and heterozygosity (in the remaining lanes) for the T341C 
SNP. (B) Electropherogram demonstrating heterozygosity for the T341C SNP, in agreement 
with allele-specific PCR (*). (C) Electropherogram demonstrating homozygosity for the T341C 






















Table 4-7  SNP frequencies; frequencies of sample hetero- and homozygotes for each SNP; 
and associated Hardy-Weinberg equilibrium probabilities. 
SNP Frequency, n (%) Heterozygotes, n (%) Homozygotes, n (%) p-value* 
G191A 4 (2.5) 4 (5.0) 0 (0.0) 0.819 
C282T 46 (28.8) 24 (30.0) 11 (13.8) 0.017 
T341C 58 (36.3) 44 (55.0) 7 (8.8) 0.089 
A434C 0 (0.0) 0 (0.0) 0 (0.0) - 
C481T 50 (31.3) 42 (53.0) 4 (5.0) 0.047 
G590A 32 (20.0) 26 (32.5) 3 (3.8) 0.889 
A803G 95 (59.4) 41 (51.3) 27 (33.8) 0.577 
A845C 0 (0.0) 0 (0.0) 0 (0.0) - 
G857A 3 (1.9) 3 (3.8) 0 (0.0) 0.864 
SNP=single nucleotide polymorphism. 
*As calculated using the Hardy-Weinberg equilibrium equation and the Χ2 test with one 
degree of freedom. 
 
4.6.2 Predicted haplotypes 
Computational PHASE haplotyping revealed 14 NAT2 haplotypes present in 
the study population (Table 4-8 ); the most frequent was NAT2*5B (28.1%), 
and wild type NAT2*4 was present in 11.9%. The PHASE case-control 
function revealed no differences in haplotype frequencies between black and 
mixed ancestry participants (p=0.28), and between participants with and 
without baseline DSP (p=0.61). Attrition in the longitudinal data precluded use 
of the PHASE case-control function to detect differences in haplotype 
frequencies between those with and without incident DSP. 
 
Table 4-8   Haplotype frequencies as predicted by 
PHASE computational haplotyping. 
Haplotype* NAT2** 2n (%)*** 
000000000 *4 19 (11.9) 
001010000 *5A 1 (0.6) 
001010100 *5B 45 (28.1) 
001000100 *5C 11 (6.9) 
001001000 *5E 1 (0.6) 
010001000 *6A 30 (18.8) 
010011000 *6C 1 (0.6) 
010000001 *7B 3 (1.9) 
000000100 *12A 33 (20.6) 
010000100 *12B 3 (1.9) 
000010100 *12C 3 (1.9) 
010000000 *13A 6 (3.8) 
100000000 *14A 1 (0.6) 
110000000 *14B 3 (1.9) 
*Haplotype with nine positions: 191, 282, 341, 434, 
481, 590, 803, 845 and 857. 
**Standard nomenclature in Human NAT2 alleles 
(haplotypes)139 (available from: http://n- 
acetyltransferasenomenclature.louisville.edu/).  












4.6.3 Predicted acetylation phenotypes 
Figure 4-15A  demonstrates the predicted NAT2 acetylation phenotypes for 
the 80 participants in whom genetic analysis was done. Nearly a quarter were 
ambiguous (either intermediate or slow) because of the presence of two or 
more loci heterozygous for a slow allele. Computational PHASE analysis 
revealed the phase of each of the 18 ambiguous genotypes. It uniformly 
placed slow alleles on opposite chromosomes, thereby predicting a slow 
phenotype in all 18 (Figure 4-15B ). 
 
  
Figure 4-15  Overall predicted NAT2 acetylation phenotypes (A) before, and (B) after PHASE 




Predicted phenotype frequencies did not differ between the black and mixed 
ancestry groups. At baseline, the proportions of slow acetylators in those with 
and without DSP did not differ (39.3 vs. 60.7%; p=0.451; PR 1.2; 95%CI 
0.8-1.8); the proportions of slow acetylators in those with and without INH-PN 
also did not differ (57.9 vs. 42.1%; p=0.392; PR 1.4; 95%CI 0.7-2.9). DSP was 
not more severe in slow acetylators. There was a trend for slow acetylators to 
develop DSP on a survival analysis in which the origin was set to the date of 




























Figure 4-16  Kaplan-Meier plot of incident DSP in slow vs. fast/intermediate acetylators with 
origin at the date of anti-TB therapy initiation. Wedges indicate censoring events. 
 
Both baseline and follow-up PLP levels failed to aggregate when grouped by 
slow vs. fast/intermediate acetylators (Figure 4-17 ); however, 
fast/intermediate acetylators achieved greater increases in PLP levels from 
baseline to follow-up compared to sl w acetylators (97.1-128.1 vs. 90.1-99.3; 




Figure 4-17  Pyridoxal 5‘-phosphate (PLP) levels by predicted NAT2 phenotype (slow vs. 
















Figure 4-18  Pyridoxal 5‘-phosphate (PLP) levels at baseline and follow-up in (A) slow 














The discussion will explore and contextualise various aspects of the project 
before offering recommendations and presenting conclusions. 
5.1 Observations 
These are drawn into broad themes. 
5.1.1 DSP is frequent after anti-TB therapy initiation and continues 
to develop during concomitant cART  
A high rate of DSP was found in this inpatient co-infected cohort recently 
commenced on anti-TB therapy with INH. More than half (56%) demonstrated 
DSP at baseline; a further 24% demonstrated ADSP. The frequency of DSP is 
similar to the frequency of DSP in the HIV mono-infected d4T-treated 
outpatient cohort of Wadley et al. (57%)12, and higher than the 37% 
demonstrated in a mixed HIV±ART, but geographically similar, outpatient 
population in Maritz et al.11. The entire cohort in Wadley et al. had been 
exposed to d4T; a high rate of DSP is therefore expected. The cohort of 
Maritz et al. was 50% ART-untreated, perhaps accounting for the lower 
prevalence. Observed rates of DSP are dependent on the criteria used to 
define a case of DSP11; differences in BPNS execution and interpretation may 
also have contributed to the discrepancy (see Sections 5.1.10). DSP rates 
may also differ between well-resourced and resource poor settings, hence the 
choice of comparison studies above. There are no prevalence data specific to 
HIV/TB-associated DSP with which to compare study findings. (Cumulative 
incidence data exist, but this analysis was precluded because of attrition.)  
 
Incident DSP in this HIV/TB cohort was higher than that reported in Lanternier 
et al.4 (12.3 vs. 5.4/100 person-months). The discrepancy may be attributed to 
prospective versus retrospective study, or use of the BPNS/TNS versus the 
criteria utilised in Lanternier et al. (see Table 2-1 ). Worsening DSP occurred 
at a higher rate, and followed a pattern distinct to that of incident DSP – 












occurred throughout the study period. Worsening DSP may not be equivalent 
to incident DSP, a concept explored further in Section 5.1.11. 
 
Participants with DSP experienced significant symptomatology; a large 
proportion (54%) experienced severe symptoms by BPNS criteria (highest 
NRS score ≥7) at baseline. The mean TNS score, which is indicative of DSP 
severity, was similar to that quoted in Robinson-Papp et al.63 (3.9 vs. 3,7) 
when a similar patient group and definition of severity was utilised. (For direct 
comparison, the data were adapted to match Robinson-Papp et al. in terms of 
a combined ADSP/SDSP group, and a 16-point score in which neuropathic 
symptoms were excluded.) Patients with co-morbidities, such as those 
represented in both of these studies, may experience more severe 
neuropathic pain167. 
5.1.2 HIV-DSP, ATN and INH-PN, and possibly TB, all contribute to 
HIV/TB-associated DSP 
Aetiological diagnosis was based on recall and temporal association (see 
Figure 2-2 ), an approach supported in the literature54, but subject to recall 
bias. However, my impression was that participants readily recalled the onset 
of their symptoms relative to the initiation of anti-TB therapy or cART, and 
they were, on the whole, certain of their recollections. Furthermore, the 
intervening period was usually short, on the order of weeks. Another 
reassuring point was that HIV-DSP, as categorised using this approach, 
associated with some factors congruent with the literature, such as lower 
CD4+ T cell count and height (see Section 5.1.3). 
 
At baseline, the majority of participants had their DSP attributed to either HIV 
or INH; the contribution of ART was minimal – ATN was present in 5%. Only 
20% of the whole cohort were receiving cART at baseline. A noteworthy 
finding was that INH-PN was more painful than HIV-DSP. A similar finding in 
Maritz et al. showed that ATN was more severe than HIV-DSP11 – 
comparable rates of DSP (see above) and a similar severity profile may 
suggest that INH-PN and ATN are pathogenetically similar, and may both 












pathological features (see Section 2.2.3.2) may also support this hypothesis. 
However, more recent symptom onset in those with INH-PN may also explain 
the greater severity – our study demonstrated that neuropathic pain showed a 
steady decrease in severity over the period of observation. 
 
The presence of a possible “TB-DSP” is a novel finding inferred from a history 
of neuropathic symptom onset concurrent with TB symptom onset. A literature 
search produced just three references to this phenomenon pre-HIV, the most 
recent in 195976 and the earliest in 1913185, none of which reported any case 
studies or systematic study of the phenomenon. The paucity of literature can 
be attributed to either the non-existence of a “TB-DSP” entity, or INH-PN 
obscuring its incidence. The “TB-DSP” observed in this study may be limited 
to those co-infected with HIV – two contemporary observations are within this 
context5,32. Again, it may be that systemic inflammation accompanying TB 
infection drives oxidative stress and exacerbates HIV-related nerve injury. An 
implication is that not all cases of DSP occurring during anti-TB therapy are 
attributable to INH – the factors driving “TB-DSP” may still be present during 
therapy.  
 
The aetiological diagnosis was ambiguous when the onset of DSP occurred 
during concomitant cART and anti-TB therapy. During follow-up, ATN was 
defined when incident or worsening DSP occurred at any point after cART 
initiation (see Table 3-4 ), but ART may not necessarily have been implicated. 
Nevertheless, most cases of incident or worsening DSP (70%) occurred after 
cART-initiation, suggesting that ART is an additional driving force behind 
incident/worsening DSP. ATN was defined even when “non-neurotoxic” 
agents, such as AZT or TDF, were prescribed. Antiretroviral agents 
traditionally thought to be non-neurotoxic may have their neurotoxicity profile 
altered by the presence of TB and/or anti-TB therapy. In addition, DSP 
incidence during TDF therapy is low but not negligible186. DSP was associated 
with cART independently of d-drug use in one study13. 
5.1.3 Previous neurological insults predict HIV/TB-associated DSP 
This study supports the view that HIV-associated DSP is a multi-factorial 












cumulative (see Section 2.3.5). Previous TB, implying INH exposure, has 
previously been identified as a risk factor for ATN11 and was similarly found to 
be a predictor of INH-PN in this study (again pointing to a similar pathogenetic 
risk profile). Previous exposure to low-dose INH is known to have a priming 
effect whereby an increase in INH dosage results in earlier-onset neuropathy 
compared with that seen in previously unexposed individuals23. Conversely, 
symptomatology may improve gradually after exposure to INH – one study 
finding was that numbness severity was inversely correlated with the latent 
period since previous TB, a finding corroborated in this study. There was no 
correlation between DSP and dose or duration of current INH therapy, arguing 
against cumulative toxicity of the agent. Previous, but not current, cART use 
was associated with HIV-DSP; ongoing cART may be protective for DSP (see 
Section 2.1.3), while previous exposure may have been of short duration, with 
neurotoxicity outweighing neuroprotection. Also, previous cART likely 
encompassed a d4T-based regimen (national protocols changed during the 
study period, see Section 3.2.1.2). 
 
A novel approach in this study was the use of an “insult score” as a proxy for 
cumulative nerve injury (see Section 4.2.4), which produced significant 
results: each additional insult (each TB episode, exposure to d-drugs or a 
CD4+ T cell count <100) increased DSP probability by 10%. The “insult score” 
was not entered into the multivariate analysis, however, because it 
compressed and categorised important covariates. Renal failure is a known 
cause of neuropathy, possibly explaining the association with incident DSP. 
However, the eGFR and creatinine were normal; renal dysfunction may 
therefore have been a proxy for advanced illness. 
 
Not all neurological insults could be accounted for. Alcohol abuse is a known 
cause of DSP, but has not yet been shown to increase the risk for HIV/TB-
associated DSP (see Section 2.1.3). The lack of association may be due to 
the measure used to assess alcohol use and abuse. For example, an overly 
inclusive definition of alcohol use can potentially underestimate its impact as 
an additional risk factor for DSP11. More accurate measures are not 












peripheral nerve injury. Within the literature surrounding HIV-associated DSP, 
various definitions have been utilised: any alcohol consumption in the prior 12 
months11, >30 standard drinks in one month35 and any alcohol-related 
complication in the previous six months101. We used a simple validated single 
question screen to identify problem drinking in the study population179 (see 
Section 3.3.5). The instrument demonstrated problem drinking in a high 
proportion; however, there was no association between problem drinking and 
DSP risk; a lack of specificity may be implicated. The impact of nutritional 
factors other than B6 could not be ascertained. 
 
Factors suggesting advanced HIV/TB disease were also contributory. The 
association of HIV-DSP with lower CD4+ T cell counts is not surprising. WHO 
HIV stage IV disease was also predictive of incident DSP on univariate 
analysis, as was the presence of extrapulmonary TB. Patients with 
extrapulmonary TB may experience greater systemic inflammation and the 
resulting oxidative stress may contribute to DSP pathogenesis. An indicator of 
general clinical condition such as the Karnofsky score may have been a useful 
covariate, but no data specific to general condition were collected.  
 
Although gender differences have been demonstrated in other studies55,187, 
the observed higher proportion of females with INH-PN when compared to 
HIV-DSP should be treated with caution – gender bias was a prominent 
feature of this study (see Section 5.1.8). Genetic disposition may explain the 
independent association of black race with baseline DSP63; however, NAT2 
genetic variation is not implicated. Further genetic or genomic investigation of 
the sample may elucidate the relationship.  
 
Increasing height was a risk factor for baseline DSP, a finding corroborating 
that of previous research in HIV populations12,55, and consistent with 
pathogenic factors such as mitochondrial mutation load (see Sections 
2.3.2.1.3 and 2.3.2.2.2); however, the increased risk was small (2% increase 
per cm) with a wide confidence interval, and fell away on multivariate analysis. 
An association with height was more evident when HIV-DSP was compared to 












INH-PN (Table 4-4 ). HIV-DSP may be more length-dependent than INH-PN, 
the onset being slow and insidious in the former, and rapid in the latter. 
Additionally, increasing height correlated with increasing DSP severity (as 
estimated by TNS score), a novel finding in this study.  
  
The independent association of increased weight with both general DSP and 
HIV-DSP in this cohort was surprising. DSP is associated with the metabolic 
syndrome (see Section 2.3.4.3), but participants in our study were not obese. 
Height may plausibly have accounted for increased weight, but the 
association with height fell away on multivariate analysis. Participants with 
HIV-DSP were heavier and had higher BMIs than those with INH-PN; again 
this finding was unexpected – HIV-DSP is associated with markers of 
advanced HIV infection, of which wasting is one. That a greater proportion of 
those with HIV-DSP were male and had a history of ART use (which may 
have improved clinical condition and therefore weight), and a lesser proportion 
had a history of previous TB when compared to those with INH-PN, may 
explain the weight difference. 
 
The prevalence ratio, as estimated by generalised linear models, rather than 
the more widely utilised odds ratio, as estimated by logistic regression, was 
used to identify predictors of baseline DSP. The appropriateness of the odds 
ratio to describe cross-s ctional data is questioned – while it does tend to the 
prevalence rate ratio (the gold standard predictor of risk) for rare outcomes, it 
overestimates the prevalence rate ratio when the outcome is frequent – it is 
better suited to case-control studies. The prevalence ratio is a better 
approximation of the prevalence rate ratio for frequent outcomes in cross-
sectional data. Furthermore, interpretation of the odds ratio is conceptually 
complex when compared to the more intuitive prevalence ratio188.  
5.1.4 The natural history of DSP in HIV/TB shows overall 
improvement over time 
Two analyses pointed to progressive improvement in baseline DSP through 
the course of the study: trend analysis of symptom NRSs (Figure 4-5B ) and a 












worsening of baseline DSP (possible “coasting”, see Section 2.2.5.3), overall 
improvement occurred in nearly half of all baseline DSP participants with 
follow-up data. Whether improvement occurred because of pyridoxine 
supplementation, improvement in general condition/immunological status or 
attrition bias, or because it is simply reflective of DSP natural history, is not 
clear. Formal analysis was prevented by heterogeneity in the cohort, 
confounding factors and attrition, as well as the complex statistical methods 
required.  
 
The natural history of neuropathic signs differed between participants with 
baseline DSP compared to those DSP-free (i.e. those not satisfying criteria for 
baseline DSP, but with primarily ADSP [see Section 5.1.9]): on average the 
scores remained constant during follow-up in those with baseline DSP, while 
scores for vibration sense and reflexes in the DSP-free group worsened 
significantly (Figure 4-5C and D). ADSP progression therefore appears to 
involve predominantly large fibres, suggesting a pathogenetic process 
different to that for symptomatic DSP, and reinforces that clinically relevant 
(i.e. painful) DSP is small-fibre-dependent. It also may further refute the 
hypothesis that HIV-associated DSP exists as a spectrum between 
symptomatic and asymptomatic neuropathy33,79,97. On the other hand, seven 
of nine cases of incident DSP in this study were technically progressions from 
ADSP to DSP, and of whom six demonstrated only large fibre signs at 
baseline. Interpretation of the trend analyses should also be treated cautiously 
– bias may have accounted for the findings: for example, the decrement in 
mean scores could be a result of retention of participants with less severe 
symptoms. Study of ADSP natural history requires a cleaner cohort, and a 
larger sample size. 
 
Four case histories provide further insight into the natural history of 












5.1.5 Pyridoxine supplementation may prevent B6 deficiency 
expected in the study population, but prior deficiency may 
have been missed 
All but one of the 25 participants who had B6 status assessments were 
receiving pyridoxine supplementation at the time of the baseline assessment – 
some for several weeks and others for several days – and all were receiving 
pyridoxine at the follow-up assessment (which was either at four weeks 
[group ”A”] or eight weeks [group “B”]). Active pyridoxine supplementation 
accounts for the observed elevated PLP and 4PA levels (see below), and, at 
doses ranging from 25-100 mg/day, was sufficient to prevent or correct the 
deficiency expected in this population. As we were not able to sample prior to 
the initiation of supplementation, and had no controls, this statement is 
inferred – existing literature clearly points to prevalent B6 deficiency in HIV/TB 
populations in the absence of supplementation (see Section 2.3.4.1.1). The 
one participant who had not received pyridoxine at the time of the baseline 
assessment had levels below the reference range utilised (≥20 nmol/l), but not 
if the less conservative ≥30 nmol/l cut-off was utilised153. The patient did not 
have DSP, and could not provide power for comparison.  
 
One concern was that the observed elevated PLP levels could be explained 
by the pharmacokinetic peak of the supplement, rather than steady-state 
plasma concentrations. Krishnamurthy et al. showed that vitamin B6 status 
was artificially inflated when sampling was performed 1-4 hours after 
pyridoxine dosing26. In the current study, the period between dosing and 
sampling exceeded five hours at all time points, which, according to one 
pharmacokinetic study162, is the point at which PLP levels approach baseline, 
and which may then exclude the possibility that we were measuring the 
pharmacokinetic peak rather than stable baseline levels. If we were truly 
measuring the pharmacokinetic peak we would also expect there to be some 
correlation between plasma levels and hours since dosing, approximating the 
plasma concentration curve as it returns to baseline; however, our findings did 
not show any correlation. Vitamin B6 metabolism and pharmacokinetics may 












in this respect163,173. Pre-dosing levels on fasted patients, the ideal sampling 
schedule, was not a viable possibility in this study. However, the pattern of 
plasma B6 markers in this study was reflective of ongoing and recent 
supplementation: PLP levels were 5-fold that defined as the lower limit of 
normal, and 4PA levels were 4-fold the upper limit of normal and >150-fold the 
lower limit154,189. 
 
Higher dose pyridoxine did not translate into higher PLP levels at either 
baseline or follow-up, while at follow-up, higher dose pyridoxine resulted in 
higher 4PA levels. These findings are consistent with the literature: urinary 
4PA correlates with administered pyridoxine dose, while PLP levels plateau at 
higher doses; excess unbound PLP is rapidly oxidised to 4PA154,161,190. 
However, at baseline, PLP levels did correlate with cumulative pyridoxine 
dose, a function of both dose and period of supplementation. By follow-up, 
this correlation fell away; it is possible that PLP levels as a function of 
supplementation had achieved steady-state at the time. PLP levels increased 
significantly between baseline and eight weeks (see below). PLP levels at 
follow-up were inversely correlated with INH dose per body weight, but the 
association fell away after adjusting for weight. INH per body weight is mainly 
a function of weight as the numerator (i.e. absolute dose) varies little 
(4-6 mg/kg).  
  
That higher doses of pyridoxine are more protective for DSP was not a 
testable hypothesis in this study because pyridoxine doses were increased by 
clinical staff in response to the diagnosis of symptomatic DSP. Furthermore, if 
DSP was identified by the study team, this was noted in the clinical records. In 
this way the study outcome influenced the exposure of interest.  
  
One caveat is that group “A” and group “B” were combined into a single 
“follow-up” group, but levels at these time points may not be equivalent. When 
comparing baseline to follow-up levels in each group, a significant increase 
was seen in group “B” but not in “A”. As the two groups were mutually 
exclusive, comparing four week levels to eight week levels was precluded 













Lack of pyridoxine supplementation at the start of anti-TB therapy and 
resulting B6 deficiency may have contributed to DSP risk; however, a history 
of pyridoxine supplementation prior to admission predicted neither baseline 
nor incident DSP, nor PLP levels. Unfortunately, data regarding prior 
supplementation are not reliable because they were dependent on participant 
recall and/or the accuracy of the referral letter – recall bias may have 
obscured any association. A poor compliance history may also have 
contributed to unreliability.  
 
Vitamin B-complex supplementation was virtually universal within the cohort 
and was therefore not expected to influence the analysis. The vitamin B6 
constituent of B-complex is variable between brands; to my knowledge, the 
B-complex administered to patients at DPM is LEN-B Co® which contains 
pyridoxine 0.5 mg/tablet (other brands may contain 2 mg/tablet). The 
contribution of this small amount of pyridoxine is negligible in the context of 
pyridoxine doses ≥25 mg. Consequently, vitamin B-complex was disregarded 
as a covariate and a total pyridoxine dose not calculated. Other research 
within our group shows that vitamin B-complex alone is insufficient to prevent 
HIV-associated DSP112. 
 
Because of the stated problems with sampling, and the apparent influence of 
supplementation inflating plasma PLP levels, we did not send further samples 
for B6 HPLC. Recommendations based on this evidence should be cautious. 
5.1.6 NAT2 genetic variation and predicted phenotypes in this 
Western Cape study population were described 
Individual SNP frequencies were similar to those reported elsewhere for 
Western Cape black and mixed ancestry populations (for the SNPs reported 
in Adams et al.: G191A, C481T, G590A and G857A)141. Predicted phenotypes also 
matched closely those of Parkin et al.119. Haplotypes have not been described 
for the Western Cape predominantly Xhosa and mixed ancestry “coloured” 
populations (or for any other South African population). Because SNP and 












considered and analysed together. The Western Cape mixed ancestry 
population is derived from multiple origins (see Section 2.3.2.1.1); however, 
the contribution of African ancestry to NAT2 genetic diversity may be 
overrepresented. 
 
As we expected, the frequency of the wild type NAT2*4 haplotype was low. 
NAT2*4 is arbitrarily assigned based on its frequency in white populations, 
and is not common in African populations116. PHASE predicted 14 different 
haplotypes present in the population, including some at very low frequencies. 
This genetic diversity is representative of that found in Africa as a whole. 
Haplotypes in this study were also similar to those of some other sub-Saharan 
African populations, most notably the Gabonese Bantu in terms of NAT2*5B, 
NAT2*6A and NAT2*12B191. Again this is not surprising as the Xhosa are a 
Bantu people. 
   
Two of the nine NAT2 SNPs typed in this study (C282T and C481T) were not in 
Hardy-Weinberg equilibrium. Lack of equilibrium could be attributed to the fact 
that the sample was not a random representation of the population – selection 
occurred not only on admission and enrolment (see Section 5.1.8), but also 
because NAT2 acetylation sta us was determined in only a subset of the 
cohort (70%) (those with any longitudinal data). As there was 100% 
agreement between RFLP analysis and sequencing for these two SNPs 
(aside from two samples in which RFLP findings were ambiguous, rather than 
conflicting, see Section 5.1.12), this would not explain the lack of equilibrium. 
Similar reported frequencies of the C481T SNP in Adams et al. (the C282T SNP 
was not typed in this study) was reassuring141. The PHASE analysis assumes 
Hardy-Weinberg equilibrium; it is not possible to gauge the impact of non-
conformity to this assumption on the derived haplotype frequencies in the 
absence of other haplotype data for the population. PHASE haplotyping of 
NAT2 in other populations has previously been shown to be in agreement with 












5.1.7 There was a trend for slow acetylators to develop DSP  
A trend for the slow acetylation phenotype to predict decreased DSP-free 
survival was evident on a survival curve, but was not significant either by the 
log-rank test for equality of survivor functions or by proportional hazards 
models. A reduced sample size (70% of the cohort was genotyped) and 
attrition may have accounted for the lack of a significant association. Various 
factors associated with phenotype/genotype discordance, such as advanced 
HIV illness, may have also contributed (see Section 2.3.3.1.1). The trend was 
not evident when the origin of the survival analysis was set at the baseline 
assessment rather than at the virtual time point of anti-TB therapy initiation. 
Assessing survival at the onset of exposure to an acetylation-dependent agent 
is intuitively the more correct analysis, even with the possibility of subject-
recall bias (see Section 5.1.8).  
 
The trend evident in the “left-shifted” analysis, although not significant, is 
made relevant when viewed in the context of the previously established 
biological association between slow acetylation and the risk for INH-PN. If the 
trend is accepted to have biological relevance, even if not statistically 
significant, then it may also be cautiously deduced that the risk for DSP in 
HIV/TB is attributable to INH, directly or indirectly. If we accept this 
assumption, we would then expect to find an associated B6 deficiency 
(B6 deficiency being the primary mechanism of INH-PN); however, deficiency 
was not demonstrated in the cohort. There are several possible explanations 
for an association with slow acetylation in the face of normal B6 status. First, 
deficiency prior to study entry cannot be excluded and deficiency at this time 
may have been contributory. Second, mechanisms other than B6 deficiency 
account for INH neurotoxicity (see Section 2.3.2.1.3) – levels of the INH by-
product, hydrazine, are higher in slow acetylators131; hydrazine induces 
oxidative stress, an important element of ATN. However, Third, INH may 
induce a functional B6 deficiency even when supplementation corrects blood 
levels26 (see Section 2.3.2.1.2). Finally, slow acetylation may represent an 
independent predictor of HIV/TB-associated DSP by unknown mechanisms. In 












neuropathy because a greater proportion of DSP-free subjects were fast 
acetylators192; however; the association was later attributed to confounding – 
fast acetylators are over-represented in the type 1 diabetic population 
(possibly because of a hyperglycaemia-induced abundance of acetyl-CoA) 
and type 1 diabetics experience less neuropathy than type 2 diabetics125. 
 
Although fast/intermediate acetylators did not demonstrate higher PLP levels 
than slow acetylators, they did show greater increases in PLP levels from 
baseline to follow-up when compared to slow acetylators. Differences in B6 
status between acetylation phenotypes have been demonstrated for the 
indirect GOT index only, and not for direct B6 assays43,68. The increase in PLP 
levels in fast/intermediate acetylators demonstrated here is consistent with 
other study findings – at follow-up, PLP levels were a function of INH dose 
(see Section 5.1.5), and presumably INH concentration, a function of 
acetylation status26,68. Lesser improvements in PLP levels may explain the 
trend for slow acetylators to develop DSP, although biologically, deficiency 
would be expected to be driving the risk. 
 
Acetylation phenotyping was not performed in this study; discordance 
between predicted phenotype and true phenotype cannot be ruled out and 
may have affected associations observed47-49. Co-administered NAT2 
substrates such as co-trimoxazole49 may plausibly have also affected the 
phenotype, as could have advanced HIV and TB disease (see Section 
2.3.3.1.1).  
5.1.8 Elements of the study design may have introduced bias 
while others were advantageous 
Selection bias was introduced on admission to DPM – only 10% of all TB 
cases in South Africa are admitted to hospital121 and the TB inpatient 
population is biased towards a patient profile of chronic illness, advanced 
untreated HIV disease, malnutrition, substance use, poor compliance history, 
low socio-economic status and multiple-episode TB history193. These factors 












deficiency and DSP. Caution in generalising these results to the broader 
population should be exercised. 
 
The DPM hospital population is highly selected specifically in terms of gender  
because DPM is a predominantly male hospital (see Section 3.2.1.2). One 
would expect the study population to have been similarly skewed, but the 
male:female ratio was in fact reversed. The discrepancy is readily explained: 
because the ratio of long-term to short-term beds at DPM is much higher for 
males than for females, the female “turnover” is much higher. Therefore, a 
higher proportion of admissions is female. According to hospital statistics, in 
February 2011, for example, admissions were 33:47 male:female. The ratio of 
“ill” to “ambulant” beds is also higher for females – a larger proportion of 
females at any one time point are ill patients. This bias may have accounted 
for the association of INH-PN with female gender (see Section 5.1.3). In the 
absence of a specific indicator of general clinical status (such as the 
Karnofsky score), I considered BMI, WHO stage, CD4+ T cell count and 
haemoglobin as proxies for overall clinical condition: females had lower CD4+ 
T cell counts and lower haemoglobin levels (see Section 4.2.1); however, the 
latter is expected in the general population. All risk factor analyses were 
adjusted for gender, as well as for age.  
  
Selection bias may have also occurred on enrolment. Participation in the 
study was restricted to patients on first-line first episode or retreatment anti-TB 
therapy. Patients with multi-drug resistance and adverse reactions to anti-TB 
therapy, who were excluded, may be particularly at risk for other 
complications, such as DSP. DSP rates in the study may therefore have 
underestimated those in the greater HIV/TB population. The advantage was a 
“cleaner” cohort. A high proportion of patients approached for recruitment into 
the study (Figure 4-1 ) declined to participate, which may have further biased 
the sample. However, sampling bias was avoided because sampling was both 
systematic (all admissions were considered for eligibility) and continuous 













During the pilot period, participants receiving cART at baseline were excluded. 
These criteria were relaxed thereafter, with the advantage that ART-use could 
be entered into the cross-sectional analysis. Furthermore, as a result of the 
change in national guidelines for cART programs in May 2010 (TDF replaced 
d4T as the first-line NRTI backbone), fewer participants were commencing 
d4T. There was therefore less scope to longitudinally assess the effect of 
d-drugs on DSP risk. 
 
The initial pilot study data were included in most aspects of the final analysis. 
The main difference between the pilot and main study participants was that 
pilot participants, by definition, were either ART-naïve or had no recent 
exposure to ART. Pilot participants were therefore excluded from analysis of 
ART-related baseline characteristics, but were included in the multivariate 
analyses, because their exclusion would have been detrimental in terms of 
sample size (at the cost of potential bias).  
 
The study did not have a control arm. While it may have been revealing to 
compare DSP rates in HIV-uninfected patients, that HIV infection increases 
the risk for DSP is already established (see Section 2.1.2). It was felt that 
inclusion of HIV-uninfected patients would dilute the effect of HIV and 
increase the sample size. Seen differently, the study was not investigating HIV 
as the exposure of interest – HIV defined the population under study (see 
Section 2.1.1).  
 
One advantage to undertaking research at an inpatient facility such as DPM is 
that it accommodates a relatively “captive” population – systematic sampling 
would be difficult at a busy outpatient facility, and unavoidable loss-to-follow-
up could be accounted for in the more controlled inpatient setting. Other 
advantages are the relative assurance of compliance to treatments and a 
reliable dosing schedule.  
 
The study included patients with prevalent DSP. This allowed a cross-
sectional component and an opportunity to study the natural history of 












incidence in those with DSP at baseline (see Section 3.6.2.2). As exposures 
were ongoing at the time of study entry, exclusion of baseline DSP may have 
resulted in a survival bias. Furthermore, a “clean” cohort may paradoxically 
have given us fewer data – because of the significant attrition, incident cases 
would not have been observed.  
 
Most aspects of the study (study design in part; field work; administration; 
data management, capture and analysis; and molecular laboratory work) were 
executed personally. Direct involvement with all aspects of the study 
promoted consistency; strengthened internal validity and the fidelity of study 
findings; and facilitated contextualisation and interpretation of the data.  
 
There was heterogeneity in terms of previous and ongoing exposures to 
factors potentially contributing to DSP – ART (including neurotoxic d4T), INH 
and pyridoxine. Figure 4-3  illustrates this heterogeneity in the study 
population. Heterogeneity, particularly of a temporal nature, is expected in this 
population (see Section 2.1.1 and Figure 2-2 ). There was further 
heterogeneity in terms of previous TB episodes, site of TB infection, and co-
morbidities.  
 
In most cases anti-TB therapy was initiated at the referring facility and 
admission occurred well after this point (median of 16.5 days). This duration 
was also highly variable within the sample (Q1-Q3 11-39.5), and was 
dependent on multiple factors, such as the availability of beds or transport 
delays. ART exposure was also variable: some participants were already on 
long-term therapy, some had previous but ill-defined ART exposure and 
others had their therapy switched during the course of the study. Over a third 
of the cohort had no recall or record of having received pyridoxine; after 
admission all received pyridoxine, but at different dosages. Pyridoxine doses 
were also changed through the course of the study. Heterogeneity, particularly 
of a temporal nature, contributed to bias and confounding, precluded 














Selection criteria attempted to reduce heterogeneity – for example, all 
participants received INH. The left-shifted survival analysis was valuable in 
mitigating the potential bias and confounding associated with a variable period 
between anti-TB therapy initiation and the baseline assessment. Variables 
were also dichotomised to reduce heterogeneity: use of ART was grouped 
into exposure ever, previous TB grouped into yes or no and pyridoxine 
standard or high dose. 
 
The sample size was designed to detect baseline DSP. Loss-to-follow-up 
precluded reliable longitudinal analyses and so the power of the cross-
sectional analysis was maximised. One participant was excluded after 
recruitment was ended; the sample is therefore one short of the intended size 
(116 vs. 117 participants). 
5.1.9 Defining and measuring DSP is problematic 
As expounded in detail in Section 2.2.4.1, there are caveats to the definition 
and diagnosis of DSP. We used the BPNS and a modified TNS to assess 
neuropathy status, in line with much of the current literature around HIV-
associated DSP (see Section 2.2.4.3). Use of a modified TNS was justified for 
practical and cost reasons – neither nerve conduction study nor quantitative 
sensory testing facilities are available at DPM. A modified TNS has now been 
used in several studies11,63,95,102, and the current trend is towards purely 
clinical DSP screening35. With respect to the BPNS, the TNS adds the 
important pinprick modality for assessing small-fibre function, and thus 
increases specificity for the diagnosis of HIV-associated DSP. Additionally, the 
TNS adds a score for toe/ankle muscle strength – distal weakness is a late 
feature of HIV-DSP, ATN and INH-PN (see Section 2.2.1) – prominent 
weakness would also alert the examiner to the possibility of other pathology 
not in keeping with a diagnosis of DSP. 
 
The case definition of DSP in this study was ≥1 neuropathic symptom and ≥1 
neuropathic sign. The relevance of one versus two signs for the definition of 
DSP has been debated13 but the former is widespread in the literature (see 












lacking in sensitivity77. A significant caveat in this study is that the DSP-free 
comparator group comprised all participants not satisfying full criteria for DSP; 
therefore, by definition, participants with ADSP or with isolated neuropathic 
symptoms were included. There were multiple possible outcomes and 
comparators: for example, DSP vs. non-DSP; DSP vs. completely normal; 
ADSP vs. non-ADSP; or any symptoms vs. no symptoms. The decision to 
define the outcome as DSP vs. non-DSP was based on the following: the low 
proportion of participants who were entirely free of neuropathic symptoms 
and/or signs at baseline (only 15%); the lack of evidence supporting a distinct 
relationship between symptomatic DSP and ADSP (the significance of ADSP 
is debated, as is the significance of isolated symptoms [see Section 2.2.5.2]); 
and a focus on the more clinically relevant symptomatic DSP. A high 
prevalence of patients not satisfying DSP criteria but with neuropathic 
symptoms or signs alone is not unique to this study: in Wadley et al. this 
group comprised 25% of the cohort12. 
 
The definition of DSP severity and worsening (increased severity over time) 
was also problematic – worsening has not been uniformly defined in the 
literature, which focuses on DSP incidence rather than natural history (see 
Section 2.2.5.5). The TNS is not felt to be valid for assessing severity in a 
meaningful sense34; nevertheless, changing TNS score has been utilised in 
some studies77,100, but the exact point-change equating to clinically 
meaningful change is essentially a guesstimate. I utilised a 2-point change 
because it would translate to either an improvement in two modalities, or a 
significant improvement in one single modality. However, a change in the 
score for symptoms could theoretically be balanced by an improvement in the 
score for signs, thereby obscuring a clinically-relevant worsening. For this 
reason I utilised an additional and separate definition of a 2-point change in 
either of the positive symptom NRSs (pain or paraesthesia). A 2-point 
improvement in pain NRS has been validated against a PGIC98, but 
worsening has not received the same treatment. My definition is therefore 
extrapolated, but may have constructional validity. One further caveat was the 












a continuous variable in the analysis; however, scoring systems are often 
treated as continuous variables11,63,77,98,194. 
5.1.10 There were some methodological questions 
The BPNS defines ankle reflex responsiveness relative to the knees, and 
failure to appreciate this relation may have affected inter-rater reliability in one 
study77. A study of acceptability of the BPNS for clinical purposes found 
accurate assessment of reflexes to be challenging to healthcare workers97. 
In the current study, emphasis was placed on discerning the ankle reflexes 
with reference to the knee reflexes, which may have reduced the false-
positive rate, and may also account for differences in observed DSP rates in 
this study and others (see Section 5.1.1).  
  
BPNS vibration scoring was hampered by ambiguous instructions. In the 
situation where a slight difference (1 or 2 seconds) between right and left toe 
vibration thresholds straddled the “normal” value of >10 seconds (e.g. 10 and 
11 seconds), the BPNS instruction to “take highest score but both right and 
left must be abnormal” was ambiguous: the highest score (i.e. the worse 
threshold) is interpreted as abnormal but both scores were not abnormal, 
precluding classification. This situation occurred in 16% of assessments. Our 
decision was to classify vibration sense as normal – the scores were 
sufficiently close to normal, and the BPNS specification that both reflexes 
should be abnormal was adhered to. 
  
The BPNS specifies activating the tuning fork by squeezing the two ends of 
the fork together followed by a sudden release, in contrast to striking the fork 
on a hard surface. My feeling is that squeezing affords a more consistent 
intensity of vibration – a constant set force is required to oppose the two ends 
of the fork (potential energy) whereas a striking force is dependent on velocity 
(momentum) and the surface being struck. Squeezing versus striking may 
very well affect observed DSP frequency and incidence as several seconds 
difference can alter the outcome. While inter-rater variability in vibration 












assessments being performed by myself – it could very well influence validity 
when comparing and generalising study findings. 
  
Another debatable point regarding vibration threshold testing arose when my 
supervisor attended a demonstration of the BPNS for clinical trial purposes 
(by David Simpson, Pfizer) in which it was stipulated that vibration thresholds 
should be timed from the point of activation of the fork, rather than from the 
point of application to the target area. This was in disagreement with the 
method we were utilising in this study and as specified in the BPNS: 
“immediately place the vibrating tuning fork on the [area] and begin counting 
the seconds”. An argument for “pre-timing” is that the vibration intensity 
decays uniformly after activation and it is this absolute intensity that is 
perceived by the subject: the subject will perceive vibration until a certain 
intensity threshold is reached irrespective of when the vibrating fork is applied. 
However, this method presupposes that the rate of decay of vibration intensity 
is uniform pre- and post-application. If the rate of decay changes when the 
fork is applied to the skin, then the period of non-contact will bias the recorded 
threshold and introduce unaccounted for variability. After discussion of these 
various points, we felt that since we were timing sensation, only the time spent 
actively sensing the vibration should be timed. As the study was well 
underway, the point was moot, and consistency in the technique was 
considered the more important factor. 
  
It was my subjective impression over the course of the study that vibration 
thresholds were reduced by cold skin and/or ambient temperature – the 
influence of cold ambient temperature on sensory modalities other than 
vibration have been demonstrated195, but data on vibration sense is lacking. 
An interesting approach would have been to measure skin and ambient 
temperatures at each visit and correlate temperatures with vibration 
thresholds, or to do a sub-study in which thresholds are assessed before and 












5.1.11 Analysis of longitudinal data presented challenges 
Attrition was a major biasing element of the study and complicated analysis. 
The high attrition rate was a result of the inpatient nature of the study – 
involvement with the study was during admission only, and participants were 
not followed-up post-discharge for practical and cost reasons. Loss-to-follow-
up was due to multiple factors (Figure 4-2 ) which were on the most part 
unavoidable – the development of acute illness and toxicity; patient transfer; 
self-discharge; and death could not be predicted or controlled. Patient 
discharge was an exception: as discharge could be anticipated in advance, 
there was a possibility of follow-up just prior. Follow-up occurred if two weeks 
had elapsed since the previous assessment, but occasionally participants due 
for discharge were missed. Participants lost to follow-up before the eight week 
assessment differed from those who survived to this point – they had higher 
BMIs, possibly because the majority of losses by eight weeks were due to 
discharge. The remaining cohort may have biased by participants who were 
sicker. Biases related to loss-to-follow-up may have influenced study findings, 
and because loss-to-follow-up in this study was not random, it is difficult to 
adjust for196. 
 
Incident and worsening DSP were considered separately – analysis of 
combined incident/worsening would be complex in the context of a survival 
analysis wherein the two outcomes are semi-competing. Furthermore, the 
population at risk for incident DSP and that at risk for worsening DSP are 
mutually exclusive. Worsening DSP is also a poorly understood entity (see 
Section 2.2.5.2) and may be a heterogeneous process not equivalent to 
incident DSP. The lack of independent associations with worsening DSP in 
this is supportive of this hypothesis. 
 
A result of separating the analysis for incident and worsening DSP was that 
the sample entered into the survival analysis for DSP incidence was reduced 
(only those DSP-free at baseline were eligible). This issue was partially 
mitigated by the left-shifted survival analysis wherein patients without follow-












larger sample sizes are required to further delineate incident and worsening 
DSP, and associated risk factors in HIV/TB populations. 
5.1.12 Molecular techniques required some troubleshooting 
The molecular component of the project involved a steep learning curve, a 
process characterised by a number of obstacles. Initially, DNA extractions 
yielded low DNA concentrations and had to be repeated for several samples. 
Troubleshooting involved replacement of several reagents, extending 
incubation times and increasing the number of washes. The latter was not 
fruitful, reducing concentrations rather than increasing them. Further 
refinement of the technique eventually produced better results. Samples of 
concentration <50 but >20 ng/µml were also successfully amplified by PCR. 
  
Restriction enzyme digestion with KpnI and MspI (digest “A”) produced an 
anomalous ~800 bp fragment in two samples (Figure 4-9 , lane 5). A fragment 
of this size would suggest the G191A and C481T SNPs occurred on the same 
chromosome; although, if this were the case, the remaining bands would 
imply three alleles. The ~800 bp fragment could not be explained by 
incomplete MspI digestion because the 96 bp fragment was present – the 
~800 bp fragment would not be possible if MspI was inactive. Digestions with 
each of KpnI and MspI were run separately in which anomalous fragments 
were also demonstrated. Contamination would account for the presence of 
three possible alleles, but repeat extractions and digestions continued to 
demonstrate the anomalous fragments. Blood transfusion is a plausible 
explanation for apparent contamination of samples collected at different time 
points, but there was no history of a transfusion. To produce the ~800 bp 
fragment there must have been decreased KpnI activity at the 481 locus, 
possibly due to some unidentified genetic or extrinsic factor. Non-specific 
amplification of NAT1 by the NAT2 primers is another possible explanation. 
Sequencing eventually confirmed heterozygosity for alleles at each of the 191 
and 481 loci (Figure 4-13 ). 
 
The allele-specific PCR for the determination of the T341C SNP proved to be 












validity of allele-specific PCR is intrinsically compromised by the employment 
of two separate reactions, effectively doubling the chance of error122. The 
technique has received further criticism in the literature: O'Neil et al. reported 
“high background”48, while Doll et al. suggests an alternative nested PCR 
restriction enzyme digestion181. Our results further support these 
observations.  
5.1.13 Ethical issues were balanced on the whole 
Potential harms in the study were few and involved the risks and discomfort of 
venesection; the effort expended to complete the assessments; and the 
potential for breech of confidentiality (for example, having one's HIV status 
inadvertently revealed because one is known to be participating in the study). 
Potential harm was avoided in the following ways: patients that were 
considered too ill to participate in the study were not enrolled; a private 
consulting room was used; study materials, samples and data were 
anonymised; and no more than two attempts at venesection were made. 
Participants were protected by the approval of an accredited ethics 
committee, and the informed consent document. 
  
The patient population at DPM may be considered disenfranchised and 
vulnerable, and some patients might not have necessarily appreciated the 
voluntary nature of research participation. Voluntary participation was 
therefore stressed, which is evidenced by the number of patients declining 
participation and opting out of the study (see Sections 4.1). (These factors 
may have introduced bias, however [see Section 5.1.8].) Participants did not 
receive any financial compensation for partaking in the study, as they did not 
incur transport costs or potential loss of income. Some patients with 
documented HIV infection were not aware of their HIV status or were in denial 
about their status, or had not received adequate post-test counselling. They 
were not enrolled into the study so as not to confront them with these issues 
during the study process. Participants who did not fully comprehend the 













There were minor benefits to the participants themselves: uncovering of 
undiagnosed DSP, ready access to neurologist advice/consultation if required 
and an additional line of communication between the patient and DPM 
medical staff. A line was drawn, however, between the research process and 
treating/advising the patient197. Harms were further balanced indirectly by 
potential contribution to science and benefits to the greater HIV/TB population 
– HIV/TB-associated DSP is a neglected topic, and management avenues are 
limited. Patients may benefit from this research in the future. 
5.2 Contributions and recommendations 
This study represents the first detailed description and analysis of 
HIV/TB-associated DSP – current literature is confined to one short report2, 
and to studies of general adverse events in HIV/TB (see Section 2.1.2). Study 
findings have already been presented as a poster presentation at the 
Neurological Association of South Africa Congress 2012. A paper intended for 
publication in an international peer-reviewed journal is currently being drafted. 
 
Despite a high level of care (relative to an outpatient clinic setting), DSP was 
under-recognised and under-treated. This situation is not unique to this 
hospital (see Section 2.4.1.1), possibly because DSP assessments were not 
routine relying on patient-reported symptoms. This situation is a product of 
over-stretched resource-limited clinical services – more serious medical 
issues will be prioritised in these settings. Our research serves to highlight the 
significant morbidity associated with HIV/TB-associated DSP in the form of 
painful and other symptoms, and the high prevalence and incidence of this 
complication. Neuropathic pain is distressing and disabling and should 
therefore not be disregarded or left untreated. Greater sensitivity in diagnosis 
and closer monitoring of DSP may address this issue. The NRS and PGIC 
scales are simple tools for gauging objective changes in symptom severity 
that may be used clinically to guide therapy. Similarly, a screening tool such 
as the BPNS could easily be incorporated into routine assessments97. 
However, a tuning fork and patellar hammer are necessary, and assessments 
can be time-consuming at times, particularly when reflexes are difficult to 












the most common neuropathic sign associated with DSP in this study was 
impaired pinprick sensation, suggesting it is the most sensitive modality. 
Assessment of pinprick sensation can be rapidly performed and requires only 
a sharp object, but is not tested in the BPNS. A caveat in resource-limited 
settings with a high prevalence of infectious disease, such as hepatitis B, is 
the danger of cross-infection when pins or other sharp objects are reused. 
History-based screening for DSP may also have utility (see Section 2.2.4.4) – 
in this study only six participants had symptoms in the absence of signs, two 
of whom subsequently developed full DSP.  
 
In this study, under two thirds of the cohort received pyridoxine 
supplementation at the referral facility prior to transfer to DPM; this figure is 
lower in an exclusively outpatient setting11. There are several possible 
reasons: supply-chain shortages; deficient guidelines; underestimation of the 
risks for and clinical impact of DSP; and an unfounded fear of precipitating a 
pyridoxine neuropathy. The literature adequately demonstrates increased risk 
for B6 deficiency in HIV/TB populations; our research shows that pyridoxine 
25 mg/day is probably sufficient to prevent or reverse this expected 
deficiency. Pyridoxine should therefore not be withheld in this population, and 
a similar emphasis on compliance afforded to other HIV/TB therapy should be 
placed (e.g. directly observed therapy and pill counts). 
 
Higher dose pyridoxine (>25 mg/day) may be unnecessary for the purpose of 
preventing or treating B6 deficiency. Furthermore, the practice of prescribing 
higher dose B6 for the treatment of established INH-PN is not evidenced, and 
an additional neuroprotective benefit of higher dose pyridoxine cannot be 
inferred in the context of adequate B6 status. It could be argued, however, 
that, in the absence of concrete evidence supporting a lack of benefit, no 
specific harm may result from pyridoxine supplementation in any dose not 
exceeding safe limits. The implications of unnecessary higher dose 
supplementation may be subtle: while pyridoxine is not an expensive agent 
(on the order of <US$0.1/25 mg), over-prescription in resource-limited settings 
may result in shortages; a perceived therapeutic benefit may result in a failure 












to therapy. An increased pill burden may impact on adherence. Pyridoxine 
should be supplemented at standard doses of 25 mg/day in the absence of 
evidence showing a benefit at higher dosages.  
 
While B6 deficiency may be prevented or corrected by pyridoxine 
supplementation, we either do not have enough information to show that it is 
neuroprotective in this population, or, if we accept the current evidence, the 
mechanism of neurological injury is not entirely B6-related. However, there 
remains a possibility that DSP rates may be even higher without 
supplementation or that prior deficiency may still be contributory. Our data did 
not associate the absence of pyridoxine prior to admission with prevalent or 
incident DSP – poor reliability of this historical data may account for the lack 
of association. As deficiency is correctable, and is an established risk factor 
for INH-PN, again, we recommend consistent supplementation from the time 
of anti-TB therapy initiation. Because vitamin B-complex, widely administered 
in HIV, is not sufficient to prevent B6 deficiency112, an argument can be made 
for instituting full B6 supplementation even before anti-TB therapy. 
 
Our research adds to the knowledge base for NAT2 genetic variation and 
acetylation phenotypes in our local populations. There are suggestions in the 
literature that acetylation status guide INH dosing schedules29,45. The trend for 
slow acetylators to dev lop DSP in this study is not sufficient to promote 
determination of acetylation status prior to anti-TB therapy prescribing in 
HIV/TB co-infection, but also does not exclude a potential benefit of this 
approach. However, the practicality of instituting widespread phenotyping or 
genotyping to determine acetylation status is doubtful in our setting.  
5.3 Further research 
The current dataset and sample bank is amenable to further study. I would 
prioritise completion of NAT2 genetic analysis for the entire cohort; a further 
33 participants may be typed. Although these participants have no follow-up 
data, they may still be entered into the cross-sectional and “left-shifted” 












However, because of uncertainty around B6 sampling, I do not feel it 
worthwhile to extend B6 analysis to the rest of the cohort.  
 
The longitudinal data, although incomplete, may benefit from further analysis. 
General estimating equations, for example, are useful for the analysis of 
unbalanced longitudinal datasets176, and for the analysis of panel data (data 
viewed as sequential cross-sections) in which the outcome may be present or 
absent at each time point. A multiple failure survival analysis may also be 
worthwhile in this respect – the benefit would then be that failure does not 
equate to data censoring. Only baseline covariates were examined, but 
several were also time-varying and should be entered into future analyses. 
Other outcomes may also be considered, such as ADSP and improvement of 
DSP (as opposed to worsening), and the cohort stratified by aetiological 
diagnoses.  
 
As plasma and serum samples are available for all participants at all time 
points, we explored the possibility of running INH assays and using the INH 
metabolic ratio to establish acetylation phenotype. The INH plasma 
concentration curve is highly variable and accurate pharmacokinetic 
assessment requires serial sampling121. Plasma was sampled at only one time 
point, however, and too great an interval post- dosing. Furthermore, a 3-hour 
sample is required for accurate phenotyping119. Other possibilities for 
laboratory analysis include mitochondrial DNA haplotyping and markers of 
oxidative stress and/or inflammation.  
 
Heterogeneity and incomplete follow-up are factors detracting from further 
study of the dataset. Ethics are in the balance: unused samples and data 
versus expending further resources on a limited project. The decision to 
abandon or continue study of the data does not necessarily need to be made 
immediately; useful genetic or biochemical markers may be discovered in the 
future. 
 
The design of future studies should be guided by the lessons learned in this 












followed for the duration of anti-TB therapy, and after. An outpatient setting 
would be suitable for this study design, but may select out well patients. A 
very well-resourced study would allow follow-up of patients as they are 
transferred from facility to facility. Vitamin B6 levels should be sampled prior to 
commencing therapy, and then pre-dosing. More detailed information 
regarding previous medical history would better elucidate possible previous 
neurological insults. The sample size should accommodate stratification of 
participants by ART exposure. Genotyping could be confirmed by appropriate 
phenotyping. The study of HIV/TB-associated DSP requires long-term follow-
up of HIV-infected patients; the feasibility of this kind of research should be 
carefully considered. 
 
One of the study aims was to inform the design of an RCT that would 
determine optimum pyridoxine dosing in this HIV/TB population. We have 
established that standard doses will prevent deficiency, but not DSP. An RCT 
may then be justifiable to test the hypothesis that higher dose pyridoxine is 
beneficial neurologically despite the correction of B6 deficiency. As there is no 
equipoise regarding the benefit of supplementation (see Section 2.4.3), a 
placebo arm would not be justifiable.  
5.4 Conclusion 
Symptomatic DSP is frequent in HIV/TB co-infected patients recently 
commenced on first line anti-TB therapy, and continues to develop or worsen 
thereafter at a high rate. However, over time, the overall trend is for 
symptomatic improvement. HIV-DSP, ATN and INH-PN all contribute to DSP 
in HIV/TB co-infection, but separating aetiological processes may require 
earlier and more prolonged longitudinal study. A possible “TB-DSP” is an 
entity that may have clinical implications, and also requires further 
investigation. The clinically significant symptoms apparent in this study were 
under recognised and under-treated – screening for DSP should be part of the 
routine assessment of the HIV/TB co-infected patient. Symptom only 
screening may be appropriate in busy resource-limited settings. 
 
The clinical risk profile for DSP supports the prevailing theory that DSP is a 












insults. Prevalent DSP was associated with previous ART use, and incident 
DSP with concomitant ART; however, the associations could be explained by 
other demographic and disease factors in multivariate analysis. Previous TB, 
implying INH exposure, was independently associated with INH-PN. More 
prolonged and consistent follow-up would strengthen risk association findings. 
 
DSP was not found to be associated with vitamin B6 deficiency in this study; 
the lack of association is because patients receiving ≥25 mg/day pyridoxine 
supplemented anti-TB therapy do not demonstrate B6 deficiency. 
Nevertheless, adequate B6 status, as estimated several time intervals after 
the initiation of pyridoxine supplementation, does not appear to prevent 
incident or worsening DSP. Pyridoxine doses in excess of the standard 
25 mg/day, prescribed in response to the diagnosis of DSP, did not improve 
B6 status as estimated by plasma PLP – the excess pyridoxine is probably 
metabolised to 4PA once steady-state is achieved. Study findings relating to 
B6 are probably not sufficiently reliable to conclusively inform the design of an 
RCT or to make definitive recommendations, mainly because of 
methodological questions around B6 sampling and dosing. 
 
Slow acetylation was not a primary risk factor for DSP in this population; 
however, there was a trend for slow acetylators to develop DSP when 
compared with fast/intermediate acetylators. Slow acetylation did not show an 
association with B6 deficiency, because deficiency was almost completely 
absent from the sample. The trend for slow acetylators to develop DSP is 
therefore not likely to be explained by this mechanism. Direct INH toxicity in 
the form of oxidative stress may be responsible, possibly exacerbating 
oxidative damage related to inflammation and d-drugs. A contribution from B6 
deficiency prior to sampling cannot be excluded and again, earlier sampling is 
advisable in future studies. NAT2 phenotyping would also help corroborate 
these findings. 
 
The primary (alternative) hypothesis is rejected: in HIV/TB co-infection, DSP is 
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UCT ICD DP Marais modified 15 Feb 10 
Patient Information Sheet for the Neuropathy Study 
Title: Isoniazid-TB treatment as risi< factor for HIV-associated Neuropathy and the role 
of adequate B6 supplementation 
-". . 
Dr C Centner & NPr6f J Heckmann (Neurology); University of Cape Town 
You are invited to participate in a research project at Of:> Marais Hospital. Before you agree 
to take part you ne.ed to understaiid the foliowing: . 
One of the possible complications of HIV infection could be damage to the long nerves 
supplying the skin of the feet and legS causing most commonly painahd tingling in the feet. 
This problem is called peripheral nel,lropathy. Unfortunately, it may also be a side effect of 
the treatment used to treat HIV, highly active antirettovirai therapy; or HAART foi' short (also 
knoWn as ARVs - a:nti~retrovirals). This is a combination of speCial medications to try aild 
" , 
stop the HIV from dividing ih the c.ells of the body and causing harm. Although HAART/ARVs 
cannot cure HIV/AIPS (i.e. some virus still stays in the cells) it has helpe.d to fight the 
development ofAIOS"and has helped aild Saved a lotof patients. So, althOugh HAARi/ARVs 
is useful in treating HIV, it may also caus.e or worsen peripheral neuropathy in some patients 
and very little is knOWn abOut this problem in South African patients. In this study we waht to 
learn mare about why some patients With HIV,andthose taking HAART/ARVs dellelol:> . 
painful feet, and how treatment for TB and vitamin levels in the body (vitamin B6 especially) 
can contribute to this problem. This will help us to developways to prevent or treat this side 
effect of HAART/ARVs. ' 
It is important to realise that not everyone on HAART/ARVs will develop peripheral 
neuropathy, but some indiViduals are at risk of developing this side effect. It Will be useful to 
identify whO are at"risk so that we can try and prevent this complication from developing, 
. ' . , . . - . 
WHY HAVE I BEEN-CHOSEN? 
. . 
, We are discussing this project with you because you are HIV-infected which will mean that 
some point in the near future you will start on ARV treatment. Also, you have tuberculosis 
which meanS that you are already receiVing TS treatments that indudeslNH, for. at least 6 
months, INH byitselfcan resultin peripheral neurbpathy in certain individuals who don't. have 
other risk factors such as HIV or ARV therapy. Additional vitamin B6 treatment usually helps 
. this symptom of painful feet. With this study we want to determine if all subjects with, . 
HIV/AIOS and TBrequire the same amount of vitamin B6 to prevent peripheral neuropathy? 
• • 
. From your hospital records we will know how muCh vitamin B6 you are taking. We want to 
' study the vitamin 136 levels in the blood. and see whether you have enough for your body's 
needs, We alsb want to take blOOd fbr a genetic test called NAT2 which we think,'may tell us 
whether a person's body needs much more vitamin B6 or not. The NAT2 gene is important in 
inacti\(ating the INH"i.s treatment.We think haff the general population are '"slow 
metabolizers or inactiVators" asa result of their NAT2 gene arrangement and that this may 
affect the individual's need for vit<lmin B6, "Slow INH inactivators' may need more B6 than 
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, , 
WHAT WILL HAPPEN IF I AGREE TO PARTICIPATE? 
The investigating dactarwill assess yausaan after yaur admilssian to. DP Marais haspital 
and again after 1 and 2 manths while you are still a patient there. The assessment will 
include a shart interview about symptoms you are having, a short examinatian of the feet and 
legs as w!;lll as ~Iaod drawing (hpt more than 15-2Q 1'111$ I 3-4 teaspoans oJ blaod will be 
taken). The bload will be sent to the i<3boratory fot vit.amin B6 and DNA genetic testing 
(NAT2). You will need:ta pravlde separate perrhiSsian fOr the DNA genetic testing. Same af 
the blaad will be froten. and kept far testing at a later stage. Stored blaod and genetic 
samples will not be labeled with your personal irifarmatian. 
The study staffwill also review all of your preVious clinic records including all of your previous 
blood and other test results (Including HIV status, viral load, CD4 count, liver function, kidney 
function) . 
WHAT ARE THE POSSIBLE DISCOMFORTS OF PARTICIPATING IN THE STUDY? 
Having blood taken will be the only discomfort in this study. Risk of infection Will b.e 
minimized by using sterile procedures, and all blood samples will be taken by a qualified 
study doctor. . 
WHAT ARE THE POSSIBLE BENEFITS? 
. 
If you are found to have complicated HIV-related nerve problems then arrangements will be 
made for you to be seen at G'rOcite Schuur Hospital where doctors 'specially trained in loa king 
after these problems Will asSess yau. More generally, you will be contributing to aur 
uhderstanding of peripheral neuropathy in HIV and it's treatment, and other patients in the 
. future will benefit from this. 
• 
DO I HAVE TO PARTICIPATE? 
You do not have to, participate in this study. Your participation is voluntary and if you agree to 
participate then yau will be reqi.Jited to sign a form. You can withdraw from the study at any 
time and this will in no way affe,ct your treatment in the future. 
WILL THE INFORMATION REMAIN CONFIDE:NTIAL? 
Yaur records will only be viewed by your doctors and people involved in this study, including 
research aversight agencies, which. support the rights of subjects involved in research (such 
as ethics committees onhe Office of Human Research Protections). Your details will not be 
made availapie to anybody not involved in this sti.Jdy: Although absolute confidentiality . 
cannot be guaranteed, the staff involved in this study will strive to keep your records as 
canfidential as passible . 
• 
CONTACT DETAILS OF STUDY STAFF • 
Should you have any questions, then please contact the study doctor Dr Chad Centner on 
082-253-7618 (via call, SMS or please-call-me) or leave a message at UCT neurology 021-
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Written Informed Consent for the Patient -
Study Number: .. ......... .......... Patient Initials: ..... ....... ... ... .... .. . _ ........ ... .... ........ .. . 
. -
I, . . . . .. . .. . .. .... ..... .... ........................... ... ................................. ~ .. ... ' ............. . 
(Name of patient in block letters) 
Have read and understood all the information given to me about my participation in this study 
and I have been given the opportunity to discuss it and ask questions. I voluntarily agree to 
take part in this study and have received an information sheet outlining the details of this • 
study. I understand that I am able to withdraw from this study at any time. . 
Please tick the boxes if you are willing to give a 20mls (4 teaspoons) of your blood for 
storage to be used by this study and lor at a later date; any further research studies must 
and will always first be cleared tiy the UCT research ethics committee before the researchers 
can use your blood. 
• I am willing to allow a blood specimen to be taken for vitamin B6 levels: YES NO. 
. . ' . 
• I am willing to allow a blood specimen for DNA extraction to determine my NAT2 
gene status: YES NO . . . ~ ~ " 
-. 
• - I am willing to allow the left-over DNA 'to be used for possible future genetic studies IF 
the research project has been cleared by the UCT research ethics committee before 
- -
the researchers can use my specimen _ YES NO. 
• I am willing to allow the left~over blood to be used for possible future studies IF the 
research project has been cleared by the UCT research ethics committee before the 
researchers can use my specimen YES NO 
• 
. ."' 
Signature of patient" ..... ... :.H ................. .. .. .. ; ... . .... ....... t Date ...... ; ... ...... ....... . 
. . 
........ I ••••••• •• • •• • • •••••• • ••••• ', ' . ..... ....... . . 
Printed Name of Patient 
• 
I have explained the nature and purpose of the study to the patient named above . 
.. , ..... 
• • , .. ........... , ..... ".~ ... .... . . ....... .... ...... ............ .. . . ... ................... . 
Signature of doct~ Print Name of Doctor Date 
3 

























HIV-Associated PN Study at DP Marais Patient Data Capture Sheet
NO: T BASELINE Date: dd mm yy
Only initials to be entered into study database Ward:
Name: Date admitted:
DOB: dd mm yy dd mm yy
F/N: Height:
Affix label here Weight:
PMHx DM Epilepsy Renal dysfunction Pregnancy
Previous TB: yy yy yy Other:
ETOH When was the last time you had more than 4/5* drinks in 1 day?
Never >1 year ago <1 year ago
TB Site Confirmation Regimen Current dose
PTB AFB x1  x2  x3 1 RHZE:
Other: Culture +  -  pend 2 RH:
Radiological Strep:
Other:
Starting date: dd mm yy Interruptions: days
HIV Tested: dd mm yy Stage: CD4C:
Current ARV regimen
nil D4T: AZT: TDF:
3TC:
EFV: NVP: Other:
Starting date: dd mm yy Interruptions: days
Previous ARV exposure
nil D4T AZT TDF 3TC EFV NVP Unkown
Last taken: dd mm yy Time on Rx: months
Neuro Dx of PN Treatment
Yes No Amytriptylline: Other:
Start: dd mm yy
B6 Pyridoxine-HCl Start: dd mm yy Dose:
Change: dd mm yy Dose:
Change: dd mm yy Dose:
Levels taken? Y      N Hours since last dose:
Vit Bco nil i ii
Rx Bactrim: Phenytoin: Other:
Bloods Date taken: dd mm yy
U: Cr: Alb: ALT: AST: WCC: Hb: MCV: Plt: HepB:











HIV-Associated PN Study at DP Marais Patient Data Capture Sheet
NO: T FOLLOW-UP Date: dd mm yy
Ward: Weight:
TB TB culture +  -  pend
Toxicity:
HIV ARV regimen
nil D4T: AZT: TDF:
3TC:
EFV: NVP: Other:
Start: dd mm yy Interruptions: days
Toxicity:
Neuro Dx of PN Treatment
Yes No Amytriptyline: Other:
Start: dd mm yy
B6 Pyridoxine-HCl Change: dd mm yy Dose:
Change: dd mm yy Dose:
Levels taken? Y      N Hours since last dose:
Vit Bco nil i ii
New Dx
New Rx
Bloods Date taken: dd mm yy























Revision V3 March 2010 
SA BRIEF PERIPHERAL NEUROPATHY SCREENING/EXAM (UCT REC 221/2008) 
 
NO: T  BASELINE  Date: dd mm yy 
 
We are going to ask you a few questions about sensation in your legs. We will also briefly examine the nerves in your 
arms and legs. We may advise the clinic doctor on treatment.  
 
BPNS : INSTRUCTIONS FOR RECORDING SYMPTOMS: Ask subject to rate the severity of each symptom in 1a to 1c 
on a scale of 0 (absent) to 10 (most severe) for right and left feet, legs- worst in last week.  Enter the score for each 
symptom in the block marked Severity.  Enter extent of symptoms eg Soles of feet/ toes (TNS=1); up to ankle (TNS=2); 
up to knee (TNS= 3) or above (TNS=4) on the TNS score overleaf. 
    
1a. Pain, aching, burning in feet or legs. Ingaba iinyawo zakho zibuhlungu, ziyaqagamba, ziyatshisa kangangee-veki 
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0 1 2 3 4 5 6 7 8 9 10 
Andinantlungu!  →                      →                           →                                  Ndineentlungu ezigqithisileyo! 
            
 
 
























0 1 2 3 4 5 6 7 8 9 10 




TOTAL SENSORY PRESENCE/SEVERITY SCORE: Obtain the single highest severity score from 1-10 in 1(a - c) above:
   
0  = Grade 0  1-3 = Grade 1  4- 6 = Grade 2  7-8 = Grade 3  9-10 = Grade 4  
 
Total sensory severity GRADE   ____/4 nn4 
 
Patient asymptomatic (1a,b,c = 0) □ 
 
1d. Has patient had any symptoms in the past which are not currently present?                    
Yes (1)          No (0)   nn5 
 
Patient symptomatic □ 
 
1e. Relationship of onset of symptoms to current TB symptoms and regimen?        
 
 Before TB Sxs (1) After TB Sxs but before TB Rx (2)    After TB Rx (3) Unsure (4)  nn27 
  
1f. Relationship of onset of symptoms to current ARV regimen? 
 
 Not on ARVs (1) Before ARVs (2)       After ARVs  (3)      Unsure (4)  nn28 
 
1g. Any medication taken for the symptoms prior to admission at DPM? Yes (1)          No (0)   nn29 
  
1h. If yes, what? _____________________________nn30   How did the symptoms respond?    
 
 Much Worse (1) Worse (2)   No change (3)   Better (4) Much Better (5)  nn31 
 






















Revision V3 March 2010 
2. INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION: 
Press the 2 ends together of a 128 Hz tuning fork, and release suddenly; place the vibrating tuning fork on the subject’s 
clavicle; can they recognise the vibration or “buzzing” (ngcungcazela) of the tuning fork? Repeat and immediately place 
the vibrating tuning fork firmly on the interphalangeal bone (not nail) of one great toe and begin counting the seconds. 
Subject to tell you when the “buzzing” stops. Repeat on the other side.  
 
Vibration Perception     0- Vibration felt for >10 seconds (normal) 
(Take highest score but both R & L must be abnormal) 1- Vibration felt for 6-10 seconds (mild loss) 
      2- Vibration felt for 5 seconds or less (moderate loss) 
      3- No feeling of vibration (severe loss)    
 
Right   Left   
Great toe interphalangeal bone  ____                 ____  (2) use highest value______/3 nn11
  
3. INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES: 
With the subject seated, the examiner uses one hand to press upward on the ball of the foot, dorsiflexing the subject’s 
ankle to 90 degrees. Using a reflex hammer (long-handled), the examiner strikes the Achilles tendon.  
 Reflexes 4- Absent 
  3- Reduced (difficult to elicit)  
  2- Normal deep tendon reflexes   
1- Hyperactive deep tendon reflexes   
0- Clonus 
 
Right  Left   
 Ankle Reflexes:   _____  _____   (3) use highest value____/4 nn12 
(Take highest score but both R & L must be abnormal) 
 
Final score for BPNS (1+2+3) ____/11  nn13 
Reduced TNS score: tick in the box : 
 0 
 
1 2 3 4  
a. Sensory symptoms 
from 1a,b,c:  Pain, 




Only in toes or 
soles of feet 
 
Symptoms extend to 
ankle or wrist 
 
Symptoms extend to 
knee or elbow 
Symptoms knee or 









Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 






c. Vibration sensibility 
(use normal as for BPNS) 
 
normal Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 
  















Ankle reflexes absent Ankle reflexes absent, 
other reduced 





e. Strength- ankle and 
toes plantar & dorsi-
flexion 










      Final score for rTNS (a+b+c+d+e) ______/20  nn19 
 
Neuropathy classification according to TNS: 
 
Symptomatic DSP= a ≥1 and b≥1 or c≥1 or d≥1 or significant touch-evoked pain  yes/ no ________ n20
  
Asymptomatic DSP= TNS ≥3         yes/ no ________ nn21 
 
Indeterminate DSP= a ≥1 only        yes/ no ________ nn22 
 
 
Punch Biopsy performed         yes/ no ________ nn23 
 
Examination shows another form of peripheral neuropathy (not symmetric distal sensory) yes/no_____   nn24 
refer for further evaluation to neuromuscular HIV clinic at GSH (1st wed am of every month; 404-3209) 
 
 












Revision V3 March 2010 
SA BRIEF PERIPHERAL NEUROPATHY SCREENING/EXAM (UCT REC 221/2008) 
 
NO: T  FOLLOWUP  Date: dd mm yy 
 
We are going to ask you a few questions about sensation in your legs. We will also briefly examine the nerves in your 
arms and legs. We may advise the clinic doctor on treatment.  
 
BPNS : INSTRUCTIONS FOR RECORDING SYMPTOMS: Ask subject to rate the severity of each symptom in 1a to 1c 
on a scale of 0 (absent) to 10 (most severe) for right and left feet, legs- worst in last week.  Enter the score for each 
symptom in the block marked Severity.  Enter extent of symptoms eg Soles of feet/ toes (TNS=1); up to ankle (TNS=2); 
up to knee (TNS= 3) or above (TNS=4) on the TNS score overleaf. 
    
1a. Pain, aching, burning in feet or legs. Ingaba iinyawo zakho zibuhlungu, ziyaqagamba, ziyatshisa kangangee-veki 
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0 1 2 3 4 5 6 7 8 9 10 
Andinantlungu!  →                      →                           →                                  Ndineentlungu ezigqithisileyo! 
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TOTAL SENSORY PRESENCE/SEVERITY SCORE: Obtain the single highest severity score from 1-10 in 1(a - c) above:
   
0  = Grade 0  1-3 = Grade 1  4- 6 = Grade 2  7-8 = Grade 3  9-10 = Grade 4  
 
Total sensory severity GRADE   ____/4 nn4 
 
Patient is symptomatic for the first time since commencing study □ 
 
1d. Relationship of onset of symptoms to ARVs?   
 
    Before ARVs (1)     After ARVs (2) Not on ARVs (3) Unsure (3) nn32 
 
 
Patient had symptoms at previous visits □ 
 
1e. How have the symptoms changed since the last visit? 
 
 Much Worse (1) Worse (2)   No change (3)   Better (4) Much Better (5)  nn33 
 
 





























Revision V3 March 2010 
2. INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION: 
Press the 2 ends together of a 128 Hz tuning fork, and release suddenly; place the vibrating tuning fork on the subject’s 
clavicle; can they recognise the vibration or “buzzing” (ngcungcazela) of the tuning fork? Repeat and immediately place 
the vibrating tuning fork firmly on the interphalangeal bone (not nail) of one great toe and begin counting the seconds. 
Subject to tell you when the “buzzing” stops. Repeat on the other side.  
 
Vibration Perception     0- Vibration felt for >10 seconds (normal) 
(Take highest score but both R & L must be abnormal) 1- Vibration felt for 6-10 seconds (mild loss) 
      2- Vibration felt for 5 seconds or less (moderate loss) 
      3- No feeling of vibration (severe loss)    
 
Right   Left   
Great toe interphalangeal bone  ____                 ____  (2) use highest value______/3 nn11
  
3. INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES: 
With the subject seated, the examiner uses one hand to press upward on the ball of the foot, dorsiflexing the subject’s 
ankle to 90 degrees. Using a reflex hammer (long-handled), the examiner strikes the Achilles tendon.  
 Reflexes 4- Absent 
  3- Reduced (difficult to elicit)  
  2- Normal deep tendon reflexes   
1- Hyperactive deep tendon reflexes   
0- Clonus 
 
Right  Left   
 Ankle Reflexes:   _____  _____   (3) use highest value____/4 nn12 
(Take highest score but both R & L must be abnormal) 
 
Final score for BPNS (1+2+3) ____/11  nn13 
Reduced TNS score: tick in the box : 
 0 
 
1 2 3 4  
a. Sensory symptoms 
from 1a,b,c:  Pain, 




Only in toes or 
soles of feet 
 
Symptoms extend to 
ankle or wrist 
 
Symptoms extend to 
knee or elbow 
Symptoms knee or 









Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 






c. Vibration sensibility 
(use normal as for BPNS) 
 
normal Reduced in fingers 
/toes 
Reduced up to wrist/ 
ankles 
  















Ankle reflexes absent Ankle reflexes absent, 
other reduced 





e. Strength- ankle and 
toes plantar & dorsi-
flexion 










      Final score for rTNS (a+b+c+d+e) ______/20  nn19 
 
Neuropathy classification according to TNS: 
 
Symptomatic DSP= a ≥1 and b≥1 or c≥1 or d≥1 or significant touch-evoked pain  yes/ no ________ n20
  
Asymptomatic DSP= TNS ≥3         yes/ no ________ nn21 
 
Indeterminate DSP= a ≥1 only        yes/ no ________ nn22 
 
 
Punch Biopsy performed         yes/ no ________ nn23 
 
Examination shows another form of peripheral neuropathy (not symmetric distal sensory) yes/no_____   nn24 
refer for further evaluation to neuromuscular HIV clinic at GSH (1st wed am of every month; 404-3209) 
 
 
























Four case studies selected from the group of participants with maximal follow-
up (20 weeks) are presented. The diversity of presentations and natural 
histories in these cases highlights the multi-factorial nature of HIV/TB-
associated DSP, and the impact of temporal exposures on the clinical picture. 
The importance of pyridoxine supplementation is highlighted in participants 
T081 and T096. The impression is that while worsening occurs initially, the 
overall trend is improvement, particularly with regards to symptoms. An 
apparent difference in small vs. large fibre natural history may account for this 
symptomatic improvement despite persistence of neuropathic signs. What is 
also evident is a dynamic clinical picture that may not have been appreciated 
if follow-up intervals were more protracted.  
Patient T116: rapid-onset asymptomatic ATN 
This 40-year old female patient with a history of two previous episodes of TB, 
and a history of eight months of ART use two years prior, was seen two weeks 
after commencing pyridoxine-supplemented (25 mg/day) anti-TB therapy for 
PTB. Her CD4+ T cell count was 173 and her acetylation status was fast. At 
baseline, she was experiencing leg cramps, but not classical neuropathic 
symptoms, and the neuropathy assessment was normal. Two weeks later, she 
commenced a d4T-based cART regimen and the follow-up assessment was 
performed after a further two weeks. At this time, she was asymptomatic, but 
reduced ankle jerks were now demonstrated. Shortly after this, due to the 
completion of the streptomycin course, d4T was switched to TDF. At 
subsequent assessments, the ankle reflexes progressed from reduced to 
absent, following which there was a reduction also in knee deep tendon 
reflexes; however, no neuropathic symptoms presented, and the rest of the 
examination was normal. This was paralleled by a gain in weight from 53.8 kg at 
baseline to 65.9 kg at eight weeks. Immune restitution could not be assessed 
due to a lack of a follow-up CD4+ T cell count reading. She was discharged 
home for outpatient completion of the treatment course. 
 
This patient experienced an isolated progressive decrement of deep tendon 
reflexes soon after commencing d4T. Despite the withdrawal of this agent 
after just two weeks, the reflex involvement progressed. Being a fast 
acetylator, her risk for INH-PN was probably low and the temporal relationship 











and neuropathic progression despite withdrawal of the agent conflicted with 
this diagnosis (although this may have been an example of “coasting”. The 
rapid onset might have been due to “priming” from previous ART exposure 
and multiple TB episodes with cumulative neurotoxic susceptibility factors.  
Patient T081: pyridoxine-responsive INH-PN 
This patient, a 30-year old ART-naïve male with a slow predicted NAT2 
phenotype and a CD4+ T cell count of 84, was assessed at baseline nearly two 
months after commencing regimen 2 anti-TB therapy for TB lymphadenitis. He 
appeared to have not received pyridoxine until admission five days prior. At 
baseline, he complained of mild pain and numbness in the toes which he 
reported had began after starting anti-TB therapy. Examination revealed 
marked vibration sense impairment and absent ankle jerks plus reduced knee 
jerks. Four weeks later, after he had commenced an AZT-based cART regimen, 
he reported improvement in symptoms. Impaired pinprick sensation to the level 
of the ankles was noted in addition to the previous findings. At the next visit, 
symptoms had improved again, and he had been prescribed high dose 
pyridoxine (150 mg/day) in the interim. All reflexes were now absent in addition 
to the previous findings. In subsequent assessments, the patient continued to 
report improvement in symptoms, while both vibration and pinprick sensation 
steadily returned to normal. At the final assessment, the only abnormality was 
globally absent reflexes. 
 
This patient demonstrated a probable INH-PN. This is supported by his lack of 
pyridoxine supplementation and improvement once pyridoxine had been 
initiated, but is not consistent with his intermediate acetylation status, 
however. A low CD4+ T cell count could possibly have increased his risk for 
INH-PN. Symptomatic improvement coincided with an initial worsening then 
improvement of neuropathic signs (other than reflexes); however, 
improvement was the overall trend, which occurred over a relatively short time 
period. He remained with a mild asymptomatic large fibre neuropathy. 
Patient T048: “TB-DSP” with worsening following anti-TB therapy 
and non-d-drug ART 
This 30-year old female patient with a CD4+ T cell count of 306 and no history of 
previous TB or ART use was seen two and a half weeks after commencing 











increased to 100 mg/day on admission. At baseline, her PLP was 134 nmol/l 
and her 4PA 4380 nmol/l, both well above normal; she was an intermediate 
acetylator. She was experiencing severe pain, paraesthesia and numbness to 
the level of the ankles, the onset of which she reported coincided with that of 
her TB symptoms but before anti-TB therapy, and for which she was receiving 
amitriptyline 25 mg/day. Examination revealed impaired pinprick sensation to 
the same level, and reduced ankle jerks. Two weeks after the baseline 
assessment she commenced a TDF-based cART regimen. At follow-up, her 
symptoms had worsened, particularly numbness, and had moved proximally, as 
had the impairment of pinprick sensation. An additional finding at this stage was 
impaired vibration sense. Her PLP and 4PA were again well over the reference 
ranges (89.5 and 1540 nmol/l, respectively). At the second follow-up, symptoms 
and signs had worsened in both severity and anatomical extent. At the third 
follow-up, symptoms were reported to the level of the knee, signs had also 
progressed proximally and ankle jerks were absent. Four weeks later; however, 
the trend was toward improvement: numbness remained as an isolated 
symptom, and signs moved distally. This trend continued toward the final 
assessment, at which point she was symptom free, vibration sense was normal, 
reflexes were elicited (but still reduced) and the primary finding was residual 
impairment of pinprick sensation to the level of the ankle. Her weight at baseline 
was 46.5 kg compared to 62.0 kg at discharge. 
 
The reported symptom onset suggested an HIV-DSP (despite a high CD4+ T 
cell count), or possibly a “TB-DSP”, which initially worsened significantly 
before improving, perhaps another example of “coasting”. The worsening was 
not related to use of d-drug ART, and high dose pyridoxine did not appear to 
prevent it. A weight gain of 16.5 kg over 5 months might have reflected an 
immune reconstitution and resulting inflammation contributing to the DSP, 
particularly in light of the initial worsening followed by improvement, although 
unlikely because of the high baseline CD4+ T cell count. 
Patient T096: worsening INH-PN in an acutely ill patient 
T096, a 25-year old male intermediate acetylator with a first episode of PTB, 
was seen at baseline just over three weeks after commencing pyridoxine-
supplemented anti-TB therapy. He was wasted with a BMI of 15.8 and anaemic 
with an Hb of 7.6, but had no co-morbid conditions other than oral candida. His 
CD4+ T cell count was 305 and he was ART-naïve. At baseline, he did not 
complain of any neuropathic symptoms; examination revealed bilateral absent 











abscess and pulmonary embolism and was transferred to a secondary hospital. 
He later returned to DPM where he was seen eight weeks after the baseline 
assessment. His general condition was poor. He was receiving oral antibiotics 
and warfarin, and was due to commence TDF-based ART in the following week. 
He also now complained of mild pain and paraesthesia in the toes, had 
impaired vibration sensation and demonstrated MRC grade 4 weakness on 
toe/ankle dorsiflexion, in addition to the absent reflexes noted previously. At the 
next assessment, his symptoms had resolved, but impaired pinprick sensation 
to the level of the knees was demonstrated in addition to the previous findings. 
These signs remained fairly static for the remaining assessments and his 
clinical condition improved slowly until discharge which followed his completion 
of six months anti-TB therapy. 
 
Despite a high CD4+ T cell count, the patient had a poor baseline and 
developed acute complications. This coincided with the development of a 
symptomatic small fibre neuropathy over a large fibre background. One 
possible explanation is that his acetylation phenotype was reversed as a 
result of his acute illness, and that pyridoxine supplementation was not 
prescribed at the secondary hospital, thereby placing him at high risk for INH-
PN. Resolution of his symptoms shortly after readmission to DPM, where 
pyridoxine supplementation is standard therapy, supports this hypothesis. The 
findings at baseline are more difficult to account for: the high CD4+ T cell 
count reduces the likelihood of HIV-DSP (although he had clinical evidence of 
advanced infection), and no other risk factors for DSP were evident. This 
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